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I Introduction 
Over the past decades manipulation of DNA in vitro has developed from the transfer of 
genetic information between prokaryotic organisms to a technology, which facilitates 
efficient and controlled production of proteins in foreign hosts. Recombinant proteins 
have been gaining significance as research tools and therapeutics in medicine, yet the 
supply of many eukaryotic proteins, which have potential clinical or industrial use, is 
often limited by their low natural availability. So far, various expression systems are 
established and exploited commercially. The recombinant protein production systems 
utilized today range from prokaryotes such as Escherichia coli (E. coli) and Bacillus 
subtilis to eukaryotes such as yeast, fungi, mammalian and insect cell cultures, animals 
and plants.  
The expression of heterologous genes in bacteria is the simplest and most inexpensive 
way available for obtaining large amounts of desired proteins for research, industrial 
and clinical research purposes. E. coli is the most widely used host for the production of 
recombinant proteins because it is such a well-characterized system. Due to availability 
of various strong promoters and techniques, the efficient production of recombinant 
proteins in E. coli has become a routine matter. Furthermore, E. coli can readily be 
grown to high cell density and this has led to the development of inexpensive high-yield 
fermentation processes for the production of therapeutic and industrial proteins on a 
large scale (Jeong and Lee 1999). Expression of human insulin in bacteria was 
successful in 1982 and it became the first protein to be approved for therapeutic use 
(Brousseau et al. 1982). 
While recombinant proteins expressed in the cytoplasm of bacteria are often insoluble 
and therefore inactive, soluble and bioactive proteins can frequently be obtained from 
eukaryotic cells. Furthermore eukaryotic cells have the capacity to carry out 
posttranslational modifications, such as glycosylation, phosphorylation on tyrosine, 
serine and threonine residues or the addition of fatty acids (Geisse et al. 1996). Many 
important pharmaceutical proteins are currently produced by using mammalian and 
insect cells. Mammalian expression systems comprise a plethora of different cell lines 
used for protein production. Most commonly, Chinese hamster ovary (CHO) cells, baby 
hamster kidney (BHK) cells and myeloma cell lines are employed as hosts for the 
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establishment of stable transfectants (Chu and Robinson 2001). The baculovirus 
expression system on the other hand has been used extensively for the expression of 
recombinant proteins in insect cells (Poul et al. 1995). Recently, recombinant 
baculovirus vectors engineered to contain mammalian cell-active promoter elements 
have been used successfully for transient and stable gene delivery in a broad spectrum 
of primary and established mammalian cells (Kost and Condreay 2002) as well. These 
production systems have the advantage of carrying out the authentic post-translational 
modifications, but the cost of setting-up and running industrial scale mammalian cell 
cultures can be prohibitive and difficult to scale up.  
Transgenic animals offer an alternative for producing recombinant proteins. A number 
of proteins, including biopharmaceuticals, have been produced in the milk of transgenic 
mice, pigs, sheep, and dairy cattle at concentrations of up to ten grams per liter 
(Velander et al. 1992; Devinoy et al. 1994). Latest experiments have demonstrated that 
the expression of recombinant proteins in egg white of transgenic chickens is a new 
alternative for the animal expression systems (Harvey et al. 2002). But there are 
potential social and ethical barriers associated with using animals as protein production 
systems. In addition, gene transfer to domestic mammals such as sheep, goat, pigs and 
cows is not a trivial process, and scale up is slow. There is generally a long 
development phase before protein production begins and there are many regulatory 
processes that have to be fulfilled (Echelard 1996). 
 
I.1 Molecular Farming 
Plants have been proven as versatile expression systems for many forms of different 
recombinant proteins. Molecular farming is the production of pharmaceutically 
important and commercially valuable proteins in plants (Schillberg et al. 2002; Fischer 
et al. 2003). The tools of plant biotechnology that have been developed to improve 
agronomics via herbicide, insect and virus resistance or to alter seed and fruit traits are 
now being applied to generate new protein products for food, feed and pharmaceutical 
industry. Plant expression systems are attractive because they offer advantages over the 
classical expression systems based on bacterial, microbial and animal cells:  
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• Plant cells have a higher eukaryote protein synthesis pathway, similar to animal 
cells with minor differences in protein glycosylation (Cabanes-Macheteau et al. 
1999) whereas bacteria cannot perform most of the important mammalian post-
translational modifications. When differences between plant and mammal post-
translational processing do represent a problem, it may be possible to engineer 
plants with altered protein maturation pathways (Bakker et al. 2001).  
• Recombinant proteins can also be directed into plants intracellular compartments 
such as vacuole, endoplasmic reticulum or protein bodies, where they are more 
stable (Conrad and Fiedler 1998) They can be expressed in definite compartments 
like chloroplast (Staub et al. 2000; Daniell et al. 2001) or even targeted to storage 
organs such as seeds, where they remain stable for months even at ambient 
temperatures, reducing the costs of distribution and storage (Stöger et al. 2000). 
• Plant systems are more economical than industrial facilities using bioreactors for 
cultivation of cell systems. 
• The technology for harvesting and processing plants and plant products on a large 
scale is already available.  
• The purification requirement can be eliminated when the plant tissue containing 
the recombinant protein is used as a food. 
• Concerns about contamination of expressed proteins with human or animal 
pathogens (HIV, hepatitis viruses) or the co-purification of blood borne pathogens 
and oncogenic sequences, are entirely avoided by using plants. 
Molecular farming in plants can be accomplished by stable or transient expression of a 
recombinant protein in plants. Transient gene expression can rapidly provide large 
amounts of recombinant proteins for detailed structural and functional characterisation. 
Both for transient and stable transformation, several aspects (for example the choice of 
the host plant or the plant organ where expression of the protein is targeted) may 
influence the details of the approach but in general the first step of the process consists 
in adapting the gene of interest for expression (Figure I.1). Depending on the chosen 
plant species, the adapted gene is introduced into plant cells, using well established 
techniques like transformation by Agrobacterium tumefaciens based gene transfer 
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(Horsch et al. 1985), transformation by biolistics (Christou 1995) or by inserting the 
transgene into a plant virus, which then enters the plant via the normal infection route 
(Kumagai et al. 2000). In contrast to transient expression systems, stable transformation 
is characterized by integration of the target gene into the host plant genome. Marker-
based selected transgenic plants are regenerated and selected for the presence of the 
recombinant protein. The transgenic plants are then analysed to determine the level of 
expression of the recombinant protein. Only those plants that produce satisfying 
amounts of the recombinant protein are kept in the process. After a passage and 
multiplication in the greenhouse, the offspring of the selected transgenic plants can be 
grown in the field to assure large scale production of the necessary biomass. The newly 
produced biomass is harvested using existing agricultural tools and the recombinant 
protein is isolated and purified from the production plant.  
As an alternative to whole plants, plant suspension cell cultures can be used for 
recombinant protein production (James et al. 2000). Plant cells maintained in liquid 
medium under gentle agitation form cell suspension cultures. The cells can be 
transformed by any of the methods, except viral inoculation, discussed above, resulting 
in cell lines that continuously produce a recombinant protein. When clinical use of 
recombinant proteins is intended, their production under defined, controllable and 
sterile conditions with straightforward purification protocols as can be done in flasks or 
fermenters may be advantageous (Fischer et al. 1999). Suspended plant cells have been 
used in several recent studies producing a variety of foreign proteins (Doran 2000). 
These include recombinant antibodies and antibody fragments (Fischer, Liao and 
Drossard 1999; Fischer et al. 1999), proteins of therapeutic value such as interferon-2 
and 4 (Magnuson et al. 1998) and human antitrypsin (Terashima et al. 1999; Huang et 
al. 2001). The most commonly used host species for protein synthesis in suspension 
cultures is tobacco (James, Wang et al. 2000; Liu et al. 2001).  For molecular farming 
purposes, the expense of setting up and maintaining suspension cells in shaker flasks or 
fermenters may be prohibitive. Recent experiments demonstrated that production of 
commercially important enzymes like ß-glucuronidase and invertase is feasible but 
unlikely to be competitive, since scaling up is too expensive when compared to the 
minimal cost of agriculture (Doran 2000). 
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Figure I.1 Schematic presentation of the production of a recombinant protein of 
therapeutic interest in transgenic tobacco plants, suspension cell cultures and transiently 
transformed tobacco leaves. 
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I.1.1 Choice of the host plant 
Crops currently being used to express recombinant proteins include cereals (rice, wheat, 
maize), legumes (pea, soybean, alfalfa) and fruit and root crops (tomato, potato). 
(Fischer, Twyman and Schillberg 2003). For practical reasons, tobacco is very often 
used to test the feasibility of producing a given recombinant protein in transgenic plants. 
The transformation of tobacco plants with A. tumefaciens based binary vectors is well 
established and easy to perform (Horsch, Fry et al. 1985). In addition it has been shown 
that tobacco plants can correctly process complex human proteins (Cramer et al. 1996). 
Tobacco as a non-food and feed crop generally has the greatest biomass yields per 
hectar because it can be cropped several times a year (Bernstein, Lowe and Sheen 1982; 
Cramer, Boothe and Oishi 1999). A single transgenic tobacco plant can produce up to a 
million seeds, thereby facilitating rapid scale up to substantial acreage. One of the two 
major disadvantages of tobacco in a molecular farming approach is that the large scale 
extraction and purification from plant leaves either has to be reduced to a very short 
period during the year, at harvest season, or rather cost intensive storage conditions for 
the fresh biomass have to be developed. The second disadvantage encountered is the 
presence of the nicotine and other toxic alkaloids that have to be eliminated during the 
purification process. From this point of view alternative plants and plant organs, like the 
seeds of cereals (Stöger, Vaquero et al. 2000), potato tubers (Park and Cheong 2002) 
and seeds of beans or peas (Perrin et al. 2000) appear to be more suitable targets for the 
production of recombinant proteins. Potato tubers would seem an organ of choice since 
the same standard processes used in the starch industry may be adapted with little 
modifications to separate proteins. Also, storage of tubers or seeds is easy so that a 
continuous production from stored biomass can be assured throughout the year. 
 
I.1.2 Plant expression cassette design 
Promoters 
Transgene expression in plants is often performed through the use of numerous 
constitutive, inducible and tissue-specific promoters available. The most commonly 
used constitutive promoters are of viral origin such as the cauliflower mosaic virus 35S 
(CaMV 35S) promoter that drives very high levels of transcription in most tissues of the 
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plant (Benfey, Ren and Chua 1990). Further increase of the activity could be achieved 
by modification of the enhancer region (Rathus, Bower and Birch 1993). Although the 
constitutive promoters of viral origin can drive very high levels of expression, in some 
cases deleterious effects such as gene slicing via cosuppression have been reported 
(Koosha, Muller and Davis 1989). This phenomenon may be less common in the case of 
constitutive promoters of plant origin such as maize ubiquitin-1 promoter (ubi-1) 
(Christensen and Quail 1996) and rice actin-1 promoter (act-1). These constitutive 
promoters facilitate widespread expression in the plant. However this is not always 
advantageous since accumulation of recombinant proteins in vegetative organs may 
adversely affect plant growth and regeneration. Rather than overexpressing a transgene 
in all tissues, another option is to target expression of the transgene to specific organs 
such as leaves, tubers or seeds. Promoters like sps1 promoter (Chavez-Barcenas et al. 
2000) for leaf specific expression or patatin promoter (Park and Cheong 2002) for 
tuber-specific expression have been identified and well characterized. A further 
advantage of this option is that it enables the production of the desired product in easily 
harvested tissues. In certain cases, it may be also advantageous for protein stability 
and/or downstream processing if recombinant proteins are expressed by the use of 
inducible promoters. A wound-inducible defence gene derived promoter (Cramer, 
Weissenborn et al. 1996; Hansen et al. 1997) is an inducible promoter example for 
recombinant protein expression in plants. The MeGA (mechanical gene activation) 
system from CropTech is using a wound-inducible HMG2 (hydroxy-3-methylglutaryl 
CoA reductase) promoter. When transgenic tobacco plants containing the MeGA 
expression cassette are subjected to mechanical stress by shearing or shredding after 
harvesting, gene expression occurs and recombinant protein is synthesized usually 
within a 24-hour period. 
Transcription terminator 
In addition to the promoters, further factors to be considered in design of a plant 
expression cassette relates to the type of polyadenylation signal or transcription 
terminator to be used. The most commonly used transcription terminator/poly(A) 
signals are derived from either the CaMV 35S RNA gene or the nopaline synthase (nos) 
gene from A. tumefaciens. This has been used successfully in a wide variety of species 
that include dicot and monocot plants (Gleave 1992). However, there are indications 
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that some plant-derived transcription terminators are more effective such as the 3` 
noncoding regions of the Me1 gene (Ali and Taylor 2001) and the wheat histone H3 
gene (Ohtsubo and Iwabuchi 1994). The use of the Me1 3 noncoding region has led to a 
generalized enhancement of several fold in gene expression from promoters of different 
classes (Ali and Taylor 2001) without any alteration in the expression pattern of the 
promoters. 
Targeting signals 
Exploiting the innate protein sorting and targeted mechanisms that plant cells use to 
target host proteins to organelles can increase accumulation levels of recombinant 
proteins in plants. Protein targeting is important for three reasons in molecular farming. 
Firstly, the destination of a protein affects its stability, which in turn affects the final 
yield of the protein because total yield reflects not only the rate of production but also 
that of degradation. Secondly, the destination of the protein is important if it needs to be 
modified. Glycoproteins, for example, must be targeted to the secretory pathway since 
glycans are added to proteins in the endoplasmic reticulum (ER) and golgi apparatus of 
plant cells (Horvath et al. 2000). Thirdly, protein targeting may be essential for plant 
survival. Proteins accumulating in the cytosol may be toxic, but the same protein 
accumulating to the same or greater levels in the chloroplast or vacuole is often 
tolerated because in this case they do not interfere with endogenous metabolism. 
Specific amino acid sequences required for targeting of proteins to particular organelles 
and for retention of proteins in organelles have been identified. Targeting signals can be 
used to direct the protein for secretion (Voss et al. 1995; Magnuson, Linzmaier et al. 
1998) or to intracellular organelles (ER, chloroplast, vacuole) (Moloney and Holbrook 
1997). For example, for retrieval of secreted proteins to the ER, an H/KDEL sequence 
near the carboxyl terminus specifies that a protein should remain in the ER, where the 
nascent glycoprotein is retained in its high mannose form, identical between plants and 
mammals. Targeting proteins for secretion to the intercellular space beneath the cell 
wall (apoplast) has advantages for downstream processing and also leads to significant 
levels of expression. But in case of naturally secreted proteins, ER retention can give 
10-100 fold higher yields, presumably due to favourable molecular environment in the 
ER lumen and the presence of chaperones (Conrad and Fiedler 1998).  
Chapter I  Introduction 
9 
Optimization of expression by codon usage 
In plants, as in other eukaryotes, most synonymous codons of the genetic code are not 
used with equal frequency but instead some codons are preferred, whereas others are 
rare (van Hoof and Green 1997). Accordingly, the choice of codons has been suggested 
to influence the rate of translation and mRNA degradation. One possible mechanism by 
which rare codons can effect the rate of translation is that a ribosome may pause when 
encountering a rare codon, because it may take longer for a rare isoaccepting t-RNA to 
enter the A-site of the ribosome (Murray, Lotzer and Eberle 1989). A shortage of a 
specific charged tRNA in bacteria can cause the ribosome to pause at codons translated 
at that tRNA. As few as one (Hsu, Harms and Umbarger 1985) or two codons 
(Yanofsky 2000) for which little charged tRNA are available can cause ribosomal 
pausing in bacteria. Especially in cases were rare codons are present at the 5'-end of the 
mRNA or in clusters expression levels are low and truncated protein products are found 
(van Hoof and Green 1997). In addition, it became clear that the pattern of relative use 
of synonymous codons was shown to differ between the taxonomic groups, primarily in 
the use of G + C in the degenerate third base (Murray, Lotzer et al. 1989). Human genes 
for example possess a GC content of 52.5%, where genes of potato plants contain only 
42.9%, tobacco plants 43.5% and wheat plants 55.6%.  
Different technically complex strategies have been used to palliate these problems. The 
first is site directed mutagenesis studies to partially modify the coding sequence of the 
gene of interest. Insecticidal toxin genes from Bacillus thrungiensis (B.t) when 
expressed in plants without modification could only accumulate to minimal amounts 
(Koziel, Carozzi and Desai 1996). Codons that inhibit efficient plant gene expression 
were selectively removed throughout the coding sequence by site directed mutagenesis 
to partially modify the gene without changing the amino acid sequence (Perlak et al. 
1991). Among the most highly expressing tobacco and tomato plants, transgenic plants 
with the partially modified (3% nucleotide difference) cryIA(b) gene had a 10-fold 
higher level of insect control protein and plants with the fully modified (21% nucleotide 
difference) cryIA(b) had a 100-fold higher level of recombinant cryIA(b) insect control 
protein compared with the wild-type gene. The second approach is complete codon 
engineering by replacing codons that are rarely found in the plant genes with more 
favourable codons throughout the whole gene. The use of partially or fully modified 
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synthetic gene has the advantage to help solving all the problems resulting from 
inappropriate codon usage and from other factors that could interfere with efficient 
expression. Using this approach, a fully synthetic gene coding for the winter flounder 
antifreeze protein (AFP) in corn (Georges, Saleem and Cutler 1990) and porcine alpha-
lactalbumin gene in the kernels of transgenic maize (Yang et al. 2002) were expressed. 
However, in both of these studies a comparison for the expression level of the authentic 
and plant codon optimised gene was not carried. Adang et al. compared plant codon 
optimized cryIIIA delta-endotoxin gene of B.t. with native gene expression by 
electroporation of dicot (carrot) and monocot (corn) protoplasts. CryIIIA-specific RNA 
and protein was detected in carrot and corn protoplasts only after electroporation with 
the rebuilt gene (Adang et al. 1993). On the other hand, it was demonstrated that plant 
codon optimization of the human interleukin 4 gene for expression in tobacco plants did 
not improve the level of the optimized protein when compared to the authentic protein 
(Dr. Nicole Raven, Institut  für Biologie VII, personal communication). 
 
I.1.3 Plant Transformation  
Plant transformation involves the transfer of genetic information from the natural source 
of the desired protein into a suitable plant expression host.  The most common methods 
used are viral vectors (Porta and Lomonossoff 1996; Scholthof, Scholthof and Jackson 
1996; MacFarlane and Popovich 2000; Toth et al. 2001), biolistic transformation 
(Christou 1995; Drakakaki, Christou and Stöger 2000; Lepri et al. 2001), protoplast 
transformation (Fromm, Taylor and Walbot 1985; Terzaghi and Cashmore 1997; 
Newell 2000) and Agrobacterium mediated gene transfer (Horsch, Fry et al. 1985; 
Hansen, Shillito and Chilton 1997; Zupan et al. 2000; Zupan, Ward and Zambryski 
2002). 
Agroinfiltration 
In agroinfiltration, agrobacteria carrying the expression vector are delivered into leaf 
tissue by vacuum infiltration. Bacterial proteins then catalyse the transfer of the gene of 
interest into the host cells and protein expression can be detected 24 hours after 
infiltration. As in conventional methods for generating transgenic plants, genes of 
interest are cloned into binary vectors that are transferred into Agrobacterium strains. A 
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bacterial suspension is then used for vacuum infiltration of the leaves (Kapila et al. 
1996; Vaquero et al. 1999) and no selection method to identify transformed cells is 
required since the leaf tissue is only used for transient protein production. In 
agroinfiltration the transferred DNA does not integrate into the host chromosome but is 
present in the nucleus, where it is transcribed and this leads to transient expression of 
the gene of interest (Kapila, De Rycke et al. 1996). Agroinfiltration is rapid and yields 
sufficient quantities of protein for initial characterization of protein stability and 
function. A major advantage is that multiple genes present in different populations of 
agrobacteria can be simultaneously expressed. Thus the assembly of complex 
multimeric proteins can be tested in plants (Vaquero, Sack et al. 1999). A further 
advantage is that agroinfiltration can be scaled up to produce milligrams of recombinant 
protein and may be even more suitable for pre-clinical trials without the need for the 
production of stably transformed plants. 
Expression in stably transformed plants 
Initial structural and functional characterization of a recombinant protein can be 
performed by transient expression in leaves. However, when long-term production of 
complex molecules is anticipated, stable transformation is a prerequisite. Expression 
levels can be optimised in stable transgenic plants, where the quantity of recombinant 
protein obtained will only be ultimately limited by the harvested acreage. In addition 
accumulation levels in stably transformed plants increased in following progenies (T1 
and T2) (Zimmermann et al. 1998; Hood, Woodard and Horn 2002). There are two 
major disadvantages to the use of stably transformed plants. The first is the timescale 
and cost development, which reflects the need for greenhouse space in the several 
months required for regeneration of the primary transformants. The second is the fact 
that integrated nuclear transgenes are exquisitely sensitive to their chromatin 
environment, resulting in a highly variable transgene expression level. 
 
I.2 Production of therapeutic proteins in plants 
The production of recombinant proteins for therapeutic use in transgenic plants has 
become an alternative to the isolation of these molecules from natural or other 
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recombinant sources. Plant bioreactors may offer the possibility of an inexpensive 
large scale production of high volumes of recombinant proteins with increased safety 
concerning contaminations with human pathogens. 
Proteins derived from human plasma have become critically important therapeutic 
products since their introduction in the 1940s. In the last 20 years, the development in 
molecular biology has paved way for alternatives to the natural blood products. Today, 
transgenic plants have been generated that express proteins such as, interferon-2 and 4 
(Magnuson, Linzmaier et al. 1998), human α and β hemoglobin (Dieryck et al. 1997), 
human α-1-antitrypsin (AAT) (Terashima, Murai et al. 1999) and two of the most 
expensive drugs: glucocerebrosidase (Cramer, Boothe et al. 1999) and granulocyte
macrophage colony-stimulating factor (GM-CSF) (Lee et al. 1997; James, Wang et al. 
2000). 
Human α-1-antitrypsin (AAT), a protein of therapeutic potential in cystic fibrosis, liver 
disease, and haemorrhages is one of the most abundant human protease inhibitor found 
in the blood. Recently it was produced in rice suspension culture in a 5 L bioreactor 
with extracellular concentrations of 51 and 40 mg active rAAT/L within 1.7 and 2.5 
days respectively (Trexler, McDonald and Jackman 2002). Another protein for 
transgenic expression in plants is glucocerebrosidase. Gauchers disease is a recessively 
inherited lysosomal storage disorder resulting from deficiencies of lysosomal hydrolase 
glucocerebrosidase enzyme (Cramer, Boothe et al. 1999). A drug developed from 
enzyme purified from human placentas is highly effective in reducing clinical 
symptoms. However, 1012 tons/year of placentas are required to produce enough 
glucocerebrosidase for the average type I Gauchers patient, making it one of the 
worlds most expensive drugs (Giddings et al. 2000). Glucocerebrosidase production in 
transgenic tobacco was patented by Cramer and colleagues in 1999. Their studies 
strongly support the future commercial viability of transgenic plants for the production 
of glucocerebrosidase, and of other lysosomal enzymes, for enzyme replacement 
therapy. Another example for molecular farming of pharmaceutical protein in plants is 
hirudin, an anticoagulant used to treat thrombosis. It was originally isolated from the 
leech Hirudo medicinalis but is now mostly produced by recombinant bacteria and 
yeast. Thus far, oilseed rape, tobacco, and Ethiopian mustard have been engineered to 
produce hirudin, but purification from seed has proved to be expensive (Parmenter et al. 
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1995). The development of transgenic plants in which hirudin genes are fused to oleosin 
genes is likely to make purification easier and cheaper. The fusion construct is designed 
to contain an endoprotease recognition site between the two genes, enabling the 
eventual cleavage of the recombinant fusion protein and the recovery of the hirudin. 
Oleosinhirudin fusion proteins are isolated with oil bodies, from which they can be 
easily separated by flotation centrifugation. This method of purification ensures that 
hirudin in the plants only becomes active after harvesting, thus limiting environmental 
exposure. Oilseed rape transgenic for hirudin is now grown commercially in Canada by 
SemBioSys (Calgary, Canada) (Giddings, Allison et al. 2000).  
 
I.2.1 Human Serum Albumin 
Human serum albumin (HSA) is a non glycoprotein, one of the few secreted proteins 
which lacks carbohydrate and is the most abundant protein component of the blood 
plasma, the normal concentration being 42g/L (Peters 1985). It contributes 80% of the 
colloid osmotic pressure that provides the driving force to retain the fluid within blood 
vessels. In addition to the osmotic function, HSA provides a high-capacity reservoir to 
stabilize the concentration of free ligands (Kragh-Hansen 1990). 
The mature HSA is a 66.5 kDa single chain protein of 585 amino acids that is produced 
in the liver. The complete nucleotide sequence of HSA was published in 1982 
(Dugaiczyk, Law and Dennison 1982). The protein contains a total of 17 disulphide 
bridges which are positioned in a repeating series of five loop-link-loop structures 
centered around eight sequential Cys-Cys pairs. In addition, the protein has one thiol 
group and one single tryptophan. The high total charge, potentially about 185 ions per 
molecule at pH 7, aids its solubility and the many disulfide bonds, a feature of most 
extracellular proteins, contribute to its stability. The translation of the albumin RNA 
starts with a signal peptide of the type commonly found on proteins destined for 
secretion. It is synthesized in the liver as a precursor, preproalbumin (Dugaiczyk, Law 
et al. 1982). The 18 amino acid prepeptide, or signal sequence is apparently removed 
upon secretion of proalbumin, into the lumen of ER. The unusual feature of albumin 
biosynthesis is the occurrence of proalbumin, which carries the basic hexapeptide Arg-
Gly-Val-Phe-Arg-Arg at the amino terminus of the polypeptide chain. The propeptide 
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does not appear to effect ligand binding or other properties of albumin, and its purpose 
may be to guide the new polypeptide chain through the cytoplasm to the Golgi complex 
for proteolytic processing and secretion (Lawn et al. 1981). 
Currently human serum albumin (HSA) is prepared by fractionation of donated blood 
plasma and is used in plasmaphoresis, fluid replacement, the treatment of burns, 
traumatic shock, diuretic-resistant oedema and for some groups of surgical patients 
(Goodey 1993). 
The characteristic binding locations and chemistry for a selection or representative 
biological and pharmaceutical ligands for HSA were determined. The protein has been 
described as the major colloid that retains fluid in the vascular system, acting as a tramp 
streamer by dithering (a mixed cargo of metabolites around various organs (Kragh-
Hansen 1990). Of these, long chain fatty acids are quantitatively the most abundant, 
with the normal loading being approximately two fatty acids per molecule of albumin 
(Petitpas et al. 2001). HSA also binds bilirubin (Petersen et al. 2000; Weisiger et al. 
2001), amino acids, numerous drugs (Ozer and Tacal 2001; Petitpas et al. 2001) and 
heavy metals and is implicated in the transfer of many ligands across organ-circulatory 
interfaces such as liver, intestine, kidney and brain. The molecule has been succinctly 
described as the protein that makes blood thicker than water. 
 
Figure I.2 The 3 dimensional structure of HSA. The amino terminus of the molecule is on 
the right. Two of the homologous domains form a compact structure on the right; IA, IB, IIA 
and IIB. The third domain is more extended, from top left to the bottom of the structure (IIIA 
and IIIB).  
Carter and co-workers reported the first crystal structure of HSA at low resolution in 
1990 (Carter and He 1990) and its redefined structure was published by the same group 
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(He and Carter 1992) (Figure 1.2). The structure composed of three domains I, II and 
III, which confer to the protein a heart shaped molecule. Each domain is a product of 
two subdomains that possess common structural motifs. The principal regions of ligand 
binding to human serum albumin are located in hydrophobic cavities in subdomains IIA 
and IIIA, which exhibit similar chemistry. The subdomains share a number of common 
features, such as the hydrophobic face, the cluster of basic amino acid residues, and 
proline residues at the tips of the long loops. However, it is known that each subdomain 
is also unique and probably exhibits a certain degree of binding specificity (Gelamo et 
al. 2002). More recently a new triclinic crystal form of native or Pichia pastoris 
expressed recombinant HSA (rHSA) was obtained at the highest resolution level (2.5 Å) 
reported so far (Sugio et al. 1999). The structures of pool plasma HSA (pHSA) and 
rHSA have a root mean square (r.m.s) deviation of 0.24 °A over all C-alpha atoms, 
which implies that two of the proteins are virtually identical. 
 
I.2.2 Recombinant HSA expression 
HSA is the most abundant protein in human plasma involved in the maintenance of a 
normal osmolarity and also in the transport of hydrophobic molecules. This protein has 
a big market requirement in that it can be used as replacement fluid during septic or 
traumatic shock, to compensate for blood loss, and to treat burn victims. At present, 
HSA is largely produced (300 tons/year) by conventional techniques involving 
fractionation of plasma obtained from blood donors (Saliola et al. 1999). It would be a 
great advantage to be able to use genetic engineering to obtain rHSA in good yield and 
at lower cost, with no danger of contamination by human pathogens. For this reason, 
great efforts have been dedicated to the production of this protein on a large scale by 
transgenic organisms. To date, expression of rHSA has been studied in E.coli, (Lawn, 
Adelman et al. 1981; Latta et al. 1990) Bacillus subtilis (Saunders et al. 1987), 
Saccharomyces  cerevisiae (Quirk et al. 1989; Sleep, Belfield and Goodey 1990; 
Okabayashi et al. 1991; Kang et al. 2000), Kluyveromyces lactis (Saliola, Mazzoni et al. 
1999), Pichia pastoris (Ohi et al. 1998; Ohtani et al. 1998) and potato (Solanum 
tuberosum) (Sijmons et al. 1990; Farran et al. 2002). (Table I.1). 
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Table I.1 Recombinant HSA expression in different heterologous organisms. Expression 
level in the table represents the highest level of rHSA produced in this host organism. 
Organism Expression level Reference 
Escherichia coli 7% of total bacterial protein (Latta, Philit et al. 1990) 
Saccharomyces  cerevisiae  85 mg/L (Okabayashi, Nakagawa et al. 1991) 
Pichia pastoris 270 mg/L (Ohtani, Nawa et al. 1998) 
Kluyveromyces lactis  1 g/L (Saliola, Mazzoni et al. 1999) 
Solanum tuberosum 0.2% of total soluble protein (Farran, Sanchez-Serrano et al. 2002) 
 
Since rHSA has to be priced competitively to make any impact on the HSA market, 
production costs must be kept to an absolute minimum. Therefore, any production 
process involving the use of expensive media of the type used in mammalian cell 
culture is effectively excluded from consideration. Another constraint is the high 
number of disulfide bridges and the size of the protein (66.5 kDA), which in terms of 
heterologous expression considered to be large. Attempts to produce large quantities of 
such proteins in an intracellular form in recombinant organisms often results in the 
accumulation of the protein in an insoluble denatured form in inclusion bodies. In such 
cases the disulfide bonds are usually formed incorrectly or not at all.  
rHSA has been expressed as insoluble aggregates in the cytoplasm of E.coli (Lawn, 
Adelman et al. 1981). However, there are distinct disadvantages in producing HSA in 
E.coli. For example, conversion of the insoluble product to the soluble form, which is 
frequently inefficient in vitro, is both time-consuming and expensive. Besides, HSA 
derived from E.coli may be contaminated by endotoxin, which causes an adverse 
reaction in patients (Okabayashi, Nakagawa et al. 1991). Therefore an early decision 
was to secrete the protein. The key advantages of such a route are that the secreted 
protein is, by definition, soluble and will not require disruption of the host organism 
prior to protein purification (Goodey 1993). Saunders and his co-workers have studied 
the secretion of rHSA from Bacillus subtilis using bacterial signal sequences (Saunders, 
Schmidt et al. 1987). It was found that the efficiency of processing of the leader 
peptides is inversely correlated with the productivity.  
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One problem with rHSA accumulation that has been observed is that a proportion of the 
secreted rHSA molecules are shorter than the full-length protein, the nature and amount 
of these truncated molecules vary according to the producer organism, growth regime 
leader sequence adopted (Sleep, Belfield et al. 1990). These molecules may be the result 
of proteolytic degradation of the full-length protein or incomplete translation of the 
mRNA. Saccharomyces cerevisiae has long been known to secrete few or no 
extracellular proteases, however investigations carried out in recent years have begun to 
reveal that extracellular proteolysis represents one of the most significant barriers to the 
secretory production of heterologous proteins in this host organism. For example, the 
main problem in the production of rHSA in S. cerevisiae was found to be the 
extracellular proteolytic cleavage of the recombinant protein during prolonged culture 
(Kang, Choi et al. 2000). In another study, rHSA expressed in the yeast S. cerevisiae 
accumulated in the insoluble fraction in a denatured form (Quirk, Geisow et al. 1989). 
Extraction of the product requires cell breakage, solubilization, reduction and 
renaturation prior to purification (Goodey 1993). Such downstream processing would 
not be practical at the scale envisaged for rHSA and would certainly not be cost 
effective.  
It was reported that the electrophoretic karyotype of S. cerevisiae may not necessarily 
be stable. For example, during serial cultivation of S. cerevisiae wild strain, 
modifications of electrophoretic karyotype were observed at 55 generations (Longo and 
Vezinhet 1993). Pichia pastoris is frequently used as an efficient host for heterologous 
gene expression, the high stability of chromosomal DNA in large-scale fermentation is 
required for stable production, especially for pharmaceutical products. From this point 
of view, the gene stability of a P. pastoris recombinant strain expressing rHSA after 
long-term serial cultivation under the conditions of vegetative and non- selective growth 
was investigated (Ohi, Okazaki et al. 1998). Isolates from 83 generations showed HSA 
production, suggesting that elimination of HSA expression constructs hardly occurred 
during serial cultivation. In addition, the cells of each generation produced the almost 
same amount of HSA, approximately 110 µg/ml. Thus, P. pastoris was found to have 
superior gene stability; therefore, it is regarded as a suitable host for heterologous gene 
expression even on an industrial scale. 
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Kluyveromyces lactis is another promising organism that can be used as an alternative 
host due to its good secretory properties. Under the control of the KlADH4 promoter K. 
lactis cells grow in complex and defined media resulting in a high biomass production 
(70 to 80 g dry-cell weight/L), and a significant amount of rHSA production was 
observed in fed-batch cultures (1 g/L) when compared to batch cultures (0.2 to 0.3 g/L) 
(Saliola, Mazzoni et al. 1999). 
Sijmons et al. (1990) have shown that rHSA can be produced in leaves of transgenic 
tobacco and potato and tobacco suspension cells. The transgenic constructs contained 
either the authentic HSA signal peptide or a preseqeunce from the extracellular PR-S 
protein from tobacco fused to the coding region of HSA. The secreted protein was either 
isolated from leaf tissue or from plant cell suspension cultures. Chromatographically 
purified rHSA was analysed by N-terminal amino acid sequencing. The recombinant 
protein containing the human signal peptide was not correctly processed, while the 
construct with the plant specific prepropeptide allowed the production of correctly 
cleaved rHSA in transgenic plants, and transgenic tobacco suspension cell lines. Plant 
specific signal sequence facilitates secretion of 0.25µg rHSA/mg protein into the culture 
medium. However, expression levels were, too low for most commercial applications 
being 0.02% of the total soluble protein in shoot and young leaves, and five times lower 
in roots and tubers.  
Recently Farran and his co-workers studied expression of rHSA in tubers of transgenic 
potato plants (Farran, Sanchez-Serrano et al. 2002). HSA gene was cloned under the 
B33 promoter of patatin (a specific tuber promoter). The rHSA amino terminal was 
fused to a tuber signal peptide (protease inhibitor II) and Agrobacterium mediated gene 
transfer to potato leaves was performed. rHSA was detected in the tubers of transgenic 
potato plants, the highest accumulation level reaching to 0.2% of the tuber soluble 
protein. This higher level than the previous report by Sijmons et al. (1990) was 
attributed to the differences in the expression cassettes used for transformation.  
 
I.4 Aim of the Study 
Plant molecular biotechnology is receiving increasing attention because it is a source for 
innovation for the agriculture, food, chemical and pharmaceutical industry. Besides 
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genetic engineering is conventionally used for transferring beneficial traits to plant, a 
recent emerging field is the production of recombinant proteins in plants. The increasing 
demand for pharmaceutically safe and active human proteins can no longer be met by 
merely purifying from original sources as the supply of human blood, placenta or other 
tissues and organs as starting material for the purification of proteins is limited. In 
addition, several examples have shown in the past that the extraction of proteins from 
human tissue is not free of risk of contamination with pathogens such as HIV, Hepatitis 
B virus or prions and thus may lead to the transmission of infectious diseases to the 
treated patients. In the future, demand for existing biopharmaceuticals (e.g., 
erythropoietin, insulin and human serum albumin), as well as new therapeutic proteins 
discovered through genomics, is expected to rise considerably. Therefore, it is prudent 
to evaluate alternative transgenic production systems and determine how the future 
availability of safe recombinant biopharmaceuticals can be ensured in a cost-effective 
manner. Plants as bioreactor offer the possibility of an inexpensive large-scale 
production of high volumes of recombinant proteins with increased safety concerning 
contaminations with human pathogens. Due to increasing demand on albumin, 
alternative ways to obtain HSA is highly attractive both to decrease the dependence on 
blood banks and to reduce possible health hazards, such as AIDS, hepatitis that may be 
transmitted during infusion of contaminated blood derived products.  
The primary task of this thesis was the establishment of an expression system for the 
production of rHSA that is used in fluid replacement, the treatment of burns, traumatic 
shock and for some groups of surgical patients. Aim of this study will be achieved by 
the following approaches: 
⇒ Plant codon optimization: Since codon usage pattern of human proteins does not 
match the pattern found in plants, HSA needs to be codon optimised for optimal 
expression in the foreign host. A new strategy will be developed for the assembly of a 
semi-synthetic plant codon optimised HSA using PCR.  
⇒ Expression of rHSA in different organisms: In order to evaluate different expression 
systems in terms of their efficiencies for molecular farming purposes, rHSA will be 
expressed in bacteria, tobacco, wheat plants and tobacco suspension cells. Protein 
accumulation endoplasmic reticulum (ER) using a KDEL retention signal.  
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⇒ Purification of rHSA from transgenic tobacco leaves: An efficient purification 
method will be needed to establish an efficient protocol in order to obtain better or equal 
to the quality of the existing HSA obtained by blood fractionation.   
A schematic overview of the thesis is presented in Figure I.3. 
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Amplification of HSA from cDNA
Cloning of HSA into plant
expression vector pSSH1
Transient expression of
rHSA in different
plant cell compartments
Generation of stable
transformed plants
expressing rHSA
Cloning of rHSA into
bacterial expression vectors
Expression of rHSA and
rHSA-DT in E.coli
Analysis of accumulation
levels
(ELISA and Immunoblot)
Expression of rHSA
in the field
Analysis of
accumulation levels
Establisment of callus
and cell suspension
cultures
Fermentation of
trasgenic tobacco
suspension cells
Purification of rHSA
Cloning of HSA-DT
into bacterial
expression vectors
Fusion of designer tail
to HSA 3' end
 
Figure I.3 Schematic presentation of the thesis work packages. 
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II Materials and Methods 
II.1 Materials  
II.1.1 Chemicals and consumables  
Laboratory chemicals used throughout the work were purchased from the following 
companies: Bio-Rad (München), Boehringer (Mannheim), Fluka (Neu-Ulm), Gibco 
BRL (Eggenstein), ICN (Eschwege), Merck (Darmstadt), MWG-Biotech (Ebersberg), 
Pharmacia (Freiburg), Pierce (Rockford, IL, USA), Roche (Mannheim), Roth 
(Karlsruhe), Serva (Heidelberg), Sigma (Deisenhofen). The consumables were 
purchased from: Biozym (Hess, Oldendorf), Eppendorf (München), Greiner (Solingen), 
Kodak (Stuttgart), Millipore (Eschborn), Nunc (Biebrich), Roth (Karlsruhe), Schott 
Glaswerke (Mainz), Serva (Heidelberg), USB/Amersham (Braunschweig), Whatman 
(Bender & Hobeim, Bruchsal) and Zeiss (Oberkochen).  
II.1.2 Enzymes and reaction kits 
Restriction enzymes either from New England Biolabs (Schwalbach) or Gibco BRL 
were used for DNA digestion. ExpandTM high fidelity DNA Taq polymerase from 
Boehringer Mannheim was used for PCR amplification (II.2.3.6). DNA Taq polymerase 
from Gibco BRL was used for identification of recombinant bacteria by PCR 
(II.2.3.6.1). 
The following kits were used: 
QIAprep spin Miniprep kit    Qiagen (Hilden)  
QIAquick gel extraction kit    Qiagen 
QIAquick PCR purification kit   Qiagen 
QIAquick plasmid Midi kit    Qiagen 
QIAquick plasmid Maxi kit    Qiagen 
Thermosequenase Cycle Sequencing Kit  USB/Amersham (Braunschweig) 
PCR 2.1 TOPO Cloning Kit    Invitrogen 
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II.1.3 Media stock solutions and buffers 
All buffers, media and solutions were prepared according to standard protocols, as 
described (Sambrook, Fritsch and Maniatis 1996; Coligan, Kruisbeek and Margulies 
1998) except special buffers listed at the end of the corresponding method description. 
Heat-sensitive additives, such as antibiotics, were prepared as stock solutions, filter-
sterilized (pore size; 0.2µm) and added to the medium after cooling to 50°C. Plant cell 
culture media and chromatography buffers were prepared with ultra pure water. 
 
II.1.4 Antibodies and substrates 
Mouse anti-human serum albumin (HSA) monoclonal antibody (Sigma) was used as the 
primary antibody and alkaline phosphatase (AP) conjugated goat anti-mouse IgG (H+L) 
(Jackson ImmunoResearch, West Grove, PA, USA; distributor: Dianova, Hamburg) as 
secondary antibody for detection of HSA by immunoblot (II.4.8). AP conjugated rabbit 
anti chicken (Fc) (Dianova, Hamburg) as primary antibodies and pNPP (Sigma) as 
substrate tablets were used in the titer determination of polyclonal antibodies from 
chicken egg yolk (II.4.9.1). Polyclonal affinity purified goat-anti-HSA antibody 
(NatuTec, Frankfurt) was used for coating of ELISA plates (II.4.9.2). Peroxidase 
conjugated IgG fraction of rabbit anti-HSA antibody (Rockland, USA) was used as the 
primary antibody. For detection of peroxidase, ABTS substrate tablets and buffer were 
purchased from Boehringer Mannheim. 
 
II.1.5 Plasmid Vectors 
II.1.5.1 pHSA36 and pHSA206 
Human serum albumin cDNA that was obtained from in vitro translation of human liver 
mRNA was cloned into two pBR322 plasmid vectors; (Dugaiczyk, Law et al. 1982) 
pHSA36 and pHSA206. These two plasmids share 0.15 kilo base of homologous DNA. 
Together they encode the entire sequence of HSA, starting with the CTT codon for Leu 
at position 10 of the prepeptide and extending into the 3 untranslated region of polyA. 
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Plasmids pHSA36 and pHSA206 were a kind gift from Prof. Dr. Kreuzaler (RWTH 
Aachen, Institute for Biology I). 
II.1.5.2 PCR 2.1-TOPO  
PCR 2.1-TOPO (Invitrogen) has a size of 3.9 kb and contains ampicillin and kanamycin 
resistance markers, lacZ reporter gene, T7 promoter, EcoRI sites flanking the PCR 
insertion site, and the f1 origin of replication. The vector has been engineered to be a 
linearized plasmid with 3' deoxythymidine (T) overhangs that is activated by being 
covalently bonded to topoisomerase I.  The 3' A overhangs of the PCR product 
complement the 3' T overhangs of the vector and allow for fast ligation with the already 
present topoisomerase I. PCR 2.1-TOPO was used for cloning the plant codon 
optimised HSA after SOE PCR amplification.   
II.1.5.3 pGEM-3(zf)+ 
pGEM-3(zf)+ (Promega, GenBank: X65306) has a size of 3.2 kb and contains the origin 
of replication of the filamentous phage f1. The pGEM-3Zf(+) vector contains SP6 and 
T7 RNA polymerase promoters flanking a region of multiple cloning sites within the 
alpha-peptide coding region of beta-galactosidase. pGEM-3zf was used for cloning and 
amplification of foreign DNA in E.coli and thereby functioned as an intermediate vector 
before cloning the plant expression cassettes into plant expression vector pSSH1 (Voss, 
Niersbach et al. 1995). 
II.1.5.4 pUC18 
For cloning and amplification of foreign DNA in E.coli high copy number pUC18 
vector was used (Yanisch-Perron, Vieira and Messing 1985). pUC18 is a derivative of 
pBR322 vector with a size of 2.7 kb. The plasmid encodes resistance to ampicillin and 
has a multiple cloning site within the lacZ alpha-fragment. Inserts cloned into this site 
disrupt beta galactosidase activity and resulting in white colonies on X-Gal/IPTG plates.  
II.1.5.5 pET 21d(+) 
The pET21a(+) vector (Novagen, Madison WI, USA) has a size of 5.4 kb and contains 
the origin of replication of the filamentous phage f1. It carries T7 promoter plus a C-
terminal his tag sequence with ampicillin resistance gene as a selectable marker. 
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pET21a(+) was used for the expression of human serum albumin (HSA) in the 
cytoplasm of E. coli and his tag sequence allowed the purification of the recombinant 
protein via immobilized metal affinity chromatography (II.6.1).  
II.1.5.6 pET 22b(+) 
The pET22b(+) vector (Novagen) has a size of 5.5 kB and contains the origin of 
replication of the filamentous phage f1. It carries a T7 promoter an N-terminal pelB 
signal sequence for periplasmic localization, plus C-terminal his tag sequence with 
ampicillin resistance gene as a selectable marker. pET22b(+) was used for the 
periplasmic expression of HSA and his tag sequence allowed the purification of the 
recombinant protein via immobilized metal affinity chromatography (II.6.1). 
II.1.5.7 pSSH1 
For transformation of Agrobacterium tumefaciens and transient and stable expression of 
rHSA in plants, plant expression vector pSSH1 (Voss, Niersbach et al. 1995) was 
utilized. Vector pSSH1 (10.3 kB, AmpR, CarbR and KmR) is a derivative of the binary 
vector pPCV002 (Koncz and Schell 1986)and contains the Cauliflower Mosaic Virus 
(CaMV35S) expression cassette from pRT101 (Töpfer et al. 1988)with a duplicated 35S 
enhancer region (Kay et al. 1987) and the termination and polyadenylation signal of the 
CaMV35S.  
II.1.5.8 pAL76 
For particle bombardment of wheat, plant expression vector pAL76 was used. It 
contains the ubiquitin 1 promoter and intron 1 from maize (Christensen and Quail 
1996)and the nos terminator. Vector pAL76 was a kindly provided by Dr. Eva Stöger 
(RWTH Aachen, Institute for Biology VII).  
Chapter II  Material and Methods  
26 
II.1.6 Oligonucleotides  
All primers used in this study were synthesized and HPLC purified by MWG-Biotech. 
Stock solutions of 100 pmol in autoclaved and filter sterilized (0.2µm) bidestilled water 
was prepared and stored at -20°C.  
• Primers used for SOE-PCR to combine two overlapping HSA cDNA 
fragments derived from the recombinant plasmids pHSA36 and pHSA206 
(III.1). 
HSAforwardnew: 5- GGC GAA TTC CAT GGA TGC ACA CAA GAG TGA GGT 
TGC-3 (36 mer) 
HSAbackward: 5-GCG AAG CTT GTC GAC TAA GCC TAA GGC AGC TTG 
ACT TG-3 (38 mer) 
SOE-HSA-For: 5-GCC AGA AGA CAT CCT TAC TTT TAT GCC CCG-3 (30 
mer) 
SOE-HSA-Back: 5-CGG GGC ATA AAA GTA AGG ATG TCT TCT GGC-3 (30 
mer) 
• Primers used for DNA sequencing (II.2.3.7). Primers were labelled at the 
5end with IRD 700 or IRD 800. 
Universe: 5-GTT GTA AAA CGA CGG CCA GT-3 (20 mer) 
Reverse: 5-ACA CAG GAA ACA GCT ATG AC-3 (20 mer) 
PSS 5: 5-ATC CTT CGC AAG ACC CTT CCT CT-3 (23 mer) 
PSS 3: 5-AGA GAG AGA TAG ATT TGT AGA GA-3 (23 mer) 
HSAseqf1: 5- GAC TCA AAT GTG CCA GTC TCC- 3(21 mer) 
HSAseqf2: 5 GTT ACA CCA AGA AAG TAC CCC AAG- 3 (24 mer) 
HSAseqb1: 5- GGT GTA ACG AAC TAA TAG CG-3 (20 mer) 
HSAseqb2: 5- GGC ACA TTT GAG TCT CTG TTT GG-3 (23 mer) 
Modseqf1: 5- AGG CTT CCT CTG CCA AAC AGA GG-3 (23 mer) 
Modseqb1: 5- TTG AGC CTC TGT TTG GCA GAG G-3 (22 mer) 
Modseqf2: 5- ACC TCT TGT GGA AGA GCC TCA G-3 (22 mer) 
Modseqb2: 5- CTG AGG CTC TTC CAC AAG AGG-3 (21 mer) 
• Primers used for SOE-PCR to optimize codon usage of HSA cDNA (III.2) 
In order to amplify plant codon optimised HSA via SOE PCR, 27- 83 nucleotides long 
32 different primers were used as the building blocks. HSAmod1-16 as forward primers 
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and HSAmod7-32 as backward primers were used in the reaction mix. Forward and 
backward primers have complementary sequences differing in length of 21-24 
nucleotides. Sequences of HSAmod1- HSAmod32 are listed in the (VIII.2). 
 
II.1.7 Biological Materials 
II.1.7.1 Escherichia coli strains  
Throughout this work, the following E.coli strains were used as recipient of foreign 
DNA for the propagation and isolation of plasmid DNA and for protein expression. 
Strain Source Genotype 
DH5α 
 
(Ausubel, Brent and 
Kingston 1994) 
endA1hsdR17(rk-mk+)supE44thi-IrecA 
1gyrA(Nalr) relA1D (lacIZYA-argF) U169 
deoR  (phi80dlacD(lacZ)M15) 
BL21(DE3) Stratagene F ompT gal [dcm] (Adang, Brody et al.) 
hsdSB (rB mB; an E. coli B strain) with 
DE3, a λ prophage carrying the T7 RNA 
polymerase gene 
 
II.1.7.2 Agrobacterium tumefaciens  
Agrobacterium tumefaciens strain GV3101 carrying the helper plasmid pMP90RK 
(GMR, KMR, RifR) (Koncz and Schell 1986) was used for Agrobacterium-mediated 
gene transfer. 
II.1.7.3 Plants 
N. tabacum L. cv. Petite Havana SR1, Badische Geudertheimer K.31, Virginia ITP, 
Adonis Schwester, Barley Jupiter, Barley Saturn, Korso, Nicotine free tobacco (NFT) 
51 and Maryland Mammoth were used for transient expression by agrobacterial vacuum 
infiltration (II.2.2.5). Petite Havana SR1 plants were also used for the generation of 
stably transformed plants (II.2.2.6).  
N. tabacum L. cv. Bright Yellow 2 (BY-2) suspension cells were used for stable 
expression of recombinant HSA (II.2.2.4). 
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Zucchini, Cucurbita maxima cv. Diamant 103 and bean, Phaseolus vulgaris cv. Marona 
were used for transient expression of rHSA by agrobacterial vacuum infiltration 
(II.2.2.5). 
II.1.7.4 Animals 
Polyclonal IgY-antisera were raised in adult, female, brown Leghorn-chicken under 
approval of the Regierungspräsidium des Landes NRW (RP-Nr.: 23.203.2 AC 12, 
21/95). 
 
II.1.8 Chromatograhpy columns matrix and membranes 
ImmobilonTM-P transfer membrane (PVDF) (0.45µm) from Millipore, HybondTM-C 
nitrocellulose membrane (0.45µm) from Amersham Life Science (Braunschweig, 
Germany) and Whatman no.1 paper from Whatman were used in the analysis. 1.4 ml of 
Source 30S matrix (Pharmacia) as cation exchange medium in BioCart5 column 
(Kronlab, Sinsheim) was utilized for ion exchange chromatography. 
 
II.1.9 Equipment 
1. Cameras: MP4 (Polaroid, Cambridge, MA, USA). E.A.S.Y 429K camera (Herolab, 
Wiesloch). 
2. Centrifuges: AvantiTM 30 and AvantiTMJ-25 (Beckman, California, USA), Biofuge 
A (Heraeus, Hanau), Sigma 3-10 and Sigma 4-10 (Sigma, St. Louis, Missouri, 
USA), RC5C and RC5B plus (Sorval instruments, Du Pont, Bad Homburg). Rotors: 
F0650, F2402H, JLA 10.500 and JA 25.50 (Beckman), #1140 and #11222 (Sigma), 
RLA-300, SS-34 and GS-3 (Du Pont). 
3. Chromatography equipment: ÄKTA explorer 10xT (Pharmacia) or an Äkta Purifier 
100 chromatography system (Pharmacia) with cation exchange columns, evaluation 
and documentation software (Pharmacia).  
4. DNA gel electrophoresis apparatus: wide mini and mini cells for DNA agarose 
electrophoresis (BioRad, München) and power supplies (BioRad). 
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5. DNA-sequencing machine: LI-COR IR2-4200 Sequencer (LI-COR, Bad Homburg) 
and Base ImageIRTM 4.0 software (LI-COR). 
6. Electroporation apparatus: Gene pulserTM, Pulse controller unit, Extender unit 
(BioRad) and 0.2 cm or 0.4 cm cuvettes (BioRad). 
7. InnovaTM 4340 incubator shaker (New Brunswick scientific, Nürtingen). 
8. PCR Thermocyclers: Primus and Primus 96 plus (MWG Biotech). 
9. Photometers: Spectrophotometer Uvikon 930 (Kontron, Neufahrn) and Cuvettes # 
67.742 (Sarstedt, Nürnbrecht), multi-channel spectrophotometer Spectromax 340 
(Molecular Devices, Sunnyvale, California).  
10. Probe sonicator (Braun, Melsungen). 
11. Protein gel electrophoresis equipment: Mini PROTEAN IITM from BioRad. Phast 
system: separation and control unit and the development unit for Phast protein gels 
(Pharmacia). Gel Air Dryer (BioRad). 
12. BioRad Protean IEF cell. 
13. UV-Transilluminators: wavelength 302nm and UVT-20M (Herolab). UV-chamber 
(Bio-Rad). 
14. BioRad He2000 particle bombardment system. 
15. Biobench 7, Applikon, Schiedam, The Netherlands. 
16. Shaker: Innova 4430 (New Brunswick Scientific GmbH, Nürtingen). 
17. Microwave: Micromat (AEG, Frankfurt). 
18. Incubator: WTB binder (Tutlingen, Germany). 
19. Balance: Sartorius BP 610, 1202 MP and BP 121 S (Santorius, Göttingen). 
20. Vortex: K-550-GE (Bender and Hobein AG, Zürich). 
21. Vacuum exicator (Glasswerk Wertheim). 
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II.2 Molecular Biology Methods 
All work with recombinant DNA and genetically modified organisms was performed in 
accordance with S1 safety regulations and was approved by the 
Regierungspräsidium des Landes NRW [(AZ 521-K-1-8/98: AI3-04/1/0866/88 (S1) 
and 55.8867/-4/93 (greenhouses)].  
II.2.1 Transformation, selection and characterisation of 
recombinant bacteria 
II.2.1.1 Growth and maintenance of Escherichia coli 
E. coli cells were grown at 37°C either in LB (amp) medium in a shaker incubator at 
225 rpm, or on agar-solidified 1.5% (w/v) LB plates. For long-term storage, 600µL of 
an overnight (o/n) liquid culture was mixed with an equal volume of 40% (v/v) glycerol 
and stored at 80°C°. 
LB medium   
Peptone  1 % (w/v) 
Yeast extract  0.5 % (w/v) 
NaCl  0.5% (w/v) 
  pH 7.4 
LB (amp) medium; LB medium +100 µg/ml Ampicillin. 
 
II.2.1.2 Growth and maintenance of Agrobacterium tumefaciens 
A. tumefaciens cells were grown in YEB medium after adding 100µg/ml rifampicin and 
25µg/ml kanamycin at 28°C in a shaker incubator at 200 rpm. For selection of 
recombinant bacteria 100µg/ml carbenicillin was added to the growth medium. For 
long-term storage 600µL of an o/n liquid culture was mixed with an equal volume of 
glycerol stock media (GSM) and stored at 80°C°. 
YEB medium  
Nutrient broth or beef extract 0.5% (w/v) 
Yeast extract 0.1% (w/v) 
Peptone 0.5% (w/v) 
Sucrose 0.5% (w/v) 
 pH 7.4 
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2 mM MgSO4, 25µg/ml kanamycin, 100µg/ml rifampicin and 100µg/ml carbenicillin 
were added after autoclaving and cooling. 
GSM  
Glycerol 50% (v/v) 
MgSO4 100 mM 
Tris-HCl 25 mM 
 pH 7.4 
 
II.2.1.3 Preparation of competent E. coli cells for heat-shock 
transformation 
E. coli strain DH5α competent cells were prepared for RbCl2-mediated heat shock 
transformation. A single bacterial colony was inoculated in 5 ml of LB broth and 
cultured at 37°C o/n. 0.5 ml of fresh o/n culture was transferred into 100 ml of LB 
broth. The cells were cultured at 37°C for 3-4 hours until the OD600nm reached 0.4-0.5 
and then transferred to an ice-cold tube. After placing on ice for 10 min, the cells were 
recovered by centrifugation (2,000g/4°C/10 min). The pellets were gently dissolved in 
30 ml ice-cold TfB-I solution and stored on ice for 10 min. The cells were recovered by 
centrifugation as described above and resuspended in 4 ml ice-cold TfB-II. 200 µl-
aliquots of the suspension were dispensed into prechilled eppendorf tubes, frozen 
immediately in liquid nitrogen and stored at -80°C. 
  TfB-I  TfB-II 
RBCl  100 mM  10 mM 
MnCl2  75 mM  - 
CaCl2  10 mM  75 mM 
LiCl  0.5 mM  - 
K acetate  35 mM  - 
glycerol  15% v/v)  15 % (v/v) 
MOPS  -  10 mM 
  pH 5.8  pH 6.8 
 
II.2.1.4 Transformation of E. coli by heat-shock 
As soon as the competent cells (II.2.1.3) were thawed, plasmid DNA (II.2.3.1) or 
ligation products (II.2.3.5) were diluted 1:5 in sterile dH2O and mixed gently with the 
competent cells then stored on ice for 30 min. The cells were incubated for 90 seconds 
at 42°C and placed on ice for 2 min. 800 µl of SOC medium were added to the 
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eppendorf tubes and transformed cells were incubated at 37°C for 45 min. 200 µl of 
cells were plated onto a LB-agar plate supplemented with appropriate antibiotics and 
incubated at 37°C overnight. 
SOC medium   
Bacto tryptone 1% (w/v)
Yeast extract 0.5% (w/v)  
NaCl 10 mM  
KCl 2.5 mM  
autoclaved and added;   
sterile MgCl2 1 M 10 ml 
sterile MgSO4 1 M 10 ml 
sterile glucose 1 M 20 ml 
filled up to 1 L and filter sterilized.   
 
II.2.1.5 Preparation of competent E. coli cells for electroporation 
E. coli strain DH5α or BL21λDE3 competent cells were prepared for electroporation as 
described (Dower, Miller and Ragsdale 1988). Briefly, a single colony was cultured in 
LB-broth at 37°C until the mid-log phase (OD600nm = 0.5-0.8); the cells were placed on 
ice and harvested by centrifugation (3,000g/4°C/10 min). Cells were washed three times 
with sterile water and suspended in ice-cold 10% (v/v) glycerol to a 300-fold 
concentration from the original culture volume (at >1010 cells/ml). 40 µl aliquots were 
stored at -80°C. 
 
II.2.1.6 Transformation of E. coli by electroporation 
Electrocompetent cells (II.2.1.5) were thawed on ice and 40 µl of the cells were mixed 
with   1 pg to 300 ng of DNA in sterile dH2O. The cell/DNA mixture was transferred 
into a prechilled electroporation cuvette (0.2 cm) and assembled into a safety chamber. 
After application of the pulse (25 µF, 2.5 kV, 200 Ω), the cells were diluted in 1 ml of 
SOC medium and incubated at 37°C with shaking for 1 h. Finally; 50-200 µl of the cells 
were plated onto LB-agar containing appropriate antibiotics and incubated at 37°C o/n. 
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II.2.1.7 Preparation of competent A. tumefaciens cells for electroporation 
A single colony of A. tumefaciens grown on a YEB-agar containing 100µg/ml 
rifampicin (Rif) and 25 µg/ml kanamycin (Km) (YEB-Rif-Km) was inoculated in 5 ml 
of YEB-Rif-Km medium in a 100 ml Erlenmeyer flask and incubated at 28°C for two 
days with shaking (250 rpm). One ml of the culture was transferred into 100 ml of 
YEB-Rif-Km medium and cultivated at 28°C for 15-20 h with shaking (250 rpm) until 
the OD660 reached 1-1.5. The cells were chilled on ice for 15 min and spun down by 
centrifugation (4,000g/4°C/5 min). The culture medium was decanted and the cells were 
washed three times with 10 ml of dH2O by centrifugation and resuspended in 500 µl of 
sterile 10% (v/v) glycerol. 45 µl-aliquots of the suspension were dispensed into 
prechilled eppendorf tubes, frozen immediately in liquid nitrogen and stored at -80°C. 
 
II.2.1.8 Transformation of Agrobacterium tumefaciens by electroporation 
0.2-1.0 µg of plasmid DNA (II.2.3.1) in sterile dH2O was added to a thawed aliquot of          
A. tumefaciens electrocompetent cells (II.2.1.7) and placed on ice for 3 min. The 
cell/DNA mixture was transferred into a prechilled electroporation cuvette (0.2 cm) and 
assembled into a safety chamber. After application of the pulse (25 µF, 2.5 kV, 200 Ω), 
the cells were diluted in 1 ml of YEB medium in a 4.0-ml tube and incubated at 28°C 
with shaking (250 rpm) for 1 h. Finally, 50-100 µl of the cells were plated on YEB-agar 
containing 100µg/ml rifampicin (rif), 25µg/ml kanamycin (Km) and 100µg/ml 
carbenicillin (carb) (YEB-Rif-Km-Carb) and incubated at 28°C for 2-3 days. As a 
negative control, dH2O was used to transform competent Agrobacterium cells. 
 
II.2.2 Transformation of plants and suspension cultures 
II.2.2.1 Growth and maintenance of Nicotiana tabacum 
Tobacco plants were grown in a greenhouse in ED73 standard soil  (Patzer, Sinntal-
Jossa) with 0-30% (v/v) sand under supplementary illumination of 10 000 Lux (plus the 
sun light), 70-90% humidity and 16h photoperiod) at 24°C (or higher depending on the 
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outside temperature). To prevent pollination from other plants, flowers were covered 
with plastic bags with micro pores. Mature, dried seeds were stored in paper bags at RT. 
 
II.2.2.2 Growth and maintenance of Nicotiana tabacum cv. BY-2 cells  
N. tabacum cv. BY-2 suspension cells and calli were grown in MSMO medium. Liquid 
medium was adjusted to pH 5.2, while medium solidified with 0.8% (w/v) agar was 
adjusted to pH 5.8. Both suspension cells and calli were cultivated at 26°C in the dark. 
Suspension cells were sub-cultured weekly using a 2% (v/v) inoculum while pinpoint-
sized clumps of callus cells were transferred to fresh plates monthly.  
MSMO medium   
MSMO salts 4.4 g/L 
thiamin/HCl 0.4 mg/L 
2,4-D 0.2 mg/L 
KH2PO4 0.2 g/L 
sucrose 30 g/L 
 pH 5.2 
 
II.2.2.3 Preparation of recombinant Agrobacterium. tumefaciens 
A single colony of a positive clone was checked by Agrobacterium-control PCR 
(II.2.3.6.1) and inoculated in 5 ml of YEB medium and cultivated at 28°C for 2-3 days 
with shaking at 250 rpm. One ml was transferred into 100 ml of YEB-Rif-Km-Carb 
medium (II.2.1.2) and cultivated o/n at 28°C with shaking at 250 rpm. The following 
day the cells were pelleted by centrifugation at 5,000 g for 10 min at 15°C and 
transferred into 250 ml of induction medium in a 500-ml flask and cultivated o/n at 
28°C with shaking at 250 rpm. Bacterial cells were centrifuged (4,000g/15-25°C/15 
min) and resuspended in 50 ml of MMA solution and kept for 2 h at RT. The cell 
suspension was diluted to an OD600nm of 2.4 and 100 ml of the diluted cell suspension 
was used for vacuum infiltration of plant leaves (II.2.2.5). 
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Induction medium  
YEB medium (pH 5.6)  
MES 10 mM 
 pH 5.6 
2 mM MgSO4, 25µg/ml kanamycin, 100µg/ml rifampicin, 100µg/ml carbenicillin, and 
20µM acetosyringone were added after autoclaving and cooling. 
 
MMA Buffer  
MS salts  0.43% (w/v)
MES 10 mM 
Sucrose 2% (w/v) 
 pH 5.6 
200µM acetosyringone was added after autoclaving and cooling. 
 
II.2.2.4 Transformation of Nicotiana tabacum cv. BY-2 
N. tabacum cv. BY-2 cells were transformed by co-cultivation with recombinant                    
A. tumefaciens. Three ml of a 3 days old BY-2 culture in the log phase of growth were 
mixed in an empty petri dish (5cm) with 150µl of an o/n culture of recombinant A. 
tumefaciens. After incubation for 3 days in the dark at 24°C, the cells were transferred 
to centrifuge tubes and sedimented (3min/100g/RT). The supernatant was removed and 
the pelleted cells washed with 10ml MS medium (II.2.2.6). After three cycles of 
sedimentation and washing in MS, the cells were resuspended in an equal volume of 
MS medium and 200µl aliquots were plated on MS agar supplemented with 75µg/ml 
kanamycin and 250µg/ml cefotaxime. The plates were incubated in the dark at 24°C. 
Pinpoint-sized clumps of kanamycin-resistant cells were visible after 20-25 days and 
were transferred to fresh plates containing the same medium and cultivation continued 
until sufficient cell material for screening by immunoblot (II.4.8) was available. 
 
II.2.2.5 Vacuum infiltration of intact plant leaves 
For transient expression of recombinant proteins in different N. tabacum cultivars and 
edible plants like zucchini and bean; young leaves (4 leaves for each construct) were 
placed in 100 ml of recombinant A. tumefaciens (II.2.2.3) suspension in a Weck glass 
and a continuous vacuum (60-80 mbar) was applied for 15-20 min. The vacuum was 
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released rapidly and the leaves were briefly rinsed in tap water and kept with adaxial 
side upward on wet Whatman paper. After incubating the leaves at 22°C with a 16 h 
photoperiod for 72 h in the plastic tray that was sealed with saran wrap, the central vein 
of the leaves were removed. Remaining of the leaves were weighed, frozen in liquid 
nitrogen and stored at -80°C until analysis (II.4.2). 
 
II.2.2.6 Stable transformation of tobacco plants 
Stable transformation of N. tabacum was performed with the help of Dr. Flora Schuster 
(RWTH Aachen, Institute für Biology VII). Transgenic N. tabacum cv. Petite Havana 
SR1 was generated by leaf disc transformation using recombinant A. tumefaciens 
(II.2.1.8) and transgenic T0 plants were regenerated from transformed calli (Fraley et al. 
1983; Horsch, Fry et al. 1985). Briefly, wild type plants were grown on MS medium in 
Weck glasses and the youngest leaves (length up to 6 cm) were used for transformation. 
The agrobacteria suspension was prepared as described (II.2.2.3) and the OD600 was 
adjusted to at least 1.0 after dilution in MMA buffer. The leaves were cut into 8-10 
pieces (without the central vein) and transferred into Weck glasses containing 50-100 
ml of recombinant agrobacteria suspension and incubated for 30 min at RT. The leaf 
pieces were then transferred onto sterile pre-wetted Whatman filters in petri dishes, 
closed with saran wrap and incubated at 26-28°C in the dark for two days. Following 
washing with distilled water containing 100µg/ml kanamycin, 200µg/ml claforan and 
200µg/ml Betabactyl (Ticarcillin/Clavulanic acid, 25:1), leaf pieces were transferred 
onto MS II-plates and incubated at 25°C in the dark for one week and with a 16 h 
photoperiod for 2-3 weeks.  
After shooting, the shoots were removed, transferred onto MS-III-plates and incubated 
at 25°C with a 16 h photoperiod for 10-14 days until roots developed. The small plants 
were transferred into Weck glasses containing MS-III medium and incubated at 25°C in 
16 h light rhythm for 2 weeks until they were transferred into soil. Young leaves from 
regenerated transgenic plants were used for extraction of total soluble proteins (II.4.2) 
and for analysis of recombinant protein accumulation by immunoblot (II.4.8) and 
ELISA (II.4.9). 
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MS medium  
MS-salts 0.43% (w/v) 
Myo-Inosite (SERVA) 0.1% (w/v) 
Sucrose  2% (w/v) 
Thiamin-HCl 0.4 mg/l 
A. bidest add to 1000 ml 
 
The pH was adjusted to 5.8 with 1 N NaOH (for preparation of solid medium, 0.8% 
(w/v) agar were added), autoclaved and 500 µl of vitamin solution I were added upon 
cooling to 55°C. 
MS-II medium  
MS medium supp. with  
BAP (in DMSO) 1 mg/l  
Kanamycin  100 mg/l 
Claforan  200-500 mg/l 
Betabactyl 200-250 mg/l 
 
MS-III medium  
MS medium supp. with  
Kanamycin 100 mg/l 
Claforan  200-500 mg/l 
Betabactyl 200-250 mg/l 
 
Vitamin solution I  
Glycine  0.4% (w/v) 
Nicotinic acid 0.1% (w/v) 
Pyridoxine  0.1% (w/v) 
Filter sterilized and stored at 4°C. 
 
II.2.2.7 Bombardment of wheat embryos 
Immature wheat (Triticum aestivum L. cv. Bobwhite) embryos were used as explants 
for the delivery of the HSA-KDEL gene integrated in pal76 vector (II.1.5.8). DNA for 
particle bombardment was prepared by mixing plasmids containing the HSA-KDEL 
gene with the selectable marker in equimolar ratios not exceeding 15 µg of total DNA 
and 2.5 mg of gold particles (0.7 µm). Coating of DNA and bombardment of wheat 
embryos in a BioRad He2000 apparatus at 900psi Helium pressure was done by Dr. Eva 
Stöger (RWTH Aachen, Institute for Biology VII). Following selection of wheat on 
PPT (2.5 mg/l), PPT resistant plant material was recovered. 
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II.2.3 Recombinant DNA techniques 
II.2.3.1 Isolation of plasmid DNA 
For simultaneous screening of numerous recombinant clones, TELT method was used 
to prepare plasmid DNA on mini-scale. To prepare DNA for nucleotide sequence 
analysis, Qiagen plasmid DNA Mini prep kit or Midi prep kit was used according 
to manufacturers instructions. 
II.2.3.1.1 TELT method 
The TELT method was performed as described (Holmes and Quigley 1981). Briefly, 
recombinant E. coli cells (II.2.1.3) from 3.0 ml overnight cultures were harvested by 
centrifugation (13,000g/RT/30 sec). The cell pellet was resuspended in 100 µl of TELT 
buffer followed by vigorous vortexing with the same volume of PCI 
(phenol/chloroform/isoamyl alcohol, 25:24:1) and centrifugation (13,000g/RT/5 min). 
The clear supernatant was transferred into an Eppendorf tube and plasmid DNA was 
precipitated using 2.5 volumes of ice-cold 100% (v/v) ethanol. The DNA pellet was 
washed twice with 70% (v/v) ethanol and air-dried for 10 min at room temperature. 
Finally plasmid DNA was dissolved in 30 µl of sterile distilled water. 
 
TELT Buffer  
Tris-HCl (pH 8.0) 50 mM 
EDTA 62.5 mM 
LiCl  2.5 mM 
Triton X-100 4% (v/v) 
TELT buffer was stored at 4°C. 
 
II.2.3.2 Restriction enzyme digestion and precipitation of DNA 
Restriction enzyme digestions were carried in the buffer supplied with the enzyme and 
in accordance with the suppliers recommendations for temperature and duration of the 
digestion. 1 µg DNA was mixed with 1-2 units of the appropriate enzyme and incubated 
for 1-3 hours at the enzymes optimal temperature. For double digestions, combination 
of the two enzymes at the most suitable buffer was carried. If combination of the two 
enzymes were not possible, DNA was digested and purified via the PCR purification kit 
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(Qiagen) prior to the digest with the second enzyme. Reactions were stopped by 
freezing at 20°C until further processing. 
For precipitation of plasmid DNA, DNA solution was mixed with 0.1 volumes of 0.3 M 
NaAc (pH 5.2) and 2.5 volumes of absolute ethanol. After storing this mix at -20°C for 
30 min, DNA was pelleted via centrifugation (10 min/13000g/4°C). Subsequently, the 
DNA pellet was washed with 70% ethanol, air dried at room temperature and finally 
suspended in 10 mM Tris-HCl (pH 8.5). 
II.2.3.3 Agarose gel electrophoresis  
Analytical as well as preparative gel electrophoresis of double-stranded DNA fragments 
was performed as described (Sambrook, Fritsch et al. 1996)in 0.8-1.5% agarose gels 
supplemented with ethidium bromide (0.1µg/ml). As marker, a defined amount of PstI 
digested Lambda DNA or 100bp ladder (New England Biolabs) was included for 
determination of fragment size and estimation of concentration. Bands were visualized 
using a UV transilluminator at 302nm. For the documentation of the bands, the video 
documentation system of the Herolab Company together with the Software Easy 
Quant and was employed. In preparative electrophoresis, the desired fragment was 
excised with a sterile scalpel directly on the transilluminator and the DNA was extracted 
from the agarose gel using the Qiaex gel extraction kit (Qiagen). The yield of the 
extraction was verified by analytical electrophoresis. 
II.2.3.4 Determination of the DNA concentration 
The concentration of the isolated and purified DNA was determined by 
spectrophotometric measurement of concentration by measuring the absorbance of the 
solution at 260 nm, the wavelength at which both DNA and RNA absorb maximally, 
50µg/ml DNA gives an absorbance of 1 at 260 nm (Sambrook, Fritsch et al. 1996). 
II.2.3.5 Ligation of DNA fragments  
DNA ligations were carried out in a total volume of 20µl. The insert: vector molar ratio 
was adjusted to 3:1 for sticky ends in 1 x T4 ligase buffer (New England Biolabs) and 
0.1U of T4 DNA ligase was added. The reactions were incubated o/n at 16°C. Ligated 
DNA was precipitated, washed with 70% (v/v) ethanol at RT, resuspended in 10µl of 
sterile ultrapure water and stored at 20°C until transformation. 
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II.2.3.6 PCR amplification 
Polymerase chain reaction (PCR) offers a fast and convenient method of amplifying a 
specific DNA segment. In this technique, a denaturated (strand-separated) DNA sample 
is incubated with Taq DNA polymerase, dNTPs and two oligonucleotide primers whose 
sequences flank the DNA segment of interest so that they direct the DNA polymerase to 
synthesize new complementary strands. Multiple cycles of the process allows 
amplification of the genes of interest (Saiki et al. 1988). The reactions were performed 
in 0.2 ml PCR reaction tubes (Biozym Diagnostik GmbH, Oldendorf) using DNA 
thermal cycler (MWG). PCR reactions were carried out in a total volume of 50 µl as 
described below: 
Components Volume Final concentration 
10X PCR buffer 5 µl 1X 
50 mM MgCl2 1.5 µl 1.5 mM 
10 mM dNTP mixture 1 µl 0.2 mM each 
10 pmol forward Primer  0.5-1 µl 5-10 pmol  
10 pmol backward primer  0.5-1 µl 5-10 pmol  
Template DNA 0.5-5 µl 10-100 ng 
Taq DNA polymerase (5U/µl) 0.25 µl 1.25 units 
dH2O  added to 50 µl  
 
PCR Conditions    
Initial denaturation 95° C 5 min  
    
Denaturation 95° C 30 sec  
Primer annealing Tm 30 sec 25-30 cycles  
Primer extension 72° C 45 sec  
Final Extension  72° C 7 min   
 4° C Continuously  
 
The annealing temperature was adapted according to Tm value of primers. The optimal 
annealing temperature (Tm) of the primers was experimentally optimised or calculated 
by the empirical formula (Wu et al. 1991): 
( ) ( )[ ]{ }TACGXTm ++++= 246.122  
PCR products were resolved on a 1-1.2% (w/v) agarose gel to check the amplification 
and integrity of the amplified product (II.2.3.3). 
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II.2.3.6.1 Colony check PCR 
For rapid identification and verification of the foreign gene in recombinant bacteria, 
control-PCR was carried out as described (Jesnowski, Naehring and Wolf 1995). 
Isolated single colonies were picked using sterile tips and suspended in 13 µl of sterile 
dH2O in 1.5-ml Eppendorf tubes. The suspension was boiled for 10 min and cell debris 
was sedimented by centrifugation (13,000g/RT/5 min). Ten µl of the supernatant was 
used for PCR reaction in a total volume of 25 µl by adding 2.5 pmol each of the forward 
and backward primer and 25 amplification cycles were performed. PCR products were 
resolved on a 1.2% (w/v) agarose gel (II.2.3.3). 
 
II.2.3.6.2 SOE-PCR amplification 
The gene splicing by overlap extension (SOE) PCR technique was used to generate 
HSA cDNA by combining two overlapping HSA fragments (III.1) and to synthesize the 
semi-synthetic HSA gene (III.2). Equimolar amounts of overlapping fragments were 
mixed in a total volume of 50µl by adding 10 pmol of each dNTP, 1 unit of ExpandTM 
high fidelity Taq DNA polymerase and the corresponding buffer according to 
manufacturers instruction (Roche). PCR amplification was carried according to the 
following table: 
PCR Conditions    
Initial denaturation 94° C 1 min  
    
Denaturation 94° C 1 min  
Primer annealing 50° C  2 min 5 cycles 
Primer extension 65° C 2 min  
Ten µl of the PCR product from the above reaction was added to 10 pmol of each 
dNTP, 1 unit of ExpandTM high fidelity Taq DNA polymerase and polymerase buffer in 
a total volume of 50 µl. This cocktail was used for a subsequent round of PCR. 
PCR Conditions    
Initial denaturation 94° C 2 min  
    
Denaturation 94° C 1 min  
Primer annealing 60° C  1.5min 25 cycles  
Primer extension 65° C 2 min  
Final Extension 65° C 10 min  
 4° C Continuously  
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II.2.3.7 DNA sequencing 
The correct nucleotide sequence of cDNA fragments and expression constructs was 
verified by DNA sequencing using a Thermosequenase sequencing kit 
(USB/Amersham) and an LICOR 4200 IR2 automated DNA sequencer (MWG) using 
fluorescently labelled primers. Extension reactions were terminated by incorporation of 
dNTPs. 
As described earlier, plasmid DNA was isolated (II.2.3.1) using one of the kits from 
Qiagen. After determination of the DNA concentration (II.2.3.4), the purity and 
integrity of the plasmid preparation was checked on an agarose gel (II.2.3.3) and was 
added as the template plasmid DNA into the sequencing reactions. For the PCR 
reactions, 1.5µl of the respective termination mix (1.25mM of each dNTP plus 1.25 mM 
of one of the four ddNTPs) were pipetted into PCR reaction tubes. 4.5µl of sequencing 
master mix (2 µl 10 x Taq DNA polymerase buffer, 2U Taq polymerase, 1µg plasmid-
DNA, 2.5 pM of each of the respective primers, 1µl DMSO, ultrapure H2O) were added 
to each of the tubes and overlaid with a drop of PCR oil. After incubation in a PCR 
thermocycler (initial denaturation 4min/94°C, followed by 35 cycles of annealing 
(20sec/50°C), extension (30s/72°C) and denaturation (20s/95°C) the reactions were 
stopped by adding 3 µl of stop buffer to each tube. The products were frozen at 20°C 
and resolved on a denaturing (6M urea) polyacrylamide gel (4.66.0%). For evaluation 
of sequencing data DNA analysis software package was used according to 
manufacturers instructions. 
 
II.3 Expression of recombinant proteins 
II.3.1 Bacterial expression 
Recombinant HSA and the fusion protein HSA-Designer Tail (III.3) were expressed in 
the cytoplasm and periplasm of E.coli using different bacterial vector systems. A 
general protocol for expression of proteins in E.coli is as follows: A single colony of E. 
coli strain BL21 (Invitrogen, Leek, the Netherlands) harbouring recombinant plasmid 
DNA was inoculated in 10 ml of 2YT medium containing 1% (w/v) glucose and 100 
µg/ml ampicillin (LBGA) and cultivated o/n at 37°C. Five ml of the o/n culture was 
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transferred into 400 ml of LBGA medium and cultured at 37°C to OD600 of 0.5-1.0. 
Expression of recombinant proteins was induced for 3-5 h at 28°C-30°C by addition of 
IPTG to a final concentration of 1.0 mM. Cells were harvested by centrifugation (4,500 
rpm/4°C/15 min) and processed either for cytoplasmic or periplasmic extraction of the 
proteins from E.coli (II.4.1). 
 
II.3.2 Expression of rHSA in the field  
The field trial site was located on the AAFC-Delhi Research Station, 1 NTR, lot 40, 
Township of Middleton, Region of Haldimand-Norfolk, Delhi, Ontario and field tests 
were performed by Dr. Jim Brandle (Agriculture and AgriFood Canada). The trial was 
transplanted by hand with greenhouse seedlings. One transgenic line, one 
untransformed control was evaluated within a randomised complete block design with 
four replications. The planting density was approximately 111,000 plants/ha and plots 
had four rows with 32 plants in each plot. Approximately 30 days following 
transplantation, the plots were harvested and the plant material bulked for evaluation of 
dry matter yield and soluble protein concentration. 
 
II.4 Protein analysis 
II.4.1 Isolation of total soluble proteins from E. coli  
For bacterial expression and purification, HSA constructs were subcloned into a 
prokaryotic vector for cytosolic expression and transformed into E. coli Bl21λDE3 
strain. Cells from induced cultures (II.3.1) were harvested by centrifugation (4,500 
rpm/4°C/15 min) and washed with 80 ml of TEN buffer. The pellet was resuspended in 
10 ml of ice-cold TEN buffer containing 10 mg/l lysozyme. After 30 min on ice the 
suspension was sonicated to lyse the cells (120 W, 5 x 30sec with 1 min break interval). 
The cell debris was pelleted by centrifugation (12,000g/4°C/30 min).  
For periplasmic extraction, pelleted cells (II.3.1) were resuspended in 10 ml of 
resuspension buffer (30 mM Tris-HCl, 20% (w/v) sucrose, pH 8.0) on ice. EDTA was 
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added to a final concentration of 1 mM. The suspension was incubated on ice with 
gentle agitation for 10 min. After centrifugation (8,000g/4°C/20 min), the supernatant 
(S1) was collected. The pellet was resuspended in 9 ml of cold 5 mM MgSO4, stirred 
for 8-9 min at 4°C and EDTA to a final concentration of 1 mM was added to the mix. 
After stirring the suspension for additional 3 min, the suspension was centrifuged 
(8,000g/4°C/20 min). The supernatant (S2), known as the osmotic shock fraction, was 
mixed with the first supernatant (S1) and dialysed against PBS prior to IMAC affinity 
purification (II.6.1). 
TEN Buffer  
Tris-HCl 10 mM 
EDTA 1 mM 
NaCl 0.14 mM 
 pH 7.4 
 
II.4.2 Isolation of total soluble proteins from plant leaves 
For extraction of total soluble proteins, frozen leaves were ground in liquid nitrogen to a 
fine powder with a mortar and pestle. Total soluble proteins were extracted using 2 ml 
of extraction buffer per gram leaf material. Cell debris was removed by centrifugation 
(16,000g/4°C/30 min) and the supernatant was used for expression analyses by SDS 
PAGE, immunoblot and ELISA (II.4.8 and II.4.9).  
Extraction Buffer  
Tris-HCl 200 mM 
EDTA 5 mM 
DTT 0.1 mM 
Tween 20  0.1% (v/v) 
 pH 7.5 
  
 
For isolation of protein prior to two dimensional gel electrophoresis (II.4.6.2), 2 g of 
fresh transgenic leaf was ground in liquid nitrogen to a fine powder. The powder was 
mixed with 2.5 volumes of 10 % (v/v) trichloro acetic acid (TCA) solution in acetone. 
After storing this mix at -20°C for 60 min, soluble proteins were pelleted via 
centrifugation (10 min/13000g/4°C). Subsequently, the protein pellet was washed with 
2.5 volumes of 99% acetone; air dried at room temperature and stored at -20°C until 
used. 
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II.4.3 Isolation of total soluble proteins from tobacco 
suspension cultures 
For extraction of total soluble proteins from N. tabacum cv BY-2 suspension cultures, a 
5 ml aliquot of the culture was centrifuged (10min/5000rpm/4°C). The supernatant (2-
3ml) removed after centrifugation was further analysed by ELISA (II.4.9) and/or 
immunoblot (II.4.8). For the extraction of intracellular proteins, 2 ml of extraction 
buffer (II.4.2) was added to 1g (wet weight) of cells and sonicated on ice until the 
membranes were disrupted (three times 2 min bursts separated by 1 min). After 
sonication the sample was spun at 10.000rpm for 10 min to collect total soluble proteins 
supernatant for ELISA or immunoblot analysis.  
 
II.4.4 Isolation of total soluble proteins from wheat seeds 
Extraction of the TSP from dry wheat seeds were done by squashing them between 
glass plates and grinding to a fine powder in a mortar. Citrate buffer (pH 6) with 100 
mM NaCl was used in a proportion of 1:3 (3 ml/g). TSP extract was analysed by ELISA 
or immunoblot analysis. 
 
II.4.5 Quantification of total soluble proteins 
Bradford assay, (Bradford 1976) using BSA as a standard, was used for quantification 
of protein concentration. The protein solution was diluted in the buffer used for 
solubilization of the protein of interest and BSA was serially diluted in the same buffer. 
Ten µl of each dilution was transferred into the wells of a low-protein-binding 96-well 
microtiter plate (Greiner, Solingen). Ten µl of the buffer was used as a blank. 200 µl of 
filtered Bradford colour reagent were added to each well, mixed with the proteins and 
incubated at RT for 10 min followed by the measurement of OD595nm. For each dilution, 
measurements were performed in duplicate and the average was taken for the 
calculation of the protein concentration.  
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II.4.6 Gel electrophoresis of proteins 
II.4.6.1 One-dimensional gel electrophoresis 
Proteins were electrophoretically separated by discontinuous SDS-PAGE as described. 
(Laemmli 1970) (Stacking gel: T = 4%, C =2.6%, pH 6.8; separating gel: T=12%, C = 
2.6%, pH 8.8). Before loading, proteins were denaturated and solubilized in 1x SDS 
sample buffer in a water bath at 100°C for 10 min. Separated proteins were revealed by 
gel staining with Coomassie brilliant blue (II.4.7.1), or transferred onto nitrocellulose 
membrane for immunoblot analysis (II.4.8). 
 
SDS-PAGE running buffer pH 8.3  
Tris-HCl 125 mM 
Glycine 960 mM 
SDS 0.5 % (w/v) 
 
10x SDS Sample Buffer pH 8.3  
Tris-HCl 0.35 M 
DTT 0.6 M 
SDS 10.3 % (w/v) 
Bromophenolblue 0.05 % /w/v) 
Glycerol 36 % (w/v) 
 
II.4.6.2 Two-dimensional gel electrophoresis 
The principle of high resolution 2-D gel electrophoresis was introduced by O´Farrell 
(O'Farrell 1975). The method separates proteins according to the physico-chemical 
parameters, charge (isoelectric point) in the first dimension and size (molecular weight) 
in the second dimension. The BioRad Protean IEF cell was used to perform isoelectric 
focusing of protein-containing samples using immobilized pH-gradient gel strips 
(Ready Strip IPG strips, BioRad). Since IPG strips are dehydrated, for passive 
rehydration, strips were placed in contact with the protein sample diluted in 
rehydration/sample buffer. The strips were covered with mineral oil to prevent 
evaporation and left overnight on the bench at RT according to manufacturers 
instructions. Prior to SDS-PAGE the IEF strips were equilibrated in an equilibration 
solution supplemented with 4.8% (v/v) iodoacetamide to prevent vertical gel spot 
Chapter II  Material and Methods  
47 
streaking. Samples were analysed in the first dimension on a pH 5-8 or 3-10 gradient 
and further separated in the second dimension on a 10% or 12% SDS PAA gel 
(II.4.6.1). 
Rehydration /Sample Buffer   
Urea 9 M 
Chaps 4 % (w/v) 
Ampholyte (pH 3-10) 0.4 %  (v/v) 
DTT 1 % (65 mM) 
 
II.4.7 Staining of protein gels 
II.4.7.1 Coomassie brilliant blue staining 
Expressed and purified recombinant HSA separated on one-dimensional SDS-PAA gels 
were visualized by Coomassie brilliant blue staining. Proteins were detected after 
incubating the gel for 30 min in Coomassie staining solution at RT under constant 
rocking. Coomassie staining was removed by destaining solution until the protein bands 
was clearly visible. The gel was dried between cellophane sheets for documentation 
purposes. 
Coomassie staining solution  
Coomassie brillant blue G-250 0.25% (w/v)
Methanol 50% (v/v) 
Glacial acetic acid  9% (v/v) 
 
Coomassie destaining solution  
Methanol 10% (v/v) 
Glacial acetic acid  10% (v/v) 
 
II.4.7.2 Silver Staining 
For higher sensitivity and to detect small amounts of proteins, two-dimensional gels 
were silver stained according to the Silver staining protocol for proteins from 
Pharmacia. Initial fixation step was carried out overnight in order to reduce background 
staining of polyacrylamide gels. The gels were sensitized by 30 min incubation in 
prestain solution, and subsequently rinsed three times with bidistilled water for 5 min 
each. After rinsing, the gels were submerged in 0.1% (w/v) silver nitrate solution for 20 
min. The silver nitrate solution was discarded, gels were rinsed twice with water for 1 
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min and then developed in sodium carbonate solution containing formaldehyde. After 
the desired intensity of staining was achieved (3-5 min), the development was 
terminated by discarding the reagent, followed by washing the gels with water. The 
development process was stopped with an aqueous EDTA solution. Silver-stained gels 
were stored in a solution of 1% (v/v) acetic acid at 4°C until analyzed. 
 
Fixation solution  
Ethanol 40% (v/v) 
Glacial acetic acid  10% (w/v) 
 
Prestain solution (Sensitizing)  
Ethanol 30% (v/v) 
Glutardialdehyde  25% (w/v) 
Sodium thiosulphate 5% (w/v) 
Sodium acetate 6.8% (w/v) 
 
Silver nitrate solution   
Silver nitrate 2.5% (w/v) 
Formaldehyde (37%) (w/v) 0.04% (v/v) 
   
Developing solution   
Sodium carbonate 2.5% (w/v) 
Formaldehyde (37%) (w/v) 0.02% (v/v) 
        
Stop solution   
EDTA- Na2.2H2O 1.46% (w/v)
 
II.4.8 Immunoblot 
Electrophoretically separated proteins were transferred from a SDS-PAA gel (II.4.6.1) 
to a HybondTM-C nitrocellulose membrane (0.45 µm) in the presence of transfer buffer. 
The membrane was blocked with PBS buffer containing 3% (w/v) skim milk (MPBS) 
and blotted proteins probed with a primary antibody (II.1.4) that reacted specifically 
with antigenic epitopes displayed by the target protein attached to the membrane. The 
bound antibody was detected by addition of an appropriate secondary polyclonal 
antibodies (II.1.4) coupled to alkaline phosphatase (AP). Both primary and secondary 
antibodies were diluted in MPBS. The target protein was finally revealed by addition of 
substrate NBT/ BCIP (BioRad). 
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The following is a general protocol for the Immunoblot analysis. 
Table II.1 Illustration of the steps for Immunoblot. All analysis steps were performed in 
10-20 ml of solution on a shaker at room temperature. 
Con.= Concentration    Dil.= Dilution 
Inc.= Incubation     Temp. = Temperature 
RT = room temperature   o/n= over night 
GAMAP = AP conjugated goat anti mouse antibody 
NBT= nitro blue tetrazolium chloride BCIP=5-bromo-4-chloro-3-indolylphosphate 
 
 Step Con. /Dil. Inc. (min) Temp (°C) 
 Blocking 5% (w/v) MPBS 30 RT 
 Primary antibody  60 RT 
 mouse anti-HSA 1:5000 in PBS   
or mouse anti-his6   1:2500 in PBS   
or mouse anti-cmyc 1:3000 in PBS   
 Secondary antibody    
 GAMAP 1:5000 in PBS 60 RT 
 NBT/BCIP  2-10 RT 
 
To remove unspecifically bound antibodies the membrane was washed 3 times for 10 
min with PBST between each step. Membrane was equilibrated with AP buffer prior to 
substrate addition. 
PBS (Phosphate buffered saline) (pH 7.3)  
NaCl 137  mM 
KCl 2.7  mM 
Na2HPO4.2H2O 8.1 mM 
KH2PO4 1.5 mM 
PBST (pH 7.3)  
PBS 1x 
Tween-20 0.05% (w/v) 
  
MPBS (Blocking buffer) (pH 7.3)  
PBS 1x 
Skim milk 3% (w/v) 
 
Transfer buffer  (pH 8.3)  
Tris-HCl, pH 8.3 25  mM 
Glycine 192 mM 
Methanol 20 % (v/v) 
 
AP buffer  (pH 9.6)  
Tris-HCl, pH 9.6 100  mM 
NaCl 100 mM 
MgCl2 5 mM 
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II.4.9 Enzyme Linked Immunosorbent Assay (ELISA) 
The Enzyme Linked Immunosorbent Assay (ELISA) is a rapid and sensitive method for 
detection of antigens (Ag) or antibodies (Ab) in a wide variety of biological samples. 
Many variations in the methodology of the ELISA have evolved since its development 
in the 1960s but the basic concept is still the immunological detection and quantification 
of single or multiple Ag or Ab in a given sample. 
 
II.4.9.1 Determination of IgY titer in egg yolk 
For titer determination of polyclonal antibodies from chicken egg yolk an indirect 
ELISA assay was performed. ELISA plates were coated with HSA (1µg/mL in coating 
buffer). After blocking of free binding sites by incubation with blocking buffer, serial 
dilutions of the yolk (1:500  1:256,000 in PBS) were added and bound IgY was 
detected using Fc-specific RACAP antibodies and PNPP substrate tablets (Sigma). The 
quantity of bound antibodies was photometrically determined at E405nm . 
Table II.2 Illustration of the steps for titer determination of chicken egg yolk. All the 
steps were performed in 10-20 ml of solution on a shaker at room temperature. 
Con.= Concentration Dil.= Dilution  Vol.= Volume  
Inc.= Incubation  CB= Coating buffer Temp= Temperature 
o/n= over night  SB= Sample buffer BSA= Bovine Serum 
Albumin 
RACAP = AP conjugated rabbit anti chicken antibody 
AP= alkaline phosphatase EMA-P= Buffer for enzyme labelled antibody 
RT= Room temperature PNPP= p-nitrophenyl phosphate 
 
Step Con. /Dil. Vol. (µl)/well Inc. (min) Temp (°C) 
Coating 1µg/ml in CB 100 60 37 
Blocking 1% (w/v) BSA in PBST 300 o/n 4 
Sample Dil. in PBS 100 120 37 
RACAP 1:5000 in EMA-P 100 60 37 
PNPP 1 mg/ml in SB 100 15-60 RT 
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Between each step wells were washed three times with 1x PBST. 
Coating buffer  (pH 9.6)  
Na2CO3 15 mM 
NaHCO3 35 mM 
Na-azid 0.02% (w/v) 
 
 
 
EMA-P buffer  (pH 7.4)  
PVP (20-30 kDa) 2% (w/v) 
BSA 0.2% (w/v) 
Na-azid 0.02% (w/v) 
Tween-20 0.05% (w/v); 
1xPBS pH 7.4  
 
Sample buffer  (pH 9.8)  
Diethanolamin 0.1 M 
MgCl2 1 mM 
 
II.4.9.2 Detection of recombinant HSA in bacteria and plant 
For detection of bacterial and plant-expressed recombinant HSA and HSA-DT fusion 
proteins, an indirect ELISA was used. Goat-anti-HSA antibody (Bachem) was coated on 
microtiter ELISA plates. After blocking of free sites by incubation with blocking buffer, 
standards and samples were added in replicates of three. Recombinant HSA was 
detected using peroxidase-conjugated rabbit anti-HSA antibody (Rockland) and ABTS 
substrate tablets dissolved in ABTS buffer (Boehringer Mannheim). The adsorption was 
read at OD690nm. 
The following schema was followed for ELISA; 
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Table II.3 Illustration of the steps for HSA quantification in bacteria and plant. All the 
steps were performed in 10-20 ml of solution on a shaker at room temperature. 
Con.= Concentration Dil.= Dilution  Vol.= Volume 
Inc.= Incubation  Temp= Temperature RT = room temperature 
o/n= over night   
α-GHSA = Goat anti-HSA antibody   
α-RHSAP = peroxidase-conjugated rabbit anti-HSA antibody 
ABTS = 3-ethylbenzthiazoline-6-sulfonic acid 
 
Step Con. /Dil. Vol. 
(µl)/well 
Inc. 
(min) 
Temp 
(°C) 
α-GHSA 1:500 in TBS 200 o/n 4 
Blocking 3% (w/v) MTBS 200 30 RT 
Sample Dil. in TBS 100 60 RT 
α-RHSAP 1:20000 in TBS 100 60 RT 
ABTS 1 mg/ml in ABTS 
buffer 
100 1-10 RT 
Between each step wells were washed three times with washing buffer. 
 
TBS buffer  (pH 8.0)  
Tris-HCl, pH 8.0 0.05  mM 
NaCl 0.138 M 
KCl 2.7 mM 
 
Washing buffer  (pH 8.0)  
TBS buffer  
Tween-20 0.05 %(v/v) 
 
MTBS (Blocking buffer)  (pH 8.0)  
TBS buffer  
non-fat dry milk 3 % (w/v) 
 
II.5 Production of IgY anti sera  
II.5.1 Immunization of chicken 
The treatment and maintenance of laboratory animals was approved by the 
Regierungspräsidium des Landes NRW (RP-Nr.: 23.203.2 AC 12, 21/95) and 
supervised by Dr. Hirsch who is responsible for biological safety at the Institute for 
Biology VII, RWTH Aachen. Initial chicken immunizations were performed with 
100µg of pure HSA (Sigma, Catalogue number: A1653) in PBS emulsified with an 
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equal volume of complete Freunds adjuvant (GibcoBRL). Two 500µl aliquots were 
injected at two different places of pectoral muscle. Three and six weeks after the initial 
immunization, injections were repeated as above, except that incomplete Freunds 
adjuvant (GibcoBRL) was used. Two weeks after the third immunization, eggs from the 
immunized chicken were collected and the specific IgY antibody titer determined by 
ELISA (II.4.9.1).  
 
II.5.2 Isolation of chicken polyclonal antibodies from egg yolk 
IgY antibodies were purified from egg-yolk by repeated precipitation with PEG-6000 as 
described. (Polson et al. 1985). All centrifugations were at 20,000x g for 20 min at 4°C. 
The yolk sacs were collected, washed with cold tap water, the yolk volume determined 
and four volumes of cold PBS added. 3.5% (w/v) of solid PEG-6000 was added and 
stirred until dissolved. After centrifugation the supernatant was filtered through 
Miracloth and Whatman 3M paper, 8.5% (w/v) of PEG-6000 was added and re-
centrifuged. The pellet was resuspended in 2.5-fold of the original yolk volume of PBS, 
treated with 12% (w/v) PEG-6000 and recentrifuged. The pellet was resuspended in 
0.25-fold the original yolk volume of PBS containing 0.02% (w/v) NaN3, treated with 
50% (v/v) ice-cold ethanol and centrifuged again to remove all PEG-6000. The 
supernatant containing the purified IgY antibodies was filter-sterilized and stored in 
aliquots at 20°C. An indirect ELISA was performed in order to determine the 
concentration of polyclonal  antibodies in egg yolk (II.4.9.1). 
 
II.6 Recombinant protein purification 
II.6.1 Immobilized Metal Affinity Chromatography (IMAC) 
His-6 tagged secreted recombinant HSA was affinity purified by IMAC. Collected 
periplasmic fractions from E.coli suspension were dialysed o/n against PBS (II.4.1). Ni-
NTA-agarose matrix was added in a disposable column, charged with 5 column 
volumes (CV) of 50 mM NiSO4 and washed with 10 CV of 0.5 M acetic acid before 
equilibration with 10-20 CV of binding buffer (1x PBS, 10 mM imidazol; 500 mM 
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NaCl). Imidazol and sodium chloride were added into the dialyzed periplasmic fraction 
(II.4.1) to a final concentration of 10 mM and 500 mM, respectively. The sample was 
passed twice through the pre-equilibrated Ni-NTA matrix. The column was washed 
with 20 volumes of wash buffer (1x PBS, 30 mM imidazol; 500 mM NaCl) and the 
proteins were eluted in three fractions with 700 µl of elution buffer (1x PBS, 250 mM 
imidazol pH 4.5). Collected fractions were immediately dialysed against PBS (pH 7.4) 
to remove imidazol and salt. To control the yield and purity of dialyzed recombinant 
HSA, 5 µl were separated by SDS-PAGE (II.2.4.6.1). 
 
II.6.2 Cation Exchange Chromatography 
Total soluble proteins were extracted using 2 ml of extraction buffer (Acetate buffer; 
pH: 4.5+5 mM EDTA) per gram leaf material. Cell debris was removed by 
centrifugation (16,000g/4°C/30 min) and the supernatant was used for cation exchange 
chromatography (CEX). Conventional chromatography in packed bed columns was 
performed by Dr. J. Drossard (Institute for Biology VII, RWTH Aachen) using a Äkta 
Explorer 10XT or a Äkta Purifier 100 chromatography system (Pharmacia) with cation 
exchange columns. Chromatography was performed using either a 1.4 ml Source 30S 
(Pharmacia) cation exchange medium in BioCart5 column (Kronlab, Sinsheim) or a 
XK50/20 cation exchange column filled with 120 ml of Seppharose Big Beads 
equilibrated with the respective loading buffer (20 mM acetate pH 4.0) with a linflow of 
300 cm/h. 
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III Results 
The objective of the present work was production of recombinant human serum albumin 
(rHSA) in transgenic organisms. Therefore HSA cDNA was cloned into different bacterial 
and plant expression vectors. Initial attempt was to express rHSA in E. coli. After 
confirmation of bacterial expression, different plant species were evaluated for high level 
production of rHSA. Transient expression of rHSA was carried via Agrobacterium mediated 
gene transfer using tobacco leaves and leaves from edible plants like zucchini and bean 
leaves. The same expression cassettes developed for agroinfiltration were used to generate 
stable transgenic tobacco plants. High level expressors were selected and evaluated for 
several generations in the greenhouse. Moreover T2 generation was analysed to confirm 
rHSA accumulation in the field. In addition, stable transformation of wheat was performed by 
bombarding wheat embryos using a HSA expression construct downstream to ubiquitin 
promoter. Stable expression of rHSA in transgenic tobacco suspension cells was performed. 
Secreted rHSA to the BY2 culture medium was analysed and stability of the secreted protein 
was improved by addition of stabilizing agents. For downstream processing of the transgenic 
tobacco plants producing rHSA, cation exchange chromatography was experienced. 
Conditions for the partial purification of rHSA from tobacco leaves were optimised.  
 
III.1 Production of polyclonal anti-HSA serum 
To detect rHSA accumulation in protein extracts of different production organisms  
polyclonal antibodies against HSA were prepared. For the generation of these antibodies, 
chicken were immunized by injecting 100µg of commercial HSA (Sigma) (II.5.1). Two 
weeks after the third boost, polyclonal chicken IgY antibodies were purified from chicken 
egg yolk (II.5.2). IgY was purified by repeated PEG precipitation (Polson, Coetzer et al. 
1985) with an average yield of 8 mg IgY per ml yolk, determined by spectrophotometry. As 
shown in Fig III.1A (lane 1) the purification of IgY antibodies resulted in some weak 
additional protein bands visible at ~40kDa. It was not determined if these bands were 
contaminants or IgY degradation products produced during purification and storage. The 
antibody titer referring to the highest dilution at which antigen-specific binding is visible by 
an E405nm of 0.2 after 1 hour substrate induction (II.4.9.1). The titer of HSA specific 
antibodies in egg yolk was determined to be 1: 130,000 by indirect ELISA (Figure III.1B).  
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Figure III.1 SDS PAGE analysis (A) and titer determination (B) of polyclonal antibodies 
purified from chicken egg yolk. A: 3 µl of purified IgY (II.5.2) per lane was separated on a 12% 
SDS-PAGE gel (II.4.6.1). The gel was stained with Coomassie Brilliant Blue after electrophoresis as 
described (II.4.7.1). 1: 1:10 diluted IgY; 2: 1:100 diluted IgY; M: Molecular weight marker (Mark 12, 
Novex); 3: 10 µg BSA; 4: 1 µg BSA; 5: 0.1 µg BSA. B: Determination of polyclonal antibody titer by 
ELISA. Commercial HSA (Sigma) (1µg/mL in coating buffer) was coated onto a microtiter plate. 
Serial dilutions of purified sera were added. Bound antibodies were detected by addition of GACAP 
polyclonal antibody (1:5000). ELISA readings were performed at OD405nm after 1 h min incubation 
with pNPP substrate at 37°C.  
 
Polyclonal anti-HSA antibodies from chicken egg were intended to use in the immunoblot 
(II.4.8) analysis of rHSA accumulation in different host organisms. However, initial 
experiments (data not shown) showed that the specificity of the generated polyclonal serum 
was not sufficient to obtain reproducible results. Therefore the polyclonal serum was replaced 
by highly specific commercially available monoclonal antibodies in the ongoing work 
(II.1.4). 
 
III.2 Construction of HSA expression constructs 
III.2.1 Cloning of rHSA  
The full length mRNA encoding HSA is 2163 nucleotides (nt) long, with a short 5 
untranslated region (UTR) of 46 nt and a 3 UTR of 207 nt (Lawn, Adelman et al. 1981). The 
HSA coding sequence is 1827 bp long encoding a 609 amino acid preproalbumin (Dugaiczyk, 
Law et al. 1982). The 18 amino acid signal sequence is apparently removed upon secretion of 
preproalbumin into the lumen of the endoplasmic reticulum. The six amino acid pro sequence 
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is subsequently removed in the Golgi apparatus (Lawn, Adelman et al. 1981). Finally the 
mature HSA protein, 585 amino acids in length is released into the blood. 
The HSA cDNA was obtained from in vitro transcription of human liver mRNA and two 
overlapping fragments were separately cloned into pBR322 plasmids resulting in pHSA36 
and pHSA206 (Dugaiczyk, Law et al. 1982). These two plasmids share 0.15 kb of 
homologous DNA (Figure III.2). Together they encode the entire sequence of HSA, starting 
with the CTT codon for Leu at position 10 of the prepeptide and extending into the 3 
untranslated region of polyA (II.1.5.1). 
In order to combine the two HSA cDNA inserts by SOE PCR (II.2.3.6.2), four primers 
(II.1.6) were designed (Figure III.2A). The primer design enabled deletion of the leader and 
hexapeptide of authentic HSA and introduction of EcoRI/NcoI sites at the 5 and SalI/HindIII 
sites at the 3 end for subsequent subcloning into expression vectors.  
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Figure III.2 Diagram of overlapping cDNA inserts (A); Analysis of SOE PCR (II.2.3.6.2) by 
agarose gel electrophoresis (B).A: Plasmids pHSA36 and pHSA206 in pBR322 are illustrated 
together with the overlapping sequence and the primers used for amplification of HSA cDNA ( 1 : 
HSAforwardnew; 2 : HSAbackward; 3 : HSAfor; 4 :HSAback). B: (1) 1.3 kb HSA cDNA fragment 
(2) 0.5 kb HSA cDNA fragment. (3) The complete cDNA of HSA, 1.8 kb. 5 µl of the amplified DNA 
was separated on 1.2% (w/v) agarose gel (II.2.3.3). M: PstI digested λ DNA.  
 
The 1.3 kb HSA cDNA fragment was amplified from pHSA36 using the primers HSAfor and 
HSAbackward. The 0.5 kb HSA cDNA fragment was amplified from the template pHSA206 
using the HSAforwardnew and HSAback primers. These two fragments were combined by 
SOE PCR (II.2.3.6.2) to obtain the complete rHSA cDNA. The 1.8 kb SOE PCR product was 
gel purified (II.2.3.3) digested with EcoRI/HindIII (II.2.3.2) and cloned into the 
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EcoRI/HindIII site of the pGEM-3zf vector (II.1.5.3). Sequencing was done using the forward 
and backward primers specific for the vector DNA and/or specific for HSA (II.1.6). 
Nucleotide sequence of rHSA cDNA was identical to the sequence published by Dugaizyck et 
al. (1982).  
 
III.2.2 Construction of plant codon optimized rHSA 
The codon usage pattern applied in different organisms varies. Presence of high contents of 
rare codons that are used at low frequencies in a host organism often leads to low levels of 
foreign protein expression or truncated products because of the premature termination in 
protein translation (Chen and Inouye 1990; Hannig and Makrides 1998). To overcome this 
problem, a novel plant codon optimised semi-synthetic gene for high-level HSA expression 
was generated. The frequencies of amino acid coding sequences (CDSs) for 8792 different 
organisms were compiled from the taxonomical divisions of the GenBank DNA sequence 
database (Nakamura, Gojobori and Ikemura 2000), source: http://www.kazusa.or.jp/codon/. 
By the help of this codon usage database it was possible to replace the codons that are poorly 
(less than 1%) presented in the tobacco, wheat and rice genome by the codons that are 
preferred.  
The albumin cDNA consists of 585 amino acids and the gene contains 18.3% rare codons for 
tobacco, wheat and rice plants expression that are distributed throughout the entire sequence. 
Distribution of rare codons in HSA sequence is illustrated in Appendix VIII.3. The DNA 
sequence of the rHSA was altered to match the plant preferred pattern of codon usage by 
codon replacement (VIII.4), while maintaining the identical amino acid sequence for 
expression of the recombinant protein. The plant codon optimised HSA was synthesized via 
PCR. The final product after PCR assembly was 1755 bp long, 1138 of which are made of the 
primers used for the amplification. This corresponds to 65% of the total sequence. 
To assemble the plant codon optimised HSA, 32 different primers (VIII.2) differing in length 
were designed. They did not cover all the HSA sequence for a complete synthetic gene rather 
only parts of the sequence were modified and only for those parts primer addition was 
required. The reason for this strategy was to reduce the complexity and cost of the PCR 
assembly for amplification of a totally synthetic gene, which would require at least 50 
primers. Since only the regions with rare codons were replaced, the rest of the sequence was 
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kept as the authentic HSA gene sequence. The length of the primers varied between 27 nt and 
83 nt. For the amplification of the plus strand as well as the minus strand consisting of 16 
primers were used. The primers were organized in such a way that, upon assembly, 
complementary regions in the primers overlapped between 21 and 24 nt (Figure III.3). 
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Figure III.3 Schematic representation of primer arrangement to generate the plant codon 
optimised rHSA. HSAmod1-16; forward primer (VIII.2); HSAmod17-32; backward primer; lengths 
of the oligos in base pair (bp) are indicated above or below the arrows; numbers under the dotted lines 
indicate length of the complementary overlapping sequence. 
 
To avoid amplification of the authentic HSA only via the primers 1 and 17 by PCR, the 
template cDNA was digested (II.2.3.2) into three smaller fragments. Using ApaLI, a template 
of 400 bp (T400bp) and using NcoI-SalI restriction enzyme combinations two templates of 
800 bp (T800bp) and 1000 bp (T1000bp) were extracted from the agarose gel (II.2.3.3). 
Twelve reactions were prepared in the presence/absence of these sub-fragments together with 
the corresponding equimolar primer combination. A schematic representation of the PCR 
assembly is illustrated in Figure III.4A. The PCR reaction was performed under the following 
condition: an initial denaturation for 3 min at 94°C followed by 20 cycles of denaturation at 
94°C for 1 min, annealing 55°C for 90 seconds, extension 72°C for 2 min and a fill-in cycle 
of 72°C for 10 min. PCR products from the assembly were separated on a 1.2% (w/v) agarose 
gel and illustrated in Figure III.4B. 
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Figure III.4 Schematic representation of PCR amplification of plant codon optimised rHSA 
(A); Analysis of PCR products by agarose gel electrophoresis (B). A. Twelve fragments using the 
template T400bp, T800bp or T1000bp or without any template were PCR amplified (II.2.3.6.2) using 
HSAmod primers 1-32. The primers used for each PCR reaction is indicated by the circles and the 
length of the amplified PCR product is shown in bp. B. 5 µl of the amplified DNA differing in length 
(between 90- 322 bp) were separated on a 1.2% (w/v) agarose gel and visualised by agarose gel 
electrophoresis (II.2.3.3). PCR product of 1: 154 bp; 2: 186 bp; 3: 120 bp; 4: 90 bp; 5: 171 bp; 6: 207 
bp; 7: 194 bp; 8: 122 bp; 9: 174 bp; 10: 322 bp; 11: 162 bp; 12: 141 bp. M: 100 bp ladder. 
 
Three contiguous overlapping fragments were SOE PCR (II.2.3.6.2) amplified by mixing four 
of the twelve fragments in each reaction (Figure III.5A). Fragments 1 to 4, 5 to 8 and 9 to 12 
were separately pooled after purification from the gel (II.2.3.3) and used as templates in the 
SOE PCR-I.1 reaction. The three samples were annealed using the following condition: an 
initial denaturation for 3 min at 94°C followed by 5 cycles of denaturation at 94°C for 1 min, 
annealing 55°C for 90 seconds, extension 72°C for 2 min and a fill-in cycle of 72°C for 10 
min. From these reactions 10µl each was taken and the combined fragments were amplified in 
three separate reactions (SOE PCR-I.2) using the primers 1 and 28 for 481bp fragment, 
primers 6 and 23 for 624bp fragment and primers 11 and 17 for 729bp fragment (Figure 
III.5A). Amplification scheme was the same as for the SOE PCR-I.1 except that amplification 
was performed for 25 cycles and annealing was at 60°C for 2 min. The SOE PCR-I.2 resulted 
in three fragments (F481 bp, F624 bp and F729 bp), which were separated on an agarose gel 
(Figure III.5B). 
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Figure III.5 Schematic representation of fragment assembly by SOE PCR-I (A); Analysis of 
SOE PCR products by agarose gel electrophoresis (B). A. Three contiguous overlapping fragments 
were amplified by mixing twelve fragments in a set of four. Primers 1 and 28 were used for the 
amplification of the 480bp fragment, primers 6 and 23 for the 624 bp fragment and primers 11 and 17 
for the 729 bp fragment. The length of the assembled fragments and the final products are indicated in 
bp. The primers used for amplification in SOE PCR-I.2 are shown in arrows. B. 5 µl of the amplified 
DNA fragments obtained SOE PCR-I.2 were separated on a 1.2% (w/v) agarose gel (II.2.3.3) and 
visualised. 1: 481 bp fragment; 2: 624 bp fragment; 3: 729 bp fragment. M: 100 bp ladder 
The resulting fragments from the SOE PCR-I were gel purified (II.2.3.3) and used as 
templates for a second round of SOE PCR (SOE PCR-II). The 481 bp, 624 bp and 729 bp 
fragments were diluted 1:100 and added to a reaction tube. The SOE PCR-II.1 was performed 
under the following condition: an initial denaturation for 3 min at 94°C followed by 5 cycles 
of denaturation at 94°C for 1 min, annealing 38°C for 10 min, extension 72°C for 2 min and a 
fill-in cycle of 72°C for 10 min. 20µl of the assembled final PCR fragment was then 
amplified in SOE PCR-II.2 using primers 1 and 17 (Figure III.6A). Amplification procedure 
was the same as the initial SOE PCR-I.2 except that amplification in the previous annealing 
was performed at 60°C and in SOE PCR II.2 at 55°C for 2 min. The final PCR product 
containing the full-length codon optimised HSA cDNA was separated on an agarose gel 
(Figure III.6B) demonstrating that a fragment of the expected size (1.8 kb) was amplified. 
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Figure III.6 Schematic representation of fragment assembly by SOE PCR-II (A); Analysis of 
SOE PCR products by agarose gel electrophoresis (B). A. Final plant codon optimized SOE PCR 
product was amplified by using three contiguous overlapping fragments (481 bp fragment, 624 bp 
fragment and 729 bp fragment) with primers 1 and 17. The length of the final products is indicated in 
bp. The primers used for amplification in SOE PCR-I.2 are shown in arrows. B. 5 µl of the amplified 
DNA fragment obtained by the SOE PCR-II.2 was separated on a 1.2% (w/v) agarose gel (II.2.3.3) 
(lane 1 and lane 2). M: PstI digested λ DNA. 
 
The plant codon optimised rHSA (1.8 kB) fragment was gel purified (II.2.3.3), digested with 
EcoRI and cloned into the EcoRI site of the TOPO TA vector (II.1.5.2). Fifty independent 
clones were sequenced with primers specific for vector DNA and/or specific for the plant 
codon optimised HSA (II.1.6). Sequence alignment showed that as many as 35 mutations per 
clone, which include insertions, deletions or base changes were detectable in the nucleotide 
sequence. Analysis of the sequence revealed that the mutations were exclusively located in 
the regions covered by the 32 primers used for the assembly and amplification, but not in the 
template regions. This demonstrates that the observed mutations are mainly introduced by the 
primers indicating the bad quality of the used oligonucleotides. 
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The clones 13 and 31 having the least errors still contained 19 and 20 mutations respectively. 
The representative schema for the location of the mutations in the sequence of the clones 13 
and 31 is given in Figure III.7.  
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NlaIII 1457
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Figure III.7 Schematic representation of the mutations in the plant codon optimised rHSA. 
Arrows with the pink colour indicate the location of mutations in clone 13, and arrows with the grey 
colour in clone 31. 
It has been demonstrated that it is possible to amplify a semi-synthetic gene by the help of the 
proper primer combination and by optimising the conditions for PCR amplification. Even 
though the assembly of the final PCR product with the expected molecular weight (Figure 
III.6B) was successful, incorporation of mutations by primers in the sequence of the plant 
codon optimised gene required additional experiments to remove these errors. Mutations in 
the final HSA cDNA could be eliminated by different approaches like in vitro site directed 
mutagenesis or combining smaller fragments possessing the correct sequence by a restriction 
enzyme digestion approach. However, the elimination of a minimum of 19 mutations would 
be labour intensive and time consuming and therefore efforts to generate a corrected plant 
codon optimised gene were undertaken. Instead the work was focused on the improved rHSA 
production parameters using the original HSA cDNA sequence. 
 
III.2.3 Generation of HSA expression constructs 
III.2.3.1 Bacterial expression constructs 
HSA is one of the secreted proteins that do not require glycosylation and it was confirmed 
previously that HSA is accumulating in cytoplasm of E. coli (Lawn, Adelman et al. 1981). In 
Chapter III  Results 
64 
this thesis, two approaches for expression of HSA in E. coli were examined. The HSA cDNA 
was cloned into the vectors pET21d (II.1.5.5) and pET22b (II.1.5.6) via NcoI and SalI 
restriction enzyme sites. Both expression vectors contain the T7 promoter, pBR322 origin, 
ampicillin resistance gene as selective marker and a C-terminal his-tag sequence for 
purification. The pET22b vector (II.1.5.6) carries additionally a pelB leader sequence for 
targeting the heterologous expressed protein to the periplasm. Recombinant plasmids 
pET21d-HSA (cytoplasmic expression) and pET22b-HSA (periplasmic expression) were 
transformed separately into E. coli strain BL21λDE3 and used for bacterial expression 
(III.4.1). 
 
III.2.3.2 Plant expression constructs 
For generation of the HSA-APO construct enabling secretion of rHSA into apoplastic space 
of plant cells, HSA in the pGEM-3zf vector (III.2.1) was digested with SalI and partially with 
NcoI. Subsequently, the hemoglobin gene (HEME) in the HEME-APO construct was 
replaced by the HSA cDNA in the pUC18 vector containing chalchone synthase                     
5 untranslated region (CHS) and the plant codon optimised signal sequence (LPL*) at the   
5 and cmyc and his6 tag at the 3 end. Finally the HSA cassette was cut from HSA-APO in 
pUC18 including CHS and LPL* via EcoRI and SalI enzymes and cloned into the pSSH1 
vectors containing either cmyc-his6 (HSA-APO) or KDEL tag (HSA-KDEL) at the 3 
terminus. The resulting HSA-APO and HSA-KDEL constructs in pSSH1 plant expression 
vector were transformed into E. coli and DNA from independent clones was sequenced 
(II.2.3.7) in order to verify the expected sequence.  
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Figure III.8 Construction of pSSH1 plant expression vectors HSA-APO and HSA-KDEL. 
CHS: 5' untranslated region of chalcon synthase; LPL*: plant codon optimized leader peptide derived 
from murine light chain of TMV-specific rAb24; HEME: hemoglobin; CaMV35SS; double enhanced 
35S promoter from CaMV; c-myc: myc epitope; His6: his-6 tag; KDEL: ER retention signal; 
termination: termination signal of CaMV 35S. 
The constructs HSA-APO and HSA-KDEL in pSSH1 were transformed into A. tumefaciens 
strain GV3101 carrying the helper plasmid pMP90RK (GMR, KMR, RifR) by electroporation 
(II.2.1.8). Seven independent recombinant colonies from each transformation were screened 
for the presence of an insert by PCR (II.2.3.6.1). Recombinant Agrobacterium cultures of 
each construct were prepared from single colonies and used for transient expression (III.4.2), 
stable transformation of N. tabacum (III.4.3) and stable transformation of BY2 tobacco 
suspension cells (III.4.5). 
In addition to the constructs HSA-APO and HSA-KDEL in pSSH1 for tobacco, zucchini and 
bean transformation, HSA-KDEL in pAL76 vector was also generated for expression of 
rHSA in wheat. HSA-KDEL cassette from HSA-KDEL in pUC18 including CHS and LPL* 
at the 5 end and KDEL tag at 3 end was digested via EcoRI and HindIII enzymes and 
cloned into the pAL76 vector which contains ubiquitin 1 promoter and intron 1 from maize 
and nos termination signal (II.1.5.8). The resulting HSA-KDEL construct in pAL76 plant 
expression vector was transformed into E. coli and DNA from independent clones was 
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sequenced (II.2.3.7) in order to verify the expected sequence. HSA-KDEL in pAL76 vector 
was used for bombardment of immature wheat embryos (Triticum aestivum L. cv. Bobwhite).  
 
III.3 Expression of rHSA  
III.3.1 Bacterial expression 
To achieve rHSA production in bacteria plasmids pET21d-HSA (cytoplasmic expression) and 
pET22b-HSA (periplasmic expression) were transformed separately into E. coli strain 
BL21λDE3 and expression was induced by 1 mM IPTG for 4 hours (II.3.1). For cytoplasmic 
extraction E. coli cells transformed with the pET21d-HSA vector DNA were suspended in 
TEN buffer and sonicated (II.4.1). For periplasmic extraction the pET22b-HSA cell pellet 
was resuspended in Tris-Sucrose solution and supernatant was collected after centrifugation 
(II.4.1). Subsequent to immobilized metal affinity chromatography (IMAC) purification 
exploiting the His-tag for binding to Ni-NTA matrix (II.6.1), cytoplasmatically and 
periplasmatically expressed rHSA was analysed by ELISA (data not shown), SDS-PAGE 
(Figure III.9A) and immunoblot (Figure III.9B). 
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Figure III.9 SDS-PAGE (A) and Immunoblot analysis (B) of purified rHSA from E. coli 
BL21λDE3 cytoplasm. Affinity purified rHSA was resolved on 12% (w/v) SDS-PAGE (II.4.6.1) then 
stained with Coomassie brilliant blue (II.4.7.1) (A) or blotted onto nitrocellulose membrane followed 
by immunoblot analysis (B) (II.4.8). Anti HSA monoclonal antibody (Sigma) was used as the primary 
antibody followed by GAMAP as secondary antibody. Immunoblot was developed by addition of 
NBT/BCIP substrate. E1-E3: 5 µl of the first, second and third elution fractions of rHSA; FT: Flow 
through; +: 50 ng HSA (Sigma); M: Molecular weight protein marker. 
The level of rHSA expressed in the periplasm of E. coli was below the threshold level for 
immunoblot analysis and ELISA (data not shown). For cytoplasmic expression two proteins 
with the same intensity migrating at around 62 kDa and 27 kDa were observed on a SDS 
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PAA gel (Figure III.9A). The 27 kDa band on the SDS PAA gel might be a co-purified 
bacterial protein after affinity purification. The 62 kDa band on the SDS PAA gel 
corresponded approximately to the expected size of rHSA (66 kDa). Immunoblot analysis of 
the same samples (Figure III.9B) with anti-HSA monoclonal antibody however showed that 
these bands were co-purified bacterial proteins and only a small fraction of the band at 62 
kDa was rHSA. In addition, a significant amount of rHSA was also present in the flow 
through (Figure III.9B lane FT), indicating that binding conditions to the Ni-NTA matrix 
needs to be further optimised. Another lower band (at around 30 kDa), which was recognized 
by the monoclonal anti-HSA antibody, is most probably a truncated form of rHSA. The yield 
of affinity purified cytoplasmatically expressed rHSA was determined by ELISA (data not 
shown) to be 0.002 mg/L bacterial culture. 
rHSA could only be detected in the cytoplasm of E.coli. The periplasmic environment did not 
allow accumulation of this protein to a detectable amount. After confirmation of the bacterial 
expression, the next step was to test the rHSA accumulation in the plant system.  
 
III.3.2 Transient expression of rHSA in plant leaves 
Transient gene expression in plants has several advantages over the generation of stably 
transformed transgenic plants. Regenerating transgenic plants from transformed cells is both 
labour intensive and time consuming. In contrast, transient expression systems allow the rapid 
evaluation and improvement of plant expressed proteins. They present a feasible method for 
testing accumulation of the foreign protein in vivo before progressing to develop stably 
transformed plants (Kapila, De Rycke et al. 1996). Therefore, rHSA was transiently 
expressed in leaves of different plant species to confirm product integrity and to screen for the 
best expression host and construct before generation of transgenic plants.  
 
III.3.2.1 Transient expression in N. tabacum cv. Petite Havana SR1 leaves 
Recombinant Agrobacteria carrying the HSA-APO and HSA-KDEL constructs (III.2.3.2) 
were used for vacuum infiltration of tobacco leaves (II.2.2.5). Four to six leaves were 
infiltrated with recombinant agrobacteria (II.2.2.5). Accumulation of rHSA in tobacco leaves 
was analysed by immunoblot 72 hours after vacuum infiltration. The identity and integrity of 
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the expressed proteins were confirmed by immunoblot analysis (II.4.8) using either specific 
anti-cmyc or anti-KDEL antibodies. Immunoblot analysis revealed a distinct band of 
approximately 66 kDa, corresponding to the molecular weight of HSA for both apoplastic and 
ER constructs (Figure III.10).  
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Figure III.10 Immunoblot analysis of HSA-APO (A) and HSA-KDEL (B) transiently 
expressed in N. tabacum cv. Petite Havana SR1 leaves. Total soluble leaf proteins were extracted 
by grinding tobacco leaf tissue in two volumes extraction buffer (II.4.2), separated by 12% (w/v) 
SDS-PAGE (II.4.6.1) and blotted onto a nitrocellulose membrane (II.4.8). Immuno detection was 
carried out with anti-c-myc antibody (1:5000) (A) or anti KDEL antibody (1:500) (B), followed by 1 h 
incubation with GAMAP (1:5000) and NBT/BCIP detection for 5 min at RT. 5 µl of TSP extracted 
from tobacco leaves transformed with HSA-KDEL (A) and HSA-APO (B) M: prestained protein 
marker. 
Due to unavailability of anti HSA antibody at that point of the project, two different detection 
antibodies (anti-cmyc and anti-KDEL) were selected to confirm the accumulation by 
immunoblot. Considering the reduced sensitivity of the anti-KDEL detection antibody 
immunoblot analysis demonstrated that higher rHSA levels were obtained when the protein 
accumulated in the ER.  
 
III.3.2.2 Alternative N. tabacum cultivars 
In addition to N. tabacum cv. Petite Havana SR1, eight additional tobacco varieties were 
evaluated in their performance of expressing rHSA in tobacco leaves. These varieties include 
Gead Korso, Barley Junifer, Adonis Schwester, Barley Saturn, Virginia, Badische 
Geudentheimer, Maryland Mammoth and Nicotine free tobacco. For comparing transient 
expression, the HSA-APO construct (III.2.3.2) was chosen that allows secretion of 
recombinant HSA into the apoplast. Accumulation of rHSA in tobacco leaves was analysed 
by immunoblot and ELISA 72 hours after vacuum infiltration. Immunoblot analysis (data not 
shown) revealed a distinct band of approximately 66 kDa, corresponding to the molecular 
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weight of rHSA for the apoplastic construct in all cultivars analysed. Furthermore in several 
samples including the negative control (wild type extract of SR1), another band at around 32 
kDa, was recognized by the monoclonal anti-HSA antibody. The presence of this smaller 
band in most of the plant extracts might be an indication of a plant protein reacting 
unspecifically with the anti-HSA antibody. According to the immunoblot results, the level of 
expression of rHSA varied considerably between the tobacco varieties. Highest level 
expression was observed in Adonis Schwester, Barley Saturn and Maryland Mammoth (data 
not shown).  
To quantify the amount of rHSA ELISA was performed and it confirmed the results of the 
immunoblot analysis. In the varieties Adonis Schwester, Barley Saturn and Maryland 
Mammoth the accumulation levels were 5-10 times higher than the other tobacco cultivars 
tested (Figure III.11). Highest accumulation level was 10 µg rHSA per g leaf material in 
Adonis Schwester and Barley Saturn, the lowest level (1 µg rHSA per g leaf material) was 
observed in transiently transformed leaves of Barley Jupiter. 
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Figure III.11 Determination of rHSA accumulation levels in transiently transformed 
tobacco cultivars by ELISA. Goat anti-HSA antibody (1:500 diluted in TBS) was coated to ELISA 
plates (II.4.9.2). After blocking with MTBS, 100 µl of the serially diluted plant extracts (II.4.2) were 
added to the coated plates. Bound rHSA was detected by addition of peroxidase-conjugated rabbit 
anti-HSA antibody (1: 20000). ELISA readings (OD 690 nm) were performed after 1-10 min incubation 
with ABTS substrate solution buffer (II.4.9.2). 
In addition to the advantage of an observed higher level of accumulation, Adonis Schwester, 
Barley Saturn and Maryland Mammoth also have higher leaf biomass in comparison with the 
SR1 tobacco and they are widely grown in the fields. Therefore these varieties could be an 
alternative to the present model tobacco variety SR1. A disadvantage with Adonis Schwester 
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and Barley Saturn varieties is the unavailability of seeds from the adult plants for the new 
generation. 
Table III.1 Production levels of rHSA in plants.  
 HSA-APO; plant expression construct carrying double enhanced 35S promoter from 
CaMV(CaMV35SS), 5 untranslated region of chalcon synthase (CHS) and plant codon optimized leader 
peptide derived from murine light chain of TMV-specific rAb24 (LPL*) at 5 end and cmyc and his6 
epitopes (cmyc/his6) for detection and purification at 3 end. HSA-KDEL; plant expression construct 
carrying double enhanced 35S promoter from CaMV(CaMV35SS), 5 untranslated region of chalcon 
synthase (CHS) and plant codon optimized leader peptide derived from murine light chain of TMV-
specific rAb24 (LPL*) at 5 end and KDEL retention signal of proteins in the endoplasmic reticulum 
(ER) at 3 end. 
 
plant species localisation cultivation expression system maximum accumulation 
N. tabacum cv. Petite 
Havana SR1 apoplast greenhouse transient 2 µg/g leaf material 
N. tabacum cv. Virginia apoplast greenhouse transient 2.3µg/g leaf material 
N. tabacum cv. Badische 
Geudentheimer apoplast greenhouse transient 2.4µg/g leaf material 
N. tabacum cv. Gead Korso apoplast greenhouse transient 2.6µg/g leaf material 
N. tabacum cv. Barley 
Jupiter apoplast greenhouse transient 0.76µg/g leaf material 
N. tabacum cv. Adonis 
Schwester apoplast greenhouse transient 10µg/g leaf material 
N. tabacum cv. Barley 
Saturn apoplast greenhouse transient 10µg/g leaf material 
N. tabacum cv. Nicotine 
free apoplast greenhouse transient 1.7µg/g leaf material 
N. tabacum cv. Maryland 
Mammoth apoplast greenhouse transient 6.3µg/g leaf material 
 
III.3.2.3 Transient expression of rHSA in zucchini and bean leaves 
In order to test the feasibility of other plant varieties for the transient expression of rHSA, 
expression of the HSA-APO construct was analysed in zucchini and bean leaves. 
Accumulation of rHSA in leaves was analyzed by immunoblot (data not shown) and ELISA 
72 hours after vacuum infiltration (Figure III.12). 
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Figure III.12 Determination of rHSA accumulation levels in transiently transformed zucchini, 
SR1 and bean leaves by ELISA. Goat anti-HSA antibody (1:500 diluted in TBS) was coated to 
ELISA plates (II.4.9.2).  After blocking with MTBS, 100 µl of the serially diluted plant extracts 
(II.4.2) were added to the coated plates. Bound rHSA was detected by addition of peroxidase-
conjugated rabbit anti-HSA antibody (1: 20000). ELISA readings (OD 690 nm) were performed after 1-
10 min. incubation with ABTS substrate solution buffer (II.4.9.2). 
 
Transient expression of rHSA in the apoplasm of bean extracts was neither detected in the 
immunoblot (data not shown) nor in ELISA. However, 2.65 µg rHSA per g leaf material was 
detected in zucchini which is slightly higher than the model host tobacco species SR1 (2 µg 
HSA per g leaf).  
This experiment has proven that other plant species could be also used for production of 
rHSA. The transient expression experiments have shown that highest rHSA accumulation was 
obtained in tobacco. Although tobacco cultivars Adonis Schwester, Barley Saturn and 
Maryland Mammoth seemed to be most suitable, Petit Havana SR1 was used for generation 
of stable transformed plants since only for this cultivar reliable transformation protocols and 
experience in crossing and breeding were available. 
 
III.3.3 Stable expression of rHSA in transgenic tobacco plants 
III.3.3.1 Transgenic tobacco plants producing HSA-APO  
Fourty independent transgenic N. tabacum cv. Petite Havana SR1 lines were generated by 
leaf disc transformation using recombinant A. tumefaciens (II.2.1.8) carrying the HSA-APO 
construct. Transgenic T0 plants were regenerated from transformed calli. Young leaves from 
regenerated transgenic plants were used for extraction of total soluble proteins (II.4.2) and for 
analysis of recombinant protein accumulation by immunoblot (II.4.8). 
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Immunoblot analysis revealed that 32 out of 40 T0 analysed plants accumulated apoplastic 
rHSA (Figure III.13). A clear band with an identical relative mobility to commercial HSA 
was detected. Sometimes additional immuno-positive bands of a smaller molecular weight 
were observed both in the untransformed (negative control tobacco SR1) and transformed 
lines (Figure III.13). Most likely these are degradation products or plant derived proteins 
cross-reacting with the detection antibody. 
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Figure III.13 Screening of stable transgenic tobacco plants expressing HSA-APO. Total soluble 
leaf proteins were extracted by grinding tobacco leaf tissue in two volumes extraction buffer (II.4.2), 
separated by a 12% (w/v) SDS-PAGE (II.4.6.1) and blotted onto a nitrocellulose membrane (II.4.8). 
Immuno detection was carried out with anti-HSA antibody (1:5000) followed by 1 h incubation with 
GAMAP (1:5000) and NBT/BCIP detection for 5 min at RT. C1-C40: 5 µl of TSP extracted from 
transgenic HSA-APO tobacco leaves; M: prestained protein marker; -: 5 µl of wild type plant extract 
+: 50 ng of HSA (Sigma). Tobacco lines selected for the establishment of homozygous lines are 
indicated by a *.  
The lines with the highest level of apoplastic rHSA (C1, C3, C5, C8, C9, C10, C12, C13, 
C22, C23, C26, C27, C30, C31, and C32) were selected and self pollinated for establishment 
of homozygous lines. From these fifteen lines seeds were collected and three of these lines 
(C10, C22 and C30) with the highest accumulation were further analysed in the following 
generations and results are illustrated in III.3.3.3. 
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III.3.3.2 Transgenic tobacco plants expressing HSA-KDEL 
Fourty independent transgenic lines were generated by leaf disc transformation using 
recombinant A. tumefaciens (II.2.1.8) carrying HSA-KDEL construct. From regenerated T0 
transgenic plants young leaves were collected and used for analysis of recombinant protein 
accumulation by immunoblot (II.4.8). 
Immunoblot analysis revealed that 37 out of 40 T0 analysed plants were positive for rHSA 
accumulation (Figure III.14) and levels vary between siblings. Recombinant HSA migrated 
according to its predicted molecular weight of 66 kDa. As it was observed in the 
immunoblots of transgenic HSA-APO plants (Figure III.13), immuno-positive band of a 
smaller protein migrating at around 30 kDa was also observed in the extracts of HSA-KDEL 
plants (Figure III.14). 
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Figure III.14 Screening of stable transgenic SR1 plants expressing HSA-KDEL. Total 
soluble leaf proteins were extracted by grinding tobacco leaf tissue in two volumes extraction buffer 
(II.4.2), separated by a 12% (w/v) SDS-PAGE (II.4.6.1) and blotted onto a nitrocellulose membrane 
(II.4.8). Immuno detection was carried out with anti-HSA antibody (1:5000) followed by 1 h 
incubation with GAMAP (1:5000) and NBT/BCIP detection for 5 min at RT. K1-K40: 5 µl of TSP 
extracted from transgenic HSA-KDEL tobacco leaves; M: prestained protein marker; -: 5 µl of wild 
type plant extract +: 50 ng of HSA (Sigma). Tobacco lines selected for the establishment of 
homozygous lines are indicated by a *.  
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The lines with the highest levels (K2, K4, K5, K8; K13, K14, K18, K19, K20, K23, K25, 
K28, K31, K32 and K33) were selected and self pollinated for establishment of homozygous 
lines. From these fifteen lines seeds were collected and three of these lines (K2, K31 and 
K32) with the highest accumulation were analysed in the next generation and results are 
illustrated in III.3.3.3. 
In general, immunoblots are not as amenable as ELISA to determine the level of 
accumulation of a foreign protein. However, band intensities are usually compared with 
known amount of a standard protein to get a rough estimate of the level of accumulation. In 
the immunoblots of HSA-APO (Figure III.13) and HSA-KDEL (Figure III.14), the intensity 
of the rHSA bands was comparable. Using this rough estimation, although variation between 
different siblings are observed, in general rHSA levels were higher in the HSA-KDEL 
producing plants when compared to the HSA-APO plants. 
 
III.3.3.3 Analysis of rHSA accumulation in the T1 generation 
From transgenic T0 plants 15 lines for each construct (HSA-APO and HSA-KDEL) were 
selfed and their seeds were collected. Transgenic T0 plants with the highest accumulation of 
rHSA (C10, C22 and C30 for HSA-APO, K2, K31 and K32 for HSA-KDEL) were selected 
for further analysis. Seeds of these lines were germinated in the greenhouse and, young leaves 
of the T1 plants were collected. Total soluble protein (TSP) from leaves of nine plants per line 
was extracted for Bradford protein determination and recombinant protein accumulation 
analysis by immunoblot. Bradford total protein quantification revealed that TSP content 
varied between 11.6-19.84 mg per g leaf (data not shown). Accumulation of the recombinant 
protein in tobacco leaves was analysed by immunoblot using crude extracts of total soluble 
leaf protein. Immunoblot experiments revealed that 7 out of 9 carrying the HSA-APO 
construct and 9 out of 9 plants with integrated HSA-KDEL construct were positive (data not 
shown). Recombinant HSA migrated according to its predicted molecular weight of 66 kDa.  
The T1 progeny was analysed for a 3:1 Mendelian segregation ratio on kanamycin selection 
plates (II.2.2.6), indicating the events of T-DNA integration at different genetic loci. Results 
were tabulated as the ratio of tolerant to susceptible seedlings and tested if they segrated in a 
3:1 ratio. Chi-square values are calculated according to the following formula: 
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Table III.2 Segregation analysis of the transgenic T1 lines expressing rHSA either in the ER 
(KDEL 2, 31, 32) or in the apoplast (APO 30, 22, 10).  
Transgenic Resistant Susceptible Chi square* 
HSA-APO    
APO-30 55 18 0.0045 
APO-22 46 16 0.0215 
APO-10 36 10 0.26 
HSA-KDEL    
KDEL-2 32 7 1.0256 
KDEL-31 27 9 0 
KDEL-32 73 20 1.0533 
(* Values less than 3.83 indicate a good fit to a 3 resistant: 1 susceptible ratio at the P = 0.05 level of 
probability with degree of freedom = 1.) Number of resistant and susceptible plants is tabulated and 
Chi-square values are calculated. 
Chi-square values of less than 3.84 fit a 3:1 segregation ratio and indicate a single dominant 
Mendelian locus with 95% of confidence. Mendelian segregation analyses indicate that more 
likely single integration of the transgenes (HSA-APO or HSA-KDEL) into the chromosomal 
DNA of all analysed transgenic line has taken place.  
 
III.3.3.4 Analysis of rHSA accumulation in homozygous T2 lines 
To obtain individuals homozygous lines, seeds from T1 plants were collected and from five 
positive T1 lines, at least 15 T2 plants were grown until young leaves for analysis were 
available. All seeds from that parent for which no recessive segregants were seen should be 
homozygous, and it should be possible to propagate this line indefinitely with no loss of the 
transgene due to segregation. Seeds from transgenic lines were collected, grown in 
greenhouse and leaf extracts were analysed until the homozygous generation could be 
obtained. Total soluble protein was extracted from leaves of homozygous T2 lines producing 
HSA-APO and HSA-KDEL and used for immunoblot analysis. It revealed that rHSA 
migrated according to its predicted molecular weight of 66 kDa. As in the transiently 
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expressed rHSA and stably transformed T0 and T1 generations a second band at around 30 
kDa was observed.  Most likely these are plant derived proteins unspecifically interacting 
with the detection antibody or degradation products.  
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Figure III.15 Screening of stable transgenic T2 plants producing HSA-APO and HSA-KDEL. 
Total soluble leaf proteins were extracted by grinding tobacco leaf tissue in two volumes extraction 
buffer (II.4.2), separated by 12% (w/v) SDS-PAGE (II.4.6.1) and blotted onto a nitrocellulose 
membrane (II.4.8). Immunodetection was carried out with anti-HSA antibody (1:5000) followed by 1 
h incubation with GAMAP (1:5000) and NBT/BCIP detection for 5 min at RT. 5 µl of total soluble 
protein extracted from T2 transgenic tobacco leaves were separated. 1-4) HSA-KDEL 2/12-1, 31/7-1, 
32/4-2, 32/4-3; 5-7) HSA-APO 22/5-5, 22/5-6, 30/1-1; -: 5 µl of wild type plant extract +: 50 ng of 
HSA (Sigma). 
 
A detailed comparison of HSA-APO and HSA-KDEL accumulation levels was performed by 
ELISA in T2 lines. The HSA-APO protein accumulated to levels of 1.8 to 6 µg rHSA per g 
leaf and HSA-KDEL to 5 up to 100 µg HSA per g leaf material (Figure III.16). 
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Figure III.16 Determination of rHSA accumulation levels in homozygous T2 lines by ELISA. 
Goat anti-HSA antibody (1:500 diluted in TBS) was coated to ELISA plates. After blocking with 
MTBS, 100 µl of the serially diluted plant extracts were added to the coated plates. Bound rHSA was 
detected by addition of peroxidase-conjugated rabbit anti-HSA antibody (1: 20000). ELISA readings 
(OD 690 nm) were performed after 1-10 min. incubation with ABTS substrate solution buffer (II.4.9.2). 
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The accumulation level in the homozygous transgenic T2 line HSA-KDEL 31/7-1 was 100 µg 
rHSA per g leaf material and this is the highest level observed among the lines tested. This 
transgenic line was further propagated for downstream processing (III.4) of rHSA from 
transgenic leaf material. Highest apoplastic rHSA level of 5.86 µg rHSA per g leaf material 
was detected in the homozygous T2 line HSA-APO 22/5-6. The seeds from this line were 
collected and send to Canada to perform a field trial (III.3.3.5). 
III.3.3.4.1 Analysis of plant derived rHSA with 2-D SDS PAGE 
The gel electrophoretic analysis of proteins in two subsequent dimensions, first according to 
their pI and then according to their molecular weight, is still the most common and successful 
technique for the comparative separation of a heterogeneous protein mixture. Despite its 
limitations such as the incomplete separation of very acidic or very basic proteins, its 
resolution in the analysis of complex mixtures is still unrivalled. For a more detailed 
investigation of rHSA accumulation in the ER of the plant cells two dimensional gel 
electrophoresis was performed. 
Total soluble proteins from transgenic leaf tissue accumulating rHSA in the ER were isolated 
as described (II.4.2). TCA precipitated soluble proteins were diluted in the 
rehydration/sample buffer (II.4.6.2) and prior to two dimensional gel electrophoresis analysed 
by SDS PAGE and immunoblot. As it is visualised in Figure III.17, the protein migrated in a 
higher relative mobility than the authentic HSA which is most probably due to presence of 
high concentration of Urea (9 M) in the rehydration buffer used to dilute the extract.  
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Figure III.17 Immunoblot analysis of transgenic HSA-KDEL T4  tobacco leaves. TSP was 
extracted by mixing ground leaf powder with 10% (v/v) Trichloroacetic acid (TCA) solution in 
Acetone (II.4.2) TCA precipitated leaf proteins were homogenized in the presence of rehydration 
buffer (II.4.6.2) separated SDS PAGE and blotted onto a nitrocellulose membrane (II.4.8). 
Immunodetection was carried out with anti-HSA antibody (1:5000) followed by 1 hr incubation with 
GAMAP (1:5000) and NBT/BCIP detection for 5 min at RT. 1) 5 µl of TSP extracted from T4 
transgenic tobacco leaves; M) prestained protein marker; +: 100 ng of HSA (Sigma). 
 
Protein extracts derived from leaves of N. tabacum SR1 wild type and HSA-KDEL transgenic 
line were diluted in rehydration/sample buffer (II.4.6.2) and then separated on pH 3-10 
gradient immobilized pH-gradient gel strips in a BioRad Protean IEF cell (II.4.6.2). The 10% 
SDS PAA gels were subsequently stained with silver (II.4.7.2). Since silver staining is 10-100 
folds more sensitive than Coomassie staining, plenty of plant proteins could be detected on 
the silver stained gels (data not shown). Abundance of other plant proteins complicated the 
localization of rHSA with the expected molecular weight and pI point. Therefore the two 
dimensionally separated proteins were immunoblotted on nitrocellulose membranes. 
Immunodetection was carried out with an anti-HSA monoclonal antibody. The results of the 
two-dimensional gel electrophoresis of rHSA accumulation in the ER correlated with those 
obtained after an initial one dimensional gel electrophoresis and immunoblotting of plant 
extracts (Figure III.18). Relative mobility and theoretical pI point of authentic HSA (5.3) is 
found to be similar to rHSA extracted from transgenic leaves. Both using the wild type SR1 
control extract and transgenic plant extract another protein at around 30 kDa was observed. 
This protein was also visualised in the one-dimensional SDS PAGE profile (Figure III.17) 
and is most probably a degradation product. 
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Figure III.18 Comparative two dimensional gel electrophoresis and Immunoblot analysis of 
wild type (A) and transgenic (B) T4 stable tobacco expressing rHSA in ER. TSP was extracted by 
mixing ground leaf powder with 10% (v/v) Trichloroacetic acid (TCA) solution in Acetone (II.4.2) 
TCA precipitated leaf proteins were homogenized in the presence of rehydration buffer separated by 
2-D SDS PAGE (II.4.6.2) and blotted onto a nitrocellulose membrane (II.4.8). Immunodetection was 
carried out with anti-HSA antibody (1:5000) followed by 1 hr incubation with GAMAP (1:5000) and 
NBT/BCIP detection for 5 min at RT. 5 µl of TSP extracted from the leaves of A) Wild type SR1; B) 
HSA-KDEL; M) prestained protein marker.  
 
III.3.3.5 Field trials of transgenic tobacco plants producing rHSA 
Greenhouse observations of the transgenic plants at different cultivation stages indicated that 
the general phenotypic characteristics of the plants were similar to wild type plants. Rarely 
negative phenotypic changes are observed in some agronomic characteristics of plants upon 
transformation and regeneration. These changes are often caused by the regeneration 
procedure and tend to create reduced fitness (Dr. Jim Brandle, personal communication). 
Such possible changes in fitness can be determined in transgenic plants after greenhouse 
observations and field testing has taken place. Furthermore, amount of rHSA obtained in the 
greenhouse plants and field grown plants could be compared to get an idea for the 
performance of the transgenic plants under field conditions.  
The seeds from the T2 line HSA-APO-22/5-6 were used for the field trial. The site was 
located in Canada and field tests were performed by Dr. Jim Brandle (Agriculture and 
AgriFood Canada) (II.3.3). Trial area was approximately 15 m2. Around 30 days following 
transplantation of greenhouse seedlings, the plots were harvested and the plant material 
bulked for evaluation of dry matter yield and soluble protein concentration. The accumulation 
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level of rHSA secreted to the apoplastic space of transgenic tobacco plants under field 
conditions are presented in Table III.3. 
Table III.3 Analysis of rHSA accumulation in the transgenic HSA-APO-22/5-6 in the field. 
Leaf yield and TSP amount were determined in transgenic plants for the 15 m2 trial area and converted 
to one hectare (1 hectare ~ 10,000 m2). TSP: Total soluble protein; kg f.w/ha: kg fresh weight per 
hectare. 
Line Leaf yield (kg f.w./ha) TSP (kg/ha) HSA (%TSP) HSA (kg/ha)
HSA-APO-22/5-6 1563 13.55 0.052 0.704 
 
Total protein quantification by Bradford revealed that TSP content was 8.6 mg per g leaf 
material. The amount of rHSA accumulation in the field was estimated as 0.052% of TSP by 
immunoblot (data not shown). A total of 1563 kg fresh transgenic leaf with a TSP of 13.55 
kg/ha was estimated to be harvested from one hectare of field area. Recombinant HSA 
account for 0.052% of this protein content. Approximately 700 g of rHSA per hectare is a 
rough estimate for the level of rHSA production in transgenic plants grown in the field. 
Transgenic plants accumulated 4.472µg rHSA per g leaf material under field condition. This 
level is in good agreement with the homozygous T2 transgenic plants grown in the 
greenhouse producing HSA-APO to levels of an average 5 µg rHSA per g leaf material 
(Figure III.16).  
 
III.3.4 Production of rHSA in transgenic wheat seeds 
Wheat seeds are used in order to exploit the production of rHSA in these protein rich storage 
organs that can be stored almost indefinitely. Immature wheat (Triticum aestivum L. cv. 
Bobwhite) embryos were used as explants for the bombardment (II.2.2.7) of the HSA-KDEL 
cDNA integrated in the pAL76 expression vector (II.1.5.8). Following selection of the wheat 
on phosphinotricin (PPT), PPT resistant plant material was recovered. The efficiency of 
transgenic plant recovery was around 1%. Transgenic lines were then analysed for rHSA 
accumulation. 
Total soluble proteins from dry wheat seeds (II.4.4) were analysed by ELISA and 
immunoblot. Using both procedures 80-100 µg rHSA per g seed material was detected in 
samples of pooled T4 wheat seeds (data not shown). Immunoblot analysis revealed a distinct 
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band of approximately 66 kDa, corresponding to the molecular weight of HSA (Figure 
III.19). In addition, two other lower bands at around 45 and 30 kDa were recognized by the 
monoclonal anti-HSA antibody. These bands were also visible in the immunoblot analysis of 
various plant protein extracts (see Figure III.14, III.19. III.20 and III.21), which might be an 
indication of degradation during extraction of the recombinant protein from different plant 
species. 
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Figure III.19 Immunoblot analysis of the ER targeted rHSA extracted from transgenic wheat 
kernels. Total soluble proteins from wheat kernels was extracted (II.4.4) and 15 µl of the extract was 
separated by 12% (w/v) SDS-PAGE (II.4.6.1) and blotted onto a nitrocellulose membrane (II.4.8). 
Immuno detection was carried out using an anti-HSA antibody (1:5000) followed by 1 h incubation 
with GAMAP (1:5000) and NBT/BCIP detection. 1-4: 15 µl of total soluble proteins extracted from 
individual wheat kernels accumulating rHSA in the ER; M: prestained protein marker.  
It is clearly demonstrated that wheat seeds are an alternative production system for molecular 
farming of rHSA. High accumulation levels in the seeds as much as 100 µg rHSA/g seed 
could be achieved. These values correspond to the rHSA level obtained in the transgenic 
tobacco plants using the same ER targeting construct. 
 
III.3.5 Production of rHSA in transgenic tobacco suspension cells 
Intact plants and their seeds are not the only expression system available for plant based 
molecular farming. Plant suspension cells are a model system that can be easily transformed 
and cultivated on a large scale in fermenters (Fischer, Emans et al. 1999). In this study, in 
addition to tobacco, zucchini, bean and wheat seeds, tobacco suspension cell culture was also 
evaluated in terms of expression and secretion of rHSA. N. tabacum cv. BY-2 cells were 
transformed by co-cultivation with recombinant A. tumefaciens carrying HSA-APO and 
HSA-KDEL constructs (III.2.3.2). Pinpoint-sized clumps of kanamycin-resistant cells were 
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screened for expression of the chimeric gene (data not shown) and highest expressors, for the 
HSA-APO and HSA-KDEL construct were selected for the initiation of cell suspension lines. 
Once a rapidly growing homogeneous suspension culture was obtained, both the culture 
medium and the cell pellet were analysed for the presence of rHSA. 
After screening kanamycin resistant cells for highest expressors, two cell lines for HSA-APO 
(HSA-APO29, HSA-APO16) and one for HSA-KDEL (HSA-KDEL12) were selected. 
Suspension cells were sub-cultured weekly using a 2% (v/v) inoculum. Samples were taken 
aseptically from 3, 5, 7 and 10 days homogenously grown cultures after subculturing to 
determine the optimal time point for cell harvest in respect to rHSA accumulation. Fresh cell 
weight (FCW) was determined by pelleting the cells taken from 1 ml sample culture. No 
significant difference in terms of FCW between the transgenic lines was observed. FCW on 
day 3 was approximately 0.18 g per ml suspension culture, reaching to 0.54 g per ml on day 5 
and remaining constant at 0.55 g per ml after 7 and 10 days of growth (data not shown).  
Recombinant protein accumulation was measurable after 3 days of subculturing. For the cell 
line HSA-APO16, the highest accumulation level of 0.811 µg per g of cells was determined 
on day 5 and highest accumulation in the culture medium (0.494 µg per ml) on day 10. No 
secretion of rHSA into the culture medium was detected when cell line HSA-KDEL12 was 
analysed during these 10 days. For HSA-APO29, the highest accumulation level of 1.87 µg 
per g of cells was determined on day 7 and the highest accumulation in the culture medium 
1.84 µg per ml was obtained on day 10 using the same cell line (Figure III.20).  
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Figure III.20 Determination of rHSA levels in the culture medium (A) and in BY2 cells (B) by 
ELISA. Goat anti-HSA antibody (1:500 diluted in TBS) was coated to ELISA plates (II.4.9.2). After 
blocking with MTBS, 100 µl of the serially diluted plant extracts (II.4.2) were added to the coated 
plates. Bound rHSA was detected by addition of peroxidase-conjugated rabbit anti-HSA antibody (1: 
20000). ELISA readings (OD 690 nm) were performed after 1-10 min. incubation with ABTS substrate 
solution buffer (II.4.9.2). 
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Expression of rHSA in the transgenic BY2 cells and secretion to the supernatant were also 
compared at different stages of growth in the suspension cells by immunoblot. In addition to 
the expected size of rHSA with variable accumulation levels of HSA-APO and HSA-KDEL 
at 3, 5, 7 and 10 days, degradation bands at around 30 kDa were also observed (data not 
shown). As shown in ELISA (Figure III.20), and immunoblot highest levels of rHSA 
accumulation and secretion was observed using HSA-APO29 cell line. Therefore this line 
was chosen for the further experiments with the transgenic BY2 suspension cells. 
 
III.3.5.1 Analysis of rHSA secreted to the culture medium 
HSA-APO29 BY2 cell suspension culture was grown for 7 days. After separating the cells 
from the culture medium the amount of secreted rHSA was determined to be 1-1.5 µg per ml 
culture supernatant. Bradford analysis of the total soluble proteins in the supernatant revealed 
the amount in the medium to be 0.3-0.5 mg per ml. Therefore the amount of recombinant 
HSA secreted to the medium is in the range of 3-5 µg per mg total secreted protein, which is 
at least 15 times more than the secretion level obtained by Sijmons et al. (1990). 
 
III.3.5.2 Improving rHSA stability in the culture medium 
Due to the occurrence of unfavourable environmental conditions, the loss of proteins due to 
product instability during plant cell culture and subsequent purification significantly 
influences product yields. Protein stability following secretion can be improved with the 
addition of appropriate chemical agents (or stabilizers) to the growth media or storage 
solution (James and Lee 2001). By using this strategy, protein yields can be increased 
significantly with the addition of inexpensive chemical agents. Polyvinyl pyrrolidone (PVP) 
(Magnuson et al. 1996), DMSO (Wahl, An and Lee 1995), gelatine (Lee et al. 2002) have 
been used to protect extracellular proteins in transgenic plant cell and organ cultures.  
In order to test the effect of additional compounds to transgenic BY2 cultures, HSA-APO29 
suspension cell culture was cocultivated starting from the first day of subculture in the 
presence of 10 mM glutamine or PVP 40.000 (0.8 g/L). A third batch of culture was initiated 
to investigate the effect of increasing the sucrose concentration in the MS medium from 3% 
to 5%. Use of glutamine or increasing the sucrose content in the suspension culture media 
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resulted in a decrease in the amount of secreted rHSA when compared to the untreated 
control. In contrast, the level of secreted protein was increased by 80% upon addition of PVP 
40.000 (Figure III.21). 
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Figure III.21 rHSA accumulation in the culture medium of the HSA-APO29 cells grown in the 
absence or presence of stabilizing agents. Goat anti-HSA antibody (1:500 diluted in TBS) was 
coated to ELISA plates. After blocking with MTBS, 100 µl of the serially diluted cell culture 
supernatants separated from the suspension cells grown with or without stabilising agents were added 
to the coated plates. Bound rHSA was detected by addition of peroxidase-conjugated rabbit anti-HSA 
antibody (1: 20000). ELISA readings (OD 690nm) were performed after 1-10 min. incubation with 
ABTS substrate solution buffer (II.4.9.2). 1) Wild type BY2 suspension; 2) HSA-APO29; 3) HSA-
APO29+10 mM glutamine; 4) HSA-APO29+50 g /L sucrose; 5) HSA-APO29+PVP 40.000 (0.8 g/L) 
 
PVP with different molecular weights were tested by adding PVP to the HSA-APO29 culture 
from the first day of subculture. The working concentration was kept at 0.8 g/L. In the 
experiments, PVP (10.000, 40.000 and 360.000) alone or mixed with wild type BY2 
suspension cultures were used as a negative control where commercial HSA mixed with 
PVPs were used as a positive control. 
 
  
Chapter III  Results 
85 
0
0.5
1
1.5
2
2.5
3
3.5
4
1 2 3 4 5
µg
 H
S
A
/m
l c
ul
tu
re
 m
ed
iu
m
 
Figure III.22 rHSA accumulation in the culture medium of the HSA-APO29 cells grown in the 
absence or presence of PVP with varying molecular weight. Goat anti-HSA antibody (1:500 
diluted in TBS) was coated to ELISA plates. After blocking with MTBS, 100 µl of the serially diluted 
cell culture supernatants separated from the suspension cells grown with or without PVP were added 
to the coated plates. Bound rHSA was detected by addition of peroxidase-conjugated rabbit anti-HSA 
antibody (1: 20000). ELISA readings (OD 690nm) were performed after 1-10 min. incubation with 
ABTS substrate solution buffer (II.4.9.2). 1) Wild type BY2 suspension; 2) HSA-APO29; 3) HSA-
APO29+PVP 10.000; 4) HSA-APO29+PVP 40.000; 5) HSA-APO29+PVP 360.000. 
 
The presence of PVP increased the level of accumulated rHSA in the culture medium at least 
2-fold from 1.5 µg HSA per ml to 3.0 µg HSA per ml independent of the molecular weight of 
PVP tested. The highest level of secretion (3.75 µg rHSA per ml culture medium) was 
achieved using PVP 40.000 (Figure III.22).  
The ELISA results were also confirmed by immunoblot analysis of the secreted rHSA (Figure 
III.27). Although there is an increased recovery of secreted rHSA by using PVP 40.000, two 
lower bands (at around 25 and 32 kDa) were recognized by the monoclonal anti-HSA 
antibody as well. These smaller truncated forms of rHSA were present in the supernatant of 
suspension culture cocultivated in the presence or absence of PVP. This was an indication 
that additional PVP might result in enhanced recovery of the product from the suspension 
culture but did not lead to an increased stability of the recombinant protein.  
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Figure III.23 Immunoblot analysis secreted rHSA from HSAcmyc29 cells grown in the 
presence or absence of PVP with varying molecular weight. The supernatant of BY2 suspension 
cells was separated by centrifugation, 10 µl was separated by SDS-PAGE (II.4.6.1) and blotted onto a 
nitrocellulose membrane (II.4.8). Immunodetection was carried out with anti-HSA antibody (1:5000) 
followed by 1 hr incubation with GAMAP (1:5000) and NBT/BCIP detection. 1) Wild type; 2) HSA-
APO29; 3) HSA-APO29; 4) HSA-APO29+PVP 10.000; 5) HSA-APO29+PVP 40.000; 6) HSA-
APO29+PVP 360.000 7) Prestained protein marker + HSA (100 ng Sigma). 
 
III.4 Downstream processing of plant produced rHSA  
Highly efficient purification schemes are a prerequisite for the isolation of recombinant 
protein from a foreign host organism. Although established protocols are available for 
purification of recombinant proteins produced by animal or microbial sources, there is little 
data available on the purification of recombinant proteins from plants, plant suspension 
culture cells, leaves or seeds (Moloney and Holbrook 1997).  
Ion exchange chromatography (IEC) is the reversible interaction between charged molecules 
and oppositely charged chromatographic column. In cation exchange, negatively, and in 
anion exchange positively charged columns are coupled to the column medium. Elution is 
performed by change in the salt concentration or pH gradient. The advantages of IEC lie in 
the reasonably priced media and buffer costs and the simplicity and robustness of the method 
(Drossard, 2000). Cation exchange chromatography (CEX) as the capture step for rHSA 
purification was chosen due to the pI point of around 5.3 and also in order to avoid co-
purification of nucleic acids, which are contaminating the protein extracts. 
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III.4.1 Optimum pH for binding of rHSA to CEX matrix 
First experiments were done in a small scale purification system that was designed to permit 
scale up without major modifications. Therefore, chromatography media with identical 
functional groups were chosen for both small and large scale applications, no expensive 
reagents were added and simple inexpensive chromatography buffers were selected. For the 
same reason, no preconcentration steps like ammonium sulphate precipitation were included 
in the protocol. 
To determine the best binding conditions to the cation exchange column, 100 µl of 10 mg per 
ml commercially available HSA (Sigma) in mQ water was used in the initial experiments. 
Chromatography was performed using a 1.4 ml Source 30S (Pharmacia) cation exchange 
medium in a BioCart5 column (Kronlab, Sinsheim) equilibrated with the respective loading 
buffer (acetate buffer pH 4.0-5.0). Samples of 100 µl were injected and bound material eluted 
using a salt gradient (0-1 M NaCl).  
 
Figure III.24 Cation exchange chromatography of commercially available HSA. Column: 
BioCart5; medium: 1.4 ml Source 30S; feed: 100 µl of 10 mg per ml HSA (Sigma) dissolved in mQ 
water; loading buffer: acetate buffer shown in colored lines, first line in the orange colour represents 
acetate buffer pH 5.0, blue pH 4.8, red 4.6, small orange 4.4 and green 4.2; elution buffer: salt 
gradient (0-1 M NaCl). 
 
The chromatogram is illustrated in Figure III.24. Binding profile of authentic HSA to the 
cation exchange column suggested that binding of HSA to the medium is pH dependent and 
optimum pH lies is in the range of pH 4.4 to pH 4.6. Therefore, extraction of the rHSA from 
transgenic leaves should be carried in this pH range, in order to assure optimum binding of 
protein to the chromatography matrix. In the previous experiments Tris buffer at pH: 8.0 (50 
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mM Tris-HCl (pH 8.0) + 100 mM NaCl + 5 mM EDTA + 0.1% (v/v) Tween 20 + 10 mM 
DTT) for extraction of the rHSA was taken.  
 
III.4.2 Purification of rHSA from transgenic leaves  
III.4.2.1 Optimisation of extraction buffer 
In order to evaluate different buffer compositions for extraction of rHSA from transgenic 
tobacco plants prior to purification, total soluble protein from 1 g of transgenic leaf material 
(HSAKDEL31) was extracted in the extraction buffers 1, 2, 3 and 6 in the following list. 
After extracting total soluble proteins with these buffers pH was adjusted to 4.0 in 4, 5, 7 and 
8. The typical buffer used for extracting rHSA from transient and stable transformed plants 
was buffer 3.  
1. Acetate buffer (pH 4.0) + 5 mM EDTA 
2. Acetate buffer (pH 4.0) + 5 mM EDTA + CompleteTM protease inhibitor (ROCHE) 
3. 50 mM Tris-HCl (pH 8.0) + 100 mM NaCl + 5 mM EDTA + 0.1% (v/v) Tween 20 + 10 
mM DTT 
4. 50 mM Tris-HCl (pH 8.0) + 100 mM NaCl + 5 mM EDTA + 0.1% (v/v) Tween 20 + 10 
mM DTT with a pH shift to 4.0  
5. 50 mM Tris-HCl (pH 8.0) + 100 mM NaCl + 5 mM EDTA + 0.1% (v/v) Tween 20 + 10 
mM DTT with a pH shift to 4.0 + CompleteTM protease inhibitor (ROCHE) 
6. PBS + 100 mM NaCl at pH 6.0   
7. PBS + 100 mM NaCl at pH 6.0 with a pH shift to 4.0 
8. PBS + 100 mM NaCl at pH 7.0 with a pH shift to 4.0 + CompleteTM protease inhibitor 
(ROCHE) 
 
EDTA and CompleteTM protease inhibitor (ROCHE) were added only for small scale test 
purposes in order to check if these additives are playing any role for increasing the stability of 
the protein during extraction protocol. The amount of rHSA extracted from stable transgenic 
plants using different buffers was evaluated by ELISA (Figure III.25).  
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Figure III.25 Determination of rHSA in tobacco leaves using different plant extraction buffers. 
Goat anti-HSA antibody (1:500 diluted in TBS) was coated to ELISA plates. After blocking with 
MTBS, 100 µl of the serially diluted plant extracts were added to the coated plates. Bound rHSA was 
detected by addition of peroxidase-conjugated rabbit anti-HSA antibody (1: 20000). ELISA readings 
(OD 690nm) were performed after 1-10 min. incubation with ABTS substrate solution buffer (II.4.9.2). 
1) Acetate buffer (pH 4.0) + 5 mM EDTA 2) Acetate buffer (pH 4.0) +5 mM EDTA + completeTM 
protease inhibitor (ROCHE) 3) 50 mM Tris-HCl (pH 8.0) + 100 mM NaCl + 5 mM EDTA + 0.1% 
Tween 20 + 10 mM DTT 4) 50 mM Tris-HCl (pH 8.0) + 100 mM NaCl + 5 mM EDTA + 0.1% 
Tween 20 + 10 mM DTT with the pH shift to 4.0 5) 50 mM Tris-HCl (pH 8.0) + 100 mM NaCl + 5 
mM EDTA + 0.1% Tween 20 + 10 mM DTT with the pH shift to 4.0 + completeTM protease inhibitor 
(ROCHE) 6) PBS+100 mM NaCl at pH 6.0 7) PBS + 100 mM NaCl at pH 6.0 with the pH shift to 4.0 
8) PBS + 100 mM NaCl at pH 7.0 with the pH shift to 4.0 + completeTM protease inhibitor (ROCHE).  
 
In Figure III.25 it is clearly shown that PBS buffer with 100 mM NaCl at pH 6.0 is the best 
buffering system for rHSA extraction from transgenic leaves. However, the optimum pH for 
binding of HSA to the cation exchange matrix was determined to be between pH 4.4-4.6 (see 
III.24). The protein solutions therefore have to undergo an acidic pH shift for optimum 
binding to cation exchange matrix. As it is indicated in Figure III.25 column 4, 5, 7 and 8, 
after this pH shift there is a drastic decrease in the amount of rHSA that could be detected by 
ELISA. On the other hand using acetate buffer at pH 4.0 together with EDTA as a chelating 
agent (Figure III.25 column 1) was also effective for the extraction of the rHSA from 
transgenic leaves and it has the advantage of being closer to the optimum pH for binding to 
the cation exchange matrix. That is the reason why acetate buffer at pH 4.0 + 5 mM EDTA 
was the buffer of choice for the extraction of rHSA from transgenic leaf material.  
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Figure III.26 SDS PAGE (A) and immunoblot analysis (B) of rHSA extracted from transgenic 
HSAKDEL31 N. Tabacum SR1 leaves using different buffers. TSP was extracted by grinding 
tobacco leaf tissue in two volumes extraction buffer (II.4.2), separated by 12% (w/v) SDS-PAGE 
(II.4.6.1) and blotted onto a nitrocellulose membrane (II.4.8). Immunodetection was carried out with 
anti-HSA antibody (1:5000) followed by 1 hr incubation with GAMAP (1:5000) and NBT/BCIP 
detection. 1) Acetate buffer (pH 4.0) + 2 mM EDTA 2) Acetate buffer (pH 4.0) + 2 mM EDTA + 
completeTM protease inhibitor (ROCHE) 3) 50 mM Tris-HCl (pH 8.0) + 100 mM NaCl + 5 mM 
EDTA + 0.1% Tween 20 + 10 mM DTT 4) 50 mM Tris-HCl (pH 8.0) + 100 mM NaCl + 5 mM 
EDTA + 0.1% Tween 20 + 10 mM DTT with the pH shift to 4.0 5) 50 mM Tris-HCl (pH 8.0) + 100 
mM NaCl + 5 mM EDTA + 0.1% Tween 20 + 10 mM DTT with the pH shift to 4.0 + completeTM 
protease inhibitor (ROCHE) 6) PBS + 100 mM NaCl at pH 6.0 7) PBS + 100 mM NaCl at pH 6.0 
with the pH shift to 4.0 8) PBS + 100 mM NaCl at pH 7.0 with the pH shift to 4.0 + completeTM 
protease inhibitor (ROCHE); M: prestained protein marker; +. 100 ng HSA (Sigma). 
As shown in Figure III.26A, many other plant proteins are visible on the SDS PAGE after 
extraction with buffer 3 (50 mM Tris-HCl (pH 8.0) + 100 mM NaCl+ 5 mM EDTA+ 0.1% 
(v/v) Tween 20+ 10 mM DTT) and buffer 6 (PBS + 100 mM NaCl at pH 6.0). Whereas using 
0.1 M acetate buffer at pH 4.0 (lanes 1 and 2) most of the plant proteins could be precipitated 
prior to purification. Differences in the amount of extracted rHSA from transgenic leaves 
observed in ELISA (Figure III.30) could not be confirmed by immunoblot (Figure III.26B). 
The intensity of the bands at the expected size of rHSA (66kDa) looked similar and different 
additional immuno-positive bands of a smaller molecular weight were detected by the anti-
HSA antibody. Addition of CompleteTM protease inhibitor (ROCHE) was not helpful to avoid 
degradation (Figure III.26B lane 2, 5 and 8), indicating that this protease inhibitor is not 
effective to prevent the action of an unknown protease in the plant cells. 
 
III.4.2.2  Influence of freezing leaves prior to extraction of rHSA 
In order to analyse conditions that avoid or reduce the degradation of the rHSA isolated from 
transgenic leaves two different tobacco leaves batches were taken for extraction. In one set 
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the leaves were collected from greenhouse and used immediately for extraction, in the second 
set the leaves that were collected, frozen in liquid N2 and stored for 6 months at 80°C were 
taken for extraction. Furthermore as a control the commercial HSA was mixed with the wild 
type tobacco extract. This was done to examine if the above mentioned unknown protease in 
the plant cell is also able to degrade the commercial HSA.  
All samples were extracted in acetate buffer (pH 4.0) plus 5 mM EDTA. The transgenic 
HSAKDEL31 tobacco leaves were used for these experiments. As a control SR1 wild type 
plant leaves were extracted in the same buffer and during extraction, the extracts were 
supplemented with the 200 ng of commercially available HSA (Sigma).  
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Figure III.27 SDS PAGE (A) and immunoblot analysis (B) of rHSA extracted from fresh and 
frozen transgenic HSAKDEL31 leaves. Total soluble proteins were extracted by grinding tobacco 
leaf tissue in two (1, 3 and 5) or four volumes (2, 4 and 6) of extraction buffer (acetate buffer pH 4.0+ 
5 mm EDTA), separated by SDS-PAGE (II.4.6.1) and blotted onto a nitrocellulose membrane (II.4.8). 
Immuno detection was carried out with anti-HSA antibody (1:5000) followed by 1 h incubation with 
GAMAP (1:5000) and NBT/BCIP detection for 5 min at RT. 1). Wild type (SR1) 1:2 diluted extract 
+200 ng HSA (Sigma); 2) Wild type (SR1) 1:4 diluted extract+ 200 ng HSA (Sigma) 3) Fresh 
HSAKDEL31 1:2 diluted extract; 4) Fresh HSAKDEL31 1:4 diluted extract; 5) -80°C frozen 
HSAKDEL31 1:2 diluted extract; 6) -80°C frozen HSAKDEL31 1:4 diluted extract; M) prestained 
protein marker; +) 100 ng HSA (Sigma). 
 
In Figure III.27A on the Coomassie stained SDS PAA gel much less total soluble proteins 
were visible in lane 5 (frozen transgenic leaf extract) when compared with the fresh leaf 
extracts (lane 3). On the immunoblot (Figure III.27B), in addition to the expected size of 
rHSA (66kDa), additional immuno-positive bands almost in all the lanes including the control 
(wild type SR1 extract +200 ng HSA) was recognized by the monoclonal anti-HSA antibody. 
The presence of these smaller bands in all of the plant extracts investigated in this study is an 
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indication of a degradation process. Presence of similar degradation bands in the wild type 
tobacco extract supplemented with commercial HSA showed that this degradation is taking 
place during total soluble protein extraction. 
Dilution of the extract in 1:2 or 1:4 resulted in the dilution of the rHSA but not in the 
reduction of the degradation products, which are equally well diluted (Figure III.27B). Using 
fresh leaves collected from greenhouse and directly processed for extraction, resulted in a 
more efficient extraction of rHSA (Figure III.27B lane 3 and 4) when compared to frozen 
leaves (lane 5 and 6). But again the degradation of the recombinant protein could not be 
lessened or avoided.  
 
III.4.2.3 Small scale purification of rHSA from transgenic tobacco leaves  
After determining the optimum pH for binding of rHSA to the cation exchange matrix (Figure 
III.24) and the optimum extraction conditions (III.4.2.1 and III.4.2.2), first experiments were 
done in a small scale purification system that was designed to permit scale up without major 
modifications. Fresh transgenic leaves from line HSAKDEL31 were extracted in two 
volumes of acetate buffer (pH 4.5). The extract was divided into two and one part of the 
protein isolate was heated at 60°C for 30 min, where the other part was used for 
chromatography directly after extraction. The aim of this heat treatment was to remove plant 
proteins that are interacting with the matrix prior to chromatography. CEX was performed 
using a 1.4 ml Source 30S (Pharmacia) cation exchange medium in BioCart5 column 
(Kronlab, Sinsheim) equilibrated with the respective loading buffer (20 mM acetate pH 4.5). 
A sample of 20 ml was used as feed and bound material was either eluted using a salt gradient 
(0-1 M NaCl) (Ea in Figure III.28A) or a salt gradient and a pH shift to 8.0 (Eb in Figure 
III.28A). 
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Figure III.28 SDS PAGE (A) and immunoblot analysis (B) of rHSA after partial purification 
by CEX. Total soluble proteins were extracted by grinding tobacco leaf tissue in two volumes of 
extraction buffer (acetate buffer pH 4.5), separated by SDS-PAGE (II.4.6.1) and blotted onto a 
nitrocellulose membrane (II.4.8). Immuno detection was carried out with anti-HSA antibody (1:5000) 
followed by 1 h incubation with GAMAP (1:5000) and NBT/BCIP detection for 5 min at RT. +) 100 ng 
HSA (Sigma) 2) HSAKDEL31 transgenic leaves extracted in acetate buffer (pH 4.5); 3) SR1 leaves 
extracted in acetate buffer (pH 4.5); 4) protein extract #2 heated at 60°C for 30 min 5) protein extract 
#3 heated at 60°C for 30 min; 6) Flow through (salt gradient); 7) Flow through from heated extract 
(salt gradient and pH shift to 8.0); 8) M: prestained protein marker; 9) Ea) Eluate (salt gradient); 10) 
Eb) Eluate (salt gradient and pH shift to 8.0) 
As shown by SDS PAGE analysis (Figure III.28A), there is a huge decrease in the amount of 
plant protein when the leaf extract was heated at 60 °C for 30 min. Amount of rHSA seemed 
to be similar both in the heated and non-heated samples (Figure III.28B lanes 2 and 4 
respectively). However, ELISA results showed that almost one half of the rHSA was lost 
when the extract was heated (Table III.4, initial feed). Although, heating the extract resulted 
in the reduction of the contaminating plant protein concentration, it resulted in a huge loss of 
the rHSA in the initial feed prior to purification. Consequently extract heating was not 
included into the extraction protocol. 
In addition, ELISA results confirmed that elution of rHSA from the cation exchange matrix 
was also a very important step to optimise. Salt gradient alone or in combination with a pH 
shift to 8.0 were investigated during the elution step. As illustrated in the Table III.4, using 
salt gradient and a pH shift to 8.0 was more effective (115 µg rHSA per ml eluate) for elution 
of rHSA than using salt gradient alone (62 µg rHSA per ml eluate). 
 
 
 
 
Chapter III  Results 
94 
Table III.4  Analysis of CEX results after partial purification of rHSA from transgenic leaf 
material by ELISA. 10 g of transgenic HSAKDEL31 leaves were extracted in two volumes of 
acetate buffer (pH 4.5). Flow through a: Flow through of the CEX from HSAKDEL transgenic leaf 
extract; Flow through b: Flow through of the CEX from HSAKDEL transgenic leaf after heating the 
extract at 60 °C for 30 min. 
 rHSA 
(µg/ml) 
Total volume 
(ml) 
Initial feed 45 20 
Initial feed heated at 60 °C for 30 min 25 20 
Flow through a 22 40 
Eluate a (salt gradient) 62 0.5 
Flow through b 27 40 
Eluate b (salt gradient and pH shift to 8.0) 115 0.5 
 
ELISA results also showed that almost half of the rHSA available in the initial feed is still in 
the flow through a (Table III.4). Further optimisation of the protocol was necessary for 
efficient binding of rHSA to the cation exchange matrix.  
For this purpose, a new batch of fresh transgenic leaves from line HSAKDEL 31 were 
extracted in acetate buffer (pH 4.5) plus 5 mM EDTA. EDTA was added to the sample to 
inhibit rHSA fragmentation observed in the previous eluates (Figure III.28B, lane Ea and Eb). 
Linflow was reduced from 600 cm/h to 300 cm/h in order to increase the contact time of the 
recombinant protein with the matrix. CEX was performed using a 1.4 ml Source 30S 
(Pharmacia) cation exchange medium in BioCart5 column (Kronlab, Sinsheim) equilibrated 
with the respective loading buffer (20 mM acetate pH 4.5) and with a linflow of 300 cm/h.  
40 ml of sample was used as feed and bound material was eluted using a salt gradient (0-1 M 
NaCl) and a pH shift to 8.0. The chromatogram is illustrated in Figure III.29. 
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Figure III.29 Cation exchange chromatography of rHSA from transgenic tobacco plants. 
Column: BioCart5; medium: 1.4 ml Source 30S; feed: 40 ml of homogenate prepared by extraction 
transgenic tobacco leaves in acetate buffer (pH 4.5) plus 5 mM EDTA; loading buffer: acetate buffer; 
linflow of 300 cm/h. elution buffer: salt gradient (0-1 M NaCl) and a pH shift to 8.0. 
A clear band with an identical relative mobility to commercial HSA was clearly visualised 
both on the SDS PAGE gel (Figure III.30A) and immunoblot (Figure III.30B). Also the 30 
kDa degradation product was visible indicating that it is co-purified or that degradation 
occurs also during purification. 
F FT E1 E2 M F FT E1 E2 M
83
62
47
32
25
16
kDa
62
47
32
25
16
kDa
+
 
 A B 
Figure III.30 SDS PAGE (A) and immunoblot analysis (B) of rHSA after partial purification 
via CEX. Total soluble proteins were extracted by grinding tobacco leaf tissue in two volumes of 
acetate buffer pH 4.5 plus 5 mM EDTA, separated by SDS-PAGE (II.4.6.1) and blotted onto a 
nitrocellulose membrane (II.4.8). Immuno detection was carried out with anti-HSA antibody (1:5000) 
followed by 1 h incubation with GAMAP (1:5000) and NBT/BCIP detection for 5 min at RT. F) Initial 
feed FT) Flow through; E1) Eluate 1; E2) Eluate 2; M: prestained protein marker; +) 100 ng HSA 
(Sigma) 
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Compared to the previous run (see Table III.4), no rHSA was observed in the flow through, 
which shows that binding to the cation exchange matrix was optimized. Concentration of the 
rHSA was determined by ELISA as described (II.4.9.2) and tabulated in Table III.5. 
Table III.5 Analysis of cation exchange chromatography results after purification of rHSA 
from transgenic leaf material by ELISA. 10 g of transgenic HSAKDEL31 leaves were extracted in 
two volumes of acetate buffer (pH 4.5) plus 2 mM EDTA. Bound material was eluted using a salt 
gradient (0-1 M NaCl) and a pH shift to 8.2 
 rHSA (µg/ml) Total volume (ml) 
Initial feed 52 20 
Flow through  0 40 
Eluate 1 222 2 
Eluate 2 186 0.5 
 
In the initial feed of 20 ml, approximately 1 mg of rHSA was determined by ELISA. 537 µg, 
around 50 % of this protein could be obtained in the eluates after CEX. 
 
III.4.2.4 Large scale purification of rHSA from transgenic tobacco leaves  
Initial experiments were performed with 10 g of transgenic leaf material in order to determine 
the most suitable feed material, extraction buffer and flow rate for the optimised 
chromatography conditions. A scale up is necessary in order to check if these conditions are 
also applicable for large scale downstream processing of the recombinant protein. After 
completing the small scale pilot experiments with the stable transgenic leaf material, 700 g of 
transgenic leaf material was extracted in the 2 volumes of acetate buffer pH 4.5 plus 5 mM 
EDTA and used for CEX. 1400 ml of the clarified leaf extract was loaded as initial feed on a 
CEX matrix. Chromatography was performed using a XK50/20 cation exchange column 
filled with 120 ml of Seppharose Big Beads equilibrated with the respective loading buffer 
(20 mM acetate pH 4.5). CEX was performed with a flow rate of 33.5 ml/min (100 cm/h). 
Bound material was eluted using a salt gradient step 0-1 M NaCl and a pH shift to 8.0. The 
eluted fractions were collected and analysed for the presence of rHSA by SDS-PAGE (Figure 
III.31) and ELISA (Table III.6). 
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Figure III.31 SDS PAGE of rHSA after partial purification via CEX. Total soluble proteins 
were extracted by grinding (II.4.2) tobacco leaf tissue in two volumes of extraction buffer (acetate 
buffer pH 4.5 plus 5 mM EDTA), separated by 12 % (w/v) SDS-PAGE (II.4.6.1). F) Initial feed for 
CEX; FT) Flow through; E1) Eluate 1; E2) Eluate 2; M: prestained protein marker; +) 100 ng HSA 
(Sigma). 
Partial purification of the rHSA was achieved by using cation exchange chromatography. 
Coomassie stained SDS PAGE showed that other plant proteins were still present after this 
first step of chromatography indicating that large scale conditions have to be optimised. 
ELISA was performed with the samples taken before, during and after purification in order to 
determine the concentration of the protein at different stages of purification (Table III.5).  
Table III.6 Analysis of CEX results after partial purification of rHSA from transgenic leaf 
material.  
 rHSA (µg/g) Total volume (ml) % Recovery 
Initial feed 81.6 1400 57 
Flow through  0 1200 0 
Eluate 370 120 22 
 
From 700 g of transgenic leaf material 22 mg of rHSA could be purified using a single step 
cation exchange chromatography. 
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IV Discussion 
IV.1. The variability of the HSA cDNA 
The human serum albumin gene is present as a single copy (Takahashi et al. 1987) coding for 
585 amino acids (Peters 1985). Sequences for HSA have been published by Meloun et al. 
(1975), Lawn et al. (1981) and Minghetti et al. (1986). These published protein sequences of 
HSA have the same length but differ in about 20 amino acids. In this work, HSA cDNA was 
amplified from two overlapping cDNA fragments (Dugaiczyk et al. 1982) and sequence was 
verified. Among the published reports of HSA sequences, the Dugaiczyk sequence is most 
similar to that of Minghetti et al. (1986), with only one amino acid change (Glu to Gly) at 
position 294. 
At all discrepant positions the nucleotide sequencing has been carefully confirmed and it is 
unlikely that DNA sequencing errors are the cause of these reported differences. The 
possibility of artefacts introduced by cDNA cloning cannot be ruled out. However, other 
likely explanations exist for the amino acid sequence differences among various reports. 
These include changes in amidation that occurs either in vivo or during protein sequencing 
(Lawn et al. 1981). Polymorphism in HSA may also account for differences in the sequence. 
About 100 variant forms of the albumin molecule (alloalbumins) have been described 
(Nicholson et al. 2000) as well as two mutations that cause nearly 30 cases of 
analbuminaemia have been detected by protein electrophoresis (Weitkamp et al. 1973). Most 
alloalbumins have a single amino acid substitution, resulting from a point mutation; a few 
alloalbumins have a truncated and altered carboxyl terminus (Madison et al. 1991; Watkins et 
al. 1994). Therefore, rather than cloning artefacts or sequencing errors, changes observed in 
this work and some of the published sequences are more likely genetic variants of HSA 
present in the nature.  
 
IV.2 Construction of the plant codon optimized HSA  
Heterologous genes containing high levels of rare codons that are used in low frequency in 
the host organism often show low levels of recombinant protein expression or truncated 
products because of premature stops in protein translation (Chen et al. 1990; Hannig et al. 
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1998; Kang et al. 2004). Many instances of poor expression of foreign genes in plants have 
been investigated, and several post-transcriptional events that led to low levels of expression, 
such as improper codon usage, (Perlak et al. 1991) abnormal splicing, (Haseloff et al. 1997) 
premature polyadenylation (Jarvis et al. 1997) and mRNA instability (Murray et al. 1989) 
have been described. The authentic HSA cDNA contains 18.3 % rare codons, dispersed over 
the entire sequence. Therefore, it was decided to adapt the codon usage in the rHSA sequence 
to the one in wheat and rice plants to optimise the plant expression.  
The protein coding sequence can be optimised by various strategies like oligonucleotide 
ligation, (Heyneker et al. 1976) self priming PCR (Dillon et al. 1990) or cloning of large 
(approx. 100 bp long) inserts into a plasmid using a technique of oligo-directed double-strand 
break repair (the FokI method) (Mandecki et al. 1988). A particularly attractive method, due 
to its inherent simplicity, is assembly PCR (Stemmer et al. 1995). This involves the 
generation of overlapping oligonucleotides which, when assembled, form the template for the 
gene of interest. The oligonucleotides are repetitively extended by PCR to assemble the full-
length gene.  
Based on a similar assembly PCR approach, a semi-synthetic HSA gene was amplified. 
Authentic HSA cDNA was digested in three smaller fragments in order to avoid amplification 
of the template HSA by the two external primers. These three templates, T400, T800 and 
T1000 were used in the assembly PCR together with 32 different primers designed for the 
exchange of rare codons in wheat and rice. Primers did not cover the complete synthetic gene 
rather only the modified sequence fragments. In this way complexity of the PCR could be 
reduced and only the regions with the rare codons were replaced while the rest was kept as 
authentic HSA sequence. After four rounds of PCR, a fragment of the expected size of 1.8 kb 
PCR was assembled and the product was subsequently purified and cloned. A pre-screen of 
the received clones by analysing a characteristic enzymatic activity of the expressed protein 
was hampered due to the absence of such an activity test for HSA. In order to identify a PCR 
assembled semi-synthetic HSA cDNA, 50 individual clones were sequenced either using 
HSA or vector specific primers. Computer-based sequence alignment of these clones revealed 
that the rHSA was successfully assembled in the right order. However, as many as 35 
mutations including deletions, insertions and base changes were detected. Clones 13 and 31 
having the lowest error rate still contained 19 and 20 base pair exchanges, respectively. 
Analysis of the plant codon optimised HSA showed that the mutations were exclusively in the 
primer regions of the final product. Therefore the observed mutations in the sequence are 
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more likely due to bad quality of the primers used in the assembly. The frequencies of the 
nucleotide errors are largely dependent on the quality of the nucleotides, rather than the 
fidelity of the polymerase (Hoover et al. 2002). The primers were synthesized and purified 
using standard procedures by MWG Biotech and delivered in the lyophilised form.  
One approach to remove these mutations is to use site directed mutagenesis (Ishii et al. 1998). 
In vitro site-directed mutagenesis is an invaluable technique for the modification of a given 
sequence. It involves (1) cloning the DNA of interest into a plasmid vector, (2) denaturing the 
plasmid DNA to produce single strands, (3) annealing synthetic oligonucleotide with desired 
mutation (point mutation, deletion, or insertion) to the target region, (4) extending the mutant 
oligonucleotide using a plasmid DNA strand as the template and (5) propagating the 
heteroduplex by transformation in E. coli. In theory, after propagation, about 50% of the 
transformants will carry a heteroduplex in which the desired mutation is incorporated. 
Although some commercial mutagenesis kits guarantee a mutation efficiency of 90 % like for 
example with Stratagenes QuikChange® site-directed mutagenesis kit, it suffers from the 
following disadvantages; (i) in general, mutations are introduced at only one site at a time 
(Kirsch et al. 1998); introduction of more than one mutation at different sites takes longer, 
since it requires a transformation and a DNA preparation step between consecutive rounds of 
mutagenesis; (ii) two complementary mutagenic oligonucleotide primers are needed for a 
mutation site. To correct clones 13 and 31 comprising 19 and 20 mutations respectively, 40 
mutagenic oligonucleotide primers are required and mutations should have been eliminated 
once at a time with following transformation and DNA preparations steps. The final products 
should have been sequenced for verification of the sequence changes. The accomplishments 
of these mutagenesis experiments were out of the scope of this present work and therefore the 
efforts to generate a synthetic plant codon optimized human serum albumin cDNA were 
stopped. 
In the retrospective, the assembly of the full-length HSA cDNA could have been modified. 
To reduce the possibility of errors during oligonucleotide synthesis, the oligonucleotides 
should be rather short, yet they must still be long enough to provide stable priming overlaps. 
In this work, the primer length for assembly of the semi-synthetic HSA cDNA varied between 
27 nt and 83 nt and they overlapped between 21 and 24 nt (Figure III.3). While assembly 
PCR approach is simple in principle, in practice numerous complications can lead to errors in 
the synthesis (Hoover et al. 2002). For example, a 1.1-kb fragment containing the TEM-1 
beta-lactamase-encoding gene (bla) was assembled in a single reaction from a total of 56 
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oligos, each 40 nucleotides (nt) in length. Five silent point mutations were introduced creating 
five new restriction sites, to differentiate the synthetic gene from the naturally occurring bla 
gene in pBR322. At the end of assembly the bla gene was sequenced and three additional 
point mutations were detected (Stemmer et al. 1995). Insertion of additional restriction sites 
into the sequence enables the removal of mutations by exchanging the mutated against the 
expected sequences. Larger genes can be divided in subfragments that are assembled 
separately. After sequence verification of the cloned subfragments, they can be assembled to 
the full-length construct. It may be an advantage to design the oligonucleotide sequences to 
generate unique restriction sites within the assembled gene to allow subsequent manipulations 
by recombinant DNA techniques. This way it could be possible to exchange the smaller 
subfragments containing mutated sequence with a subfragment containing the expected 
sequence. By combination of these two parameters, the nucleotide sequence of a major 
industrial lipase, lip1 gene was first subdivided into four separately synthesized segments of 
ca. 400 bp. Unique restriction sites were strategically positioned throughout the gene to 
facilitate the analysis of primary subclones containing the four blocks and the construction of 
the gene by their assembly. The final codon optimised version of the gene was 1688 bp in 
length and had a 77 % nucleotide sequence identity with the natural gene using P. pastoris 
cells, the synthetic gene was functionally overexpressed, allowing for the first time to produce 
recombinant lip1 of high purity at a level of 150 U/mL culture medium (Brocca et al. 1998).  
In plant system, several examples of codon optimization strategies are present. The gene 
encoding green fluorescent protein (GFP) from Aequorea victoria was resynthesized to adapt 
its codon usage for expression in plants by increasing the frequency of codons with a C or a G 
in the third position from 32 to 60 %. A comparison of GFP production in transgenics with 
the wild type and the synthetic gfp gene under the control of the enhanced CaMV 35S 
promoter showed that the large-scale alterations in the gfp gene increased the frequency of 
high expressors in the transgenic population but hardly changed the maximum GFP 
concentrations. The authors attributed this to a reduced regeneration capacity of transformed 
cells with higher GFP concentrations (Rouwendal et al. 1997). Similarly, another marker 
gene, luciferase was also codon optimized for high level expression in plants (Lonsdale et al. 
1998). In tobacco cells, a codon modified form of the luciferase gene (luc+) available from 
Promega, shows no significant enhancement of activity over that of the wild-type gene, 
although there are 53- to 59- and 14- to 23-fold enhancements of activity in wheat scutellum 
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and Black Mexican Sweet (BMS) maize cells, respectively. Lonsdate et al., (1998) attributed 
these differences to the different tRNA pools present in different tissues and species. 
Recently, the coding sequence of the cholera toxin B subunit (CTB) was optimized, based on 
the modification of codon usage to that of tobacco plant genes and the removal of mRNA-
destabilizing sequences (Kang et al. 2004). The recombinant CTB protein constituted 
approximately 1.5 % of the total soluble protein in transgenic tobacco leaves. This level of 
CTB production was approximately 15-fold higher than that in tobacco plants that were 
transformed with the bacterial CTB gene. 
These studies in heterologous expression hosts have shown that codon usage can influence 
the expression of foreign proteins. However, in general the increase in protein levels that may 
be obtained by codon optimization is relatively modest and it is in a few fold range. In 
conclusion, mindful attention to cryptic features like codon bias changes to correctly match 
the tRNA complement of the new host, investigation of accumulating sequence motifs that 
would be recognized as premature polyadenylation signals or cryptic intron splice sites in 
plants can lead to improvement of these strategies. Similarly, consideration of mRNA 
secondary structures that might hinder expression or RNA stability in the transgenic host can 
lead to development of modified trangenes whose expression increases several hundred folds. 
 
IV.3 Production of recombinant HSA in bacteria and plant cells 
HSA is a monomeric globular pre-protein whose mature form consists of a single polypeptide 
chain of 585 amino acids (66.5 kDa with 17 disulfide bonds). It is highly susceptible to 
proteolytic degradation in recombinant systems and is expensive to purify. Estimates by 
industry suggest that the cost-effective yield for pharmaceutical production in plants is 0.1 mg 
of rHSA per g of fresh weight (Fernandez-San Millan et al. 2003). In addition, good 
recombinant systems are still not available for many human proteins that are expensive to 
purify or highly susceptible to proteolytic degradation. It is known that traditional purification 
of biopharmaceuticals using columns accounts for 30 % of the production cost and 70 % of 
the setup cost (Daniell 2003).  
The increasing production of proteins in heterologous hosts through the use of recombinant 
DNA technology has brought the problem of proteolytic degradation into focus; heterologous 
proteins appear to be more prone to proteolysis. Recombinant proteins are often regarded by a 
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cell as foreign, and therefore are degraded much faster than most endogenous proteins. 
Proteolytic stability of recombinant proteins is a significant factor influencing the final yield. 
In this work bacterial and plant production platforms were evaluated for the expression of 
rHSA. 
 
IV.3.1 Bacterial expression  
HSA is characterized by a low content of tryptophan and methionine and a high content of 
cysteine and the charged amino acids, aspartic and glutamic acids, lysine and arginine. In this 
work, two different constructs were used for expression of rHSA in the cytoplasm or 
periplasm of E. coli. Expression of rHSA was achieved in the cytoplasm but in very low 
amounts. The concentration of the affinity purified cytoplasmic rHSA was determined to be 
0.002 mg per liter bacterial culture (III.3.1). In nature, the presence of 17 disulphide bridges 
is the unique feature of the albumin molecule (Carter et al. 1990). HSA cDNA was cloned 
into the pET21d vector, allowing expression in the cytoplasm. It is a reducing environment 
and due to this reason it might be difficult to ensure proper disulphide bond formation.  
The change of compartment can lead to better protein folding resulting in higher expression 
levels. Therefore, the second approach was to secrete HSA into the periplasm by means of the 
pelB leader sequence. Secretion of the target protein to the periplasm has a number of distinct 
advantages like the oxidizing environment of the periplasm allows for the formation of 
disulfide bonds, which does not occur in the reducing environment of the cytoplasm. Also, 
the periplasm contains two foldases that catalyze the formation and isomerization of disulfide 
bonds. Since the periplasm contains only 4 % of the total cellular proteins, the target protein 
is effectively concentrated and can be purified with less contaminant. In addition protein 
degradation in the periplasm is also less extensive in the periplasm (Talmadge et al. 1982). 
However, capacity for secretion and post-translational modification are usually limited 
{Hannig et al. 1998} and not all expressed protein are secreted into the periplasm but also 
found in the medium, the cytoplasm or the cytoplasmic membrane. 
To our knowledge there is no published report describing high level expression of rHSA in E. 
coli. For a successful bacterial expression system either in E. coli or in another strain, 
optimization of culture conditions must be carried out. The expression of the recombinant 
protein can be optimized by doing a time course of induction, altering induction temperature 
or screening growth media. For each test, the recombinant protein should be analyzed by 
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ELISA, SDS-PAGE and/or Western blot to determine optimal conditions for protein 
production. Instead of optimizing conditions for bacterial expression, the thesis was focused 
on the expression of rHSA in plant cell and suspension cultures.  
 
IV.3.2 Expression of rHSA in plants  
Molecular farming in plants has the potential to provide virtually unlimited quantities of 
recombinant proteins for use as diagnostic and therapeutic tools in health care and the life 
sciences (Twyman et al. 2003). Plants produce a large amount of biomass and protein 
production can be increased using plant suspension cell culture or by the propagation of 
stably transformed plant lines in the field.  
In this work, we have used nuclear transformation of various plant species to enable targeting 
of recombinant HSA to the secretory pathway, which should ensure proper folding and 
formation of the disulfide-bridges. Transgenic tobacco and wheat plants as well as tobacco 
suspension cells were generated using appropriate targeting signals to achieve subcellular 
HSA localisation in the plant cell apoplast or ER. Transient gene expression system offer 
several advantages over analyses of stable expression, for example initiation of gene 
expression, and synthesis of the protein can be analyzed within a very short time and is not 
affected by position effects (Vaquero et al. 1999). The results can be evaluated before 
initiating stable transformation of plants and experimental procedure does not require 
sophisticated equipment and is inexpensive. Therefore this system is suitable for the 
development and initial characterization of new recombinant protein. 
Tobacco is a non-food and non-feed crop and an ideal choice for the production of therapeutic 
proteins because of its relative tractability to genetic manipulation and an impending need to 
explore alternate uses for this crop. Tobacco is an excellent biomass producer (in excess of 40 
tons of leaf fresh weight/acre, based on multiple cuttings per season) and a prolific seed 
producer (up to one million seeds produced per plant), thus hastening the time in which a 
product can be scaled up and brought to market. Tobacco is widely used as a model system to 
test the suitability of plant-based expression systems for production of therapeutic proteins 
and other transgenes (Daniell 2003). More transgenes have been introduced into the tobacco 
chloroplast or nuclear genome than all other crop species combined. Both nuclear and 
chloroplast genomes of tobacco have been transformed with relative ease. Tobacco is a self-
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pollinating crop and there are no known wild or cultivated relatives in North America. 
Several studies have established that transgenes are maternally inherited when introduced via 
the chloroplast genome in tobacco. In addition, both male sterility and seed sterility 
techniques have been developed already for tobacco. Thus, advanced technology is readily 
available for containment of gene flow through pollen and seeds. 
In this study, eight different tobacco cultivars were evaluated by transient expression and the 
maximum accumulation levels obtained was compiled in Table III.1. For six of the cultivars 
tested, expression levels varied between 0.76 to 6.3 µg per g leaf material. For the cultivars 
Adonis Schwester and Barley Saturn, accumulation levels of 10 µg per g leaf material were 
achieved in the apoplasm. Although leaf size in these varieties is bigger than the model Petit 
Havana SR1 tobacco plants, which is an advantage for molecular farming purposes, a 
disadvantage of these cultivars is the unavailability of the seeds for the next generation which 
will be a major drawback for the stable transformation.  
Clearly, transient expression is a prerequisite to stable transformation because it allows both 
the expression vectors and protein stability to be tested. For stably transforming tobacco 
plants, HSA gene was cloned into a binary vector that can be moved between E. coli and A. 
tumefaciens. Transformation was followed by selection for cells with stably integrated copies 
of the rHSA by following a selectable marker resistance gene that is introduced in the 
expression vector. Using plant extracts from stably transformed tobacco plants, correct size of 
the recombinant protein was confirmed by immunoblot analysis and the quantity of protein 
was estimated by ELISA. Maximum accumulation level of 100 µg per gram plant material 
(0.51 % of TSP) was obtained when the recombinant protein was targeted to the ER. These 
levels are at least 2.5 fold higher than those reported in the literature for nuclear 
transformation of potato by Farran et al. (2002). By including the appropriate signal peptide 
sequence or fusion responsible for directing expression and deposition, it is possible to target 
recombinant proteins to the lumen of the ER, vacuole or other cellular compartments. These 
type of targeting signals can be used to protect the foreign protein from proteolytic 
degradation, preserve their integrity and to increase accumulation levels (Moloney et al. 
1997). In this work, usage of KDEL retention signal boosted the production of rHSA in 
tobacco plants. Although it is conceivable that the different transcripts are translated with 
different efficiencies, a more plausible explanation for the differences in the protein yield is 
that rHSA is more stable, or more rHSA is correctly folded in the ER than in the apoplast, as 
reported for the scFv expression in other plant species (Artsaenko et al. 1995). Schouten et al. 
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(1997) have demonstrated the addition of a C-terminal KDEL peptide increased cytosolic 
expression level of a scFv fragment. Maximum expression levels of up to 0.2% of the total 
soluble protein were measured, whereas the same scFv fragments without KDEL did not 
show any accumulation in the cytosol of transgenic plants. They suggested that short 
polypeptides such as KDEL sequence may protect the scFv antibody from proteolytic 
degradation (Schouten et al. 1997).  
Besides different tobacco varieties three edible plants, zucchini, bean and wheat were also 
used for expression of rHSA (Table III.1). In bean leaves, accumulation levels were below 
detection levels for ELISA and western blot. In zucchini and in model tobacco SR1, transient 
accumulation levels of 2.65 µg per g and 2 µg per g leaf material were achieved, respectively. 
Besides intact tobacco plants, immature wheat embryos were also used for bombardment of 
HSA-KDEL construct containing ubiquitin promoter. Expression levels in dry wheat seeds 
were determined as 100 µg per gram seed. The use of transgenic wheat seeds enables the 
storage of rHSA in seeds for long time periods. We have stored transgenic wheat seeds for 
more than 12 months without significant loss of product yield. Stöger et al. (2000) 
investigated the expression of a construct containing scFvT84.66 tagged with a C-terminal 
KDEL sequence in wheat and rice (Stöger et al. 2000). The highest expression levels of 29 µg 
per g in leaves and 32 µg per g in seeds were detected using ubiquitin promoter. In our study, 
although the expression levels were much higher than this, it should be possible to enhance 
production levels further, for example by testing a range of alternative promoters, including 
seed-specific promoters. 
In addition to these studies using the plants grown in the greenhouse, in year 2000 a field trial 
has been performed in Canada using transgenic N. tabacum cv. Petite Havana SR1 plants 
producing rHSA accumulating in the plant apoplast. The analyses revealed that similar levels 
were obtained when compared to plants cultivated in the greenhouse demonstrating that these 
transgenic plants are suitable for production of rHSA in the field at large scale. In the 
literature, performance comparison of greenhouse and field grown plants were done mainly 
for herbicide resistance transgenic plants. Ramachandran et al. (1998) evaluated the 
performance of selected transgenic herbicide resistance canola lines under greenhouse and 
field conditions. Tested transgenic lines provided high levels of resistance against 
diamondback at all growth stages under greenhouse conditions. Transgenic canola also 
provided excellent control of diamondback moth under field conditions both as a pure stand 
and in mixtures (Ramachandran et al. 1998).  
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Sijmons et al. made the first reported attempt to express rHSA in transgenic plants in 1990, 
but very low expression levels were obtained (0.02% of TSP). Later in 2002, Farrran et al. 
showed that rHSA was accumulated in the tubers of transgenic potato plants with the highest 
accumulation level reaching to 0.2% of the tuber soluble protein. Recently, Fernandez-San 
Millan et al. (2003) reported a more efficient method of rHSA production via a novel 
approach, chloroplast genetic engineering. Modification of HSA regulatory sequences using 
chloroplast untranslated regions (UTRs) resulted in rHSA accumulation of up to 11.1% of 
TSP, compensating for excessive proteolytic degradation. This is 500-fold higher than 
previous reports on rHSA expression upon nuclear transformation (Daniell 2003). However, 
rHSA accumulated in inclusion bodies, which facilitated purification, but solubilization with 
Gu-HCl and subsequent refolding was necessary for extraction. No data for functionality of 
the resolubilised HSA has been reported so far. Since HSA has 17 disulfide-bridges 
resolubilisation under reducing conditions and subsequent oxidative refolding is not expected 
to be capable of producing high quantities of correctly folded and biologically active HSA. 
This is evident from the fact that all platforms currently used for production are eucaryotic 
systems and this is required to ensure proper disulfide-bridge formation. Therefore, 
chloroplast expression with equal properties to procaryotic production systems seems not to 
be a viable option for HSA production. 
Estimates by industry suggest that the cost-effective yield for pharmaceutical production is 
0.1 mg of HSA per g of fresh weight (Fernandez-San Millan et al. 2003). In this study the 
highest expression level 100 µg rHSA per g leaf material could be achieved in stably 
transformed tobacco plants and 100 µg rHSA per g in wheat seed, in bombarded wheat 
embryos. Two different technologies were used in order to generate these transgenic plants. 
Agrobacterium mediated gene transfer has a restricted host range and does not efficiently 
infect monocots, where for monocots, biolistic delivery of genes is the method in use 
(Christou 1995).  
In conclusion, new techniques for producing transgenic plants will improve the efficiency of 
the process and will help resolve some of the environmental and health concerns. Among the 
expected changes are the following: 
• More efficient transformation that is a higher percentage of plant cells will 
successfully incorporate the transgene. 
• Better marker genes to replace the usage of antibiotic genes 
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• Better control of gene expression through more specific promoters, so that the inserted 
gene will be active only when and where needed. 
• Transfer of multi-gene DNA fragments to modify more complex traits. 
 
IV.3.3 Expression of rHSA in plant cell suspension cultures 
Culture cells are convenient for the controlled production of heterologous proteins, especially 
for pharmacological application. Although most interest during the past 15-20 years has 
focused on microbial and animal cell cultures, plant cells are now considered to be useful 
systems for large-scale protein production (Lee et al. 2002). Plant cell cultures have several 
advantages compared with microbial and animal cell cultures. They have a reduced risk of 
mammalian viral contaminants, oncogenes and bacterial toxins, and they can also produce 
correctly folded proteins and assemble multimeric proteins such as antibodies (Fischer et al. 
1999).  
In this thesis, production of rHSA in plant cells followed by secretion into the culture medium 
was achieved using transgenic BY2 suspension cell culture. Accumulation levels in the cells 
varied between 0.4-1.87 µg per g of cells and secretion into the culture supernatant was 
0.494-1.84 µg per ml culture medium.  
The human milk protein sCD14 was expressed in tobacco BY2 plant cell cultures. Tobacco 
cells were transformed with either the native human signal peptide (SP) or a plant SP, under 
the control of the CaMV35S promoter. The protein was detected by western blot analysis at 
an estimated level of 5 µg per L in a non-soluble fraction of the culture medium (Girard et al. 
2004).  
Expression of rHSA in tobacco suspension culture and secretion by the cultured plant cells 
into the culture medium was previously shown by Sijmons et al. (1990). The construct used 
for transformation of the tobacco suspension cells contained a fusion of mature HSA with the 
presequence from the pathogenesis related signal (PR-S) protein from tobacco, which is used 
as the signal sequence for secretion of HSA across the plant plasma membrane. Recombinant 
HSA was found to be correctly processed and indistinguishable from the authentic human 
protein. It was detected in the culture medium at a level of 0.25 µg per mg protein when 
compared with the cellular HSA concentration in the immunoblot and appeared to represent 
the majority of the synthesized protein, suggesting almost all of it was secreted (Sijmons et al. 
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1990). The highest rHSA level reported in this work, 1.87 µg per ml culture supernatant is 
higher than the previously described report of Sijmons et al., although in both of the works 
same CaMV35SS promoter was used. The expression cassettes used differ in two ways (i) 
tobacco PR-S signal peptide versus plant codon optimized leader peptide derived from 
murine light chain of TMV (ii) NOS terminator versus termination signal of CaMV35S. 
Sijmons et al in his work compared usage of human and plant signal sequences and found 
that only the plant-derived signal generates the authentic mature protein in plants. The human 
prepro-sequence gives rise to proper targeting to the extracellular space, but yields an 
intermediate precursor protein. Therefore these results prove that it was necessary to delete 
the leader and hexapeptide of authentic HSA prior to cloning into expression vectors. 
Foreign proteins produced in plant cell cultures are harvested from plant biomass or from 
culture supernatant. Despite the dilution of the secreted protein to low concentrations in a 
relatively large liquid volume, plant cell culture of foreign protein can be advantageous. 
However, accumulation of the protein in the cell and in the culture medium depends largely 
on its stability in the extracellular environment and this is of particular importance for 
proteins with complicated structures like HSA.  
During the Second World War, polyvinylpyrrolidone (PVP) was used to dilute the limited 
blood supply and therefore PVP was analysed as a stabilizer in the tobacco suspension 
cultures secreting rHSA. PVP with varying molecular weights were added to the HSA-
APO29 culture from the first day of subculture. Although 2.5 fold more secretion of rHSA in 
to the culture medium could be achieved, increase in the stability of the protein was not 
observed. Smaller truncated forms of rHSA were present in the supernatant of suspension 
culture cocultivated in the presence or absence of PVP (III.3.5.2). Change in working 
concentration (0.8 g/L) or addition of PVP at different time intervals was not investigated. 
The use of protein stabilizing agents such as PVP has been shown to improve antibody 
production in suspension cultures, suggesting that the medium is the site of antibody 
degradation (La Count et al. 1997). Similarly, studies with bioactive hGM-CSF production in 
tobacco suspension culture shown that, accumulation of hGM-CSF was drastically reduced 
during the exponential phase of cell growth. In order to improve the yield of hGM-CSF in 
tobacco suspension cultures three different polymer stabilizing agents were tested. Addition 
of PVP (0.05%) and PEG (2%) could not stabilize hGM-CSF and all hGM-CSF was degraded 
in 1 day. Following gelatine (2%) addition, about 90% of hGM-CSF remained stable up to 
day 5, however most of the protein was degraded rapidly (Lee et al. 2002).  
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In conclusion, a great advantage of plant cell suspension cultures is that recombinant protein 
can be produced under certified conditions (GMP, GLP) (Torres et al. 1999). Recent 
improvement in the design of novel promoters and gene targeting will lead to significant 
improvements in recombinant product yields in plant cell lines that are devoid of noxious 
compounds. However, media optimisation, improvement of nutrient supply, (Sato et al. 1996) 
feeding of precursors or elicitors, (Yukimune et al. 1996) improved fermenter design and 
agitation conditions (Böhme et al. 1997) need to be evaluated to obtain higher productivity 
during extended use of plant cell suspension cultures in recombinant protein production.  
 
IV.4 Production systems for rHSA, system of choice 
Recombinant HSA production has been examined in bacteria, yeast, plant cells and transgenic 
animals. Among these systems, rHSA production by Sacharomyces cerevisiae, Pichia 
pastoris and Kluyveromyces lactis are being followed up to develop a commercially viable 
technology. Amersham Pharmacia Biotech invented a manufacturing process to make HSA 
by genetic manipulation of P. pastoris on a commercial scale. Application for government 
approval of the process was lodged in 1997. The application was made under the brand name 
Albrec. Typical production levels in yeast cultures are approximately 150 mg per L. 
Yet the rHSA production in plants remains a reasonable strategy in view of the high 
production volume with low cost (Giddings et al. 2000; Hood et al. 2002; Fischer et al. 
2003). The advantages of intact plants lie in the fast biomass build-up, the low cultivation 
costs and the easy storage and distribution of transgenic seed material. In this work, different 
transgenic plants and tobacco suspension cultures were tested in terms of their performance in 
expressing a recombinant human protein. Among these systems, tobacco and wheat were 
determined to be the best producers for rHSA. In stably transformed tobacco plants, 
expression levels reached 100 µg rHSA/g leaf material and in bombarded wheat embryos 100 
µg rHSA/g wheat seed. Consequently, these two alternative plants represent a viable 
alternative to mammalian and prokaryotic expression systems for the production of rHSA.  
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IV.5 Downstream processing 
HSA has been used clinically to treat a number of diseases with high dosage. It is currently 
used in greater volume than any other biopharmaceutical solution that is available 
(Matejtschuk et al. 2000). Extremely pure product is required in large-scale production. 
Albumin is now predominantly derived from human plasma, although both time-expired 
blood and in some countries, placental material have been used as sources in the past.  
The classic cold ethanol precipitation method developed and it has been used for the 
production of albumin from human plasma since 1946 (Cohn et al. 1946). Since then, some 
pharmaceutical providers have chosen to supplement this process with additional purification 
steps (Adcock et al. 1998). However, chromatographic purification of HSA has been 
increasingly studied in the last few years. Application of chromatography, especially ion 
exchange, affinity, and size-exclusion, has opened a new area in the production of pHSA 
(plasma derived HSA). Ion exchange chromatography and hydrophobic chromatography play 
a central role in the purification scheme. Integration with other chromatographic techniques 
such as size-exclusion, metal chelate, and affinity gives improved purification results. 
In this work, a single cation exchange chromatography step resulted in removal of most of the 
plant proteins. The purification of HSA is challenging since this protein binds to various 
compounds which makes it difficult to separate contaminants during downstream processing. 
According to our results (III.4.1), the optimum pH lies in the range of pH 4.4 to 4.6 for cation 
exchange chromatography using commercially available HSA, the optimum buffer is 
determined as 0.1 M acetate buffer at pH 4.0 for extraction of rHSA from transgenic tobacco 
leaves. Besides, using fresh leaves collected from greenhouse and directly processed for 
extraction resulted in higher amounts of rHSA when compared with the shock frozen leaves. 
In order to remove contaminating plant proteins, heating of the extract was also evaluated 
however a huge loss in the recombinant protein was observed and therefore this step was not 
pursued any further.  
In order to verify both a correct processing of the rHSA signal peptide and an N-terminal end 
identical to native HSA, Farran et al. (2002) partially purified rHSA from fresh transgenic 
potato tubers. Extraction scheme included homogenization in phosphate buffer (pH 7.4), an 
initial purification using DEAE Seppharose FF column, a linear gradient salt elution, 
desalting using HiPrep column and affinity purification using Blue Seppharose FF column. 
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Partial purification achieved this way was sufficient for amino terminal sequencing of the 
rHSA.  
In this study, a single step chromatography was performed by using 700 g of transgenic 
tobacco leaf material. 22 mg of rHSA could be partially purified. Additional steps like salt 
precipitation and affinity purification using rHSA itself or different tags must be added to the 
purification protocol in order to achieve a higher level of purification. Time and cost 
investments are two important factors to consider in the protocol. It is known that traditional 
purification of biopharmaceuticals using columns accounts for 30% of the production cost 
and 70% of the setup cost (Daniell 2003).  
Recombinant HSA produced in P. pastoris yielded up to 150 mg per L broth of culture 
supernatant. The rHSA was isolated and purified by hollow-fiber ultrafiltration, Phenyl-
Seppharose hydrophobic chromatography and antibody-immunoadsorbent chromatography. 
And finally rHSA was purified to electrophoretic purity (Qiu et al. 2000). Kobayashi et al. 
(1998) used Pichia host system as well. Fermentation process involved methanol feeding for 
the secretion of rHSA into the culture broth. After optimizing the physiological and 
environmental aspects of the fermentation, the production level of rHSA exceeded 10 g rHSA 
per L (Kobayashi et al. 1998). The purification process employed STREAMLINE 
expanded bed adsorption for direct capture of the target product. Recombinant HSA was 
adsorbed to the column, while yeast cells and impurities passed through.  
A combined method, whereby chromatographic purification steps supplement the cold 
ethanol fractionation process has been adopted by a number of manufacturers for blood 
plasma derived HSA. Addition of a single anion exchange chromatography by preparation of 
the product Zenalb® markedly improved the quality of the product. Similarly, using 
transgenic tobacco plants different polishing approaches like gel filtration or anion exchange 
chromatography needs to be further investigated. Optimum design of these steps will lead to a 
recombinant product which can then be tested for various clinical tests.  
 
IV.6 Conclusions and future perspectives 
Plants have many advantages compared with traditional systems for the molecular farming of 
pharmaceutical proteins. These include the low cost of production, rapid scalability, the 
absence of human pathogens and the ability to fold and assemble complex proteins accurately 
(Ma et al. 2003).  
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In this work it could be shown that rHSA can be produced in different organisms including 
bacteria, plants and plant cell suspension cultures with varying production levels. Estimates 
by industry suggest that the cost-effective yield for pharmaceutical production in plants is 0.1 
mg of rHSA per g of fresh weight (Fernandez-San Millan et al. 2003). This level was 
achieved when rHSA was expressed stably in the ER of N. tabacum cv. Petite Havana SR1 
plants. In recent experiments we have transformed the tobacco cultivar Maryland Mammoth 
that produces more biomass per hectare than Petite Havana SR1. Transient expression 
analyses showed that rHSA levels were comparable to that obtained in the cultivar Petite 
Havana SR1. Currently, stable transformation of this line is ongoing. These levels could be 
improved by selfing and crossing elite plant lines. It has been demonstrated that recombinant 
protein levels can be significantly increased using these breeding procedures (Zimmermann et 
al. 1998; Hood et al. 2002). In addition to tobacco plants, wheat seeds are determined as an 
alternative high- expression system and further advantage is the easy storage of the seed 
kernels for prolonged time. Transgenic wheat seeds accumulating rHSA were stored for more 
than 12 months without the significant loss of product yield. 
Recent approvals for the commercialization of GM crops containing antibiotic resistance 
markers have raised concern in Europe about the risk of spreading antibiotic resistance genes 
to previously unsusceptible microbes and hence making them resistant to antibiotics used. As 
a consequence governments in the European Union have recommended phasing out GM 
crops containing antibiotic resistance markers by 2005 (web site 
http://biosafety.ihe.be/ARGMO/Documents/EFB_AntibioticRM_English.pdf). Therefore in 
order to commercialise rHSA expressed in a host organism, marker free crops should be 
generated. For this purpose design of a marker free system has been carried out and a project 
for the expression of this protein is ongoing.  
In this thesis it could be also shown that an alternative production technology is the use of 
plant cells followed by secretion into the culture medium. Fermentations of transgenic 
tobacco cell lines were performed at 5 L working volume and in batch fermentation. It has 
been shown that the system is productive for more than 30 days. Improvement of the batch 
and continued fermentation system parameters are in progress in order to have superior 
accumulation of rHSA in the culture medium.  
Independent of the expression system of choice, downstream processing of the protein should 
be carried in the most cost-effective way with highest percent recovery. Experiments carried 
out during this study proved the importance of optimising the purification conditions. It has 
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been shown that with proper extraction conditions, a single cation exchange chromatography 
step led to removal of most of the plant proteins. 
Further improvement in the purification strategies is necessary in order to efficiently purify 
rHSA from the host organism. Purified rHSA can be than evaluated for structural identity and 
function by comparing its biochemical properties to the human counterpart. Biochemical 
characterization could be done using by fluorometric methods or by surface plasmon 
resonance technology in order to study known interactions between various drugs (e.g. 
warfarin, salicylate ion, and bilirubin) and rHSA.  
Chapter V  Summary 
115 
V Summary 
Human serum albumin (HSA) is the most abundant protein in the circulatory system. The 
principal function of HSA is to transport fatty acids, but it is also capable of binding a great 
variety of metabolites and drugs. The potential of HSA in various applications, like usage as a 
plasma expander, stabilizing agent, drug delivery protein and as an adjunct in insulin action 
prolongation demands a great supply of pure HSA. Presently HSA is manufactured from the 
blood pooled from commercial blood donors. There is no guarantee regarding contamination 
of the product by viral pathogens and prions, causing dreadful diseases. The annual world 
need exceeds 500 tons, representing a market value of more than 1.5 billion US$ (Fernandez-
San Millan et al. 2003). Considering the amount of plasma expanders required in critically ill 
patients, the use of albumin represents a significant cost (Nicholson et al. 2000). 
Such a huge demand can not longer be met by merely purifying HSA from original sources, 
as the supply of human blood is limited. Alternative ways to obtain HSA are highly attractive 
both to decrease the dependence on blood banks and to reduce possible health hazards, such 
as AIDS and hepatitis that may be transmitted during/by infusion of products derived of 
contaminated blood.  
The initial attempt was to generate a novel plant codon optimised semi-synthetic HSA gene 
by PCR amplification. The strategy was to eliminate the rare codons that are used at low 
frequencies in the plant host system resulting in an optimized codon usage pattern for high-
level expression of recombinant HSA (rHSA). Sequence analysis revealed the presence of 
high number mutations in the final product, including insertions and deletions of several 
bases which could not be eliminated.  
The main focus of the work was to establish an alternative expression system for the 
production of the authentic HSA cDNA. Further analysis included expression and 
characterization of rHSA in E. coli, transient expression in leaves of tobacco, zucchini and 
bean, stable expression in (intact) tobacco and wheat plants and tobacco cell suspension 
culture. For bacterial expression of rHSA, cytoplasmic and periplasmic expression vectors 
were generated. After verifying expression in E. coli, purification of the recombinant protein 
was carried out. Tobacco, zucchini and bean host systems were assessed for expression of 
rHSA. No difference in transient accumulation levels were observed when the protein was 
either secreted to the apoplast or targeted to endoplasmic reticulum (ER). Further analysis 
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included stable transformation of tobacco plants via Agrobacterium mediated gene transfer. 
Accumulation of rHSA in the ER and secretion into the apoplast were confirmed by 
immunoblot analysis. In parallel to the expression studies in intact plants, tobacco suspension 
cultures were initiated and both intracellular and secreted protein could be detected in batch 
culture of the transgenic BY2 cells. Protein stability following secretion could be improved 
with the addition of appropriate chemical agents (stabilizers) to the growth media. The results 
achieved by all expression systems and their comparison were performed. 
Finally downstream processing of the rHSA from transgenic tobacco leaves was investigated. 
Conditions for an efficient extraction of the recombinant protein from plant system were 
optimised and cation exchange chromatography to partially purify rHSA was carried out. 
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VII Appendices 
VII.1 Abbreviations 
ABTS 2,2-Azino-di-(3-ethylbenzthiazoline sulphonate) diamonium salt 
Ab Antibody 
Ag Antigen 
Amp Ampicillin 
AP Alkaline phosphatase 
BCIP 5-Bromo-4-Chloro-3-Indolyl-Phosphat 
bp Base pair 
BSA Bovine serum albumin 
CaCl2 Calcium chloride 
CaMV Cauliflower mosaic virus 
Carb Carbenicillin 
cDNA Complementary DNA 
CHS Chalchone synthase 
CI Chloroform/isoamyl alcohol (24:1) 
Cys Cysteine 
cv. Cultivar 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNTP Deoxyribonucleoside triphosphate 
DTT 1, 4-dithiothreitol 
E. coli  Escherichia coli 
EDTA Ethylenediamine tetraacetic acid 
ELISA Enzyme-linked Immunosorbent assay 
ER Endoplasmic reticulum 
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EtOH Ethanol 
EtBr Ethidium bromide 
Fc Fragment crystalline 
g Relative centrifugal force (RCF) 
GAM Goat anti-mouse antibody 
GAMAP Alkaline phosphatase conjugated goat anti mouse antibody 
GAR Goat anti-rabbit antibody 
GSM Agrobacteria glycerol stock media 
h Hour(s) 
HCl Hydrochloric acid 
his Histidine 
HSA Human serum albumin 
IEF Isoelectric focusing 
IPTG Isopropyl B-D-thiogalactopyranoside 
IMAC Immobilized metal ion affinity chromatography 
iv intravenous 
kb Kilobase pair 
kDa Kilodalton 
KDEL  KDEL (Lys-Asp-Glu-leu) ER retention signal 
Km  Kanamycin 
λ Lambda 
L Liter  
µ Micro 
m Mili 
M  Molar 
MgSO4 Magnesium sulphate 
MES 2-(N-morpholino)-ethanesulphonic acid 
min Minute(s) 
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MPBS  Non-fat skim milk powder in PBS 
MgSO4  Magnesium sulphate 
MOPS 3-(morpholino)propanesulfonic acid 
mRNA Messenger RNA 
Mw Molecular weight 
N nano 
nd. not detectable 
nt nucleotide 
NaCl Sodium chloride 
NBT p-nitro blue tetrazolium chloride 
Ω Ohm 
OD Optical density 
o/n  Overnight 
ORF  Open reading frame 
Ori Origin of replication 
PAA Polyacrylamide 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PBST 0.1% (v/v) Tween-20 in PBS 
PCI  Phenol/chloroform/isoamyl alcohol (25:24:1) 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
pH A logarithmic measure of hydrogen ion concentration 
pNPP para-nitrophenyl phosphate 
poly A Polyadenylation signal 
PVP Polyvinyl pyrrolidone 
RAC rabbit anti chicken antibodies 
rHSA recombinant human serum albumin 
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rif Rifampicilin 
RNA Ribonucleic acid 
Rnase Ribonuclease 
rpm  Rounds per minute 
RT Reverse transcription 
sec second(s) 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Taq Thermus aquaticus 
TBE  Tris borate EDTA 
TEMED  N, N, N, N-tetramethylene-ethylenediamine 
Tris Tris (Hydroxymethyl) aminomethane 
Tween 20 Polyoxyethylene sorbitan monolaureate 
UTR untranslated region 
UV Ultraviolet 
Vol. volume 
v/v Volume per volume 
w/v Weight per volume 
w/w Weight per weight 
 
VII.2 List of primers used for the amplification of plant 
codon optimised HSA  
HSAmod1-16 as forward primers and HSAmod7-32 as backward primers were used in the 
reaction mix. Forward and backward primers have complementary sequences differing in 
length of 21-24 nucleotides. Schematic representation of arrangement of primers for SOE 
PCR of plant codon optimised HSA are given in Figure III.2. 
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HSAmod1 
5 GCG GAA TTC CAT GGA TGC ACA CAA GAG CGA GGT TGC TCA CCG CTT 
TAA AGA TTT G 3 
HSAmod2 
5 GTG AAA TTG GTG AAT GAA GTC ACT GAA TTT GCA AAA ACC TGC GTG 
GCT GAT GAG TCC GCT GAA AAT TGC GAC 3 
HSAmod3 
5 GGA GAC AAA TTG TGC ACC GTT GCA ACT CTT CGC GAA ACC TAC GGT 
GAA ATG 3 
HSAmod4 
5 CAA GAA CCT GAG AGG AAT GAA TGC TTC 3 
HSAmod5 
5 GCT TTT CAC GAC AAT GAA GAG ACC TTT TTG AAA AAA TAC TTG TAC 
GAA ATT GCC AGG AGG CAC CCT TAC 3 
HSAmod6 
5 TTT TAC GCC CCG GAA CTC CTT TTC TTT GCT AAA AGG TAC AAA GCT GCT 
TTT ACC GAA TGC TGC CAA GCT G 3 
HSAmod7 
5 CTC AAA TGC GCC AGC CTC CAA AAA TTT GGA GAA AGG GCT TTC AAA 
GCA TGG GCA GTG GCT CGC CTG AGC 3 
HSAmod8 
5 TTG CAG AAG TTT CCA AGT TGG TGA CCG ATC TTA CCA AAG TCC ACA 
CCG AAT GCT GCC ACG GAG ATC TGC TT 3 
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HSAmod9 
5 ACC TTG CCA AGT ACA TCT GCG AAA ATC AGG ATT CCA TCT CCA GCA 
AAC TGA AGG AAT GCT GCG AAA AAC CTC TG 3 
HSAmod10 
5 GCA AAA ACT ACG CTG AGG CAA AGG ATG TCT TCC TGG GCA TGT TTT 
TGT ACG AAT ACG CAA GGA GGC ACC CT 3 
HSAmod11 
5 CTT GCC AAG ACC TAC GAA ACC ACT CTG GAG AAG TGC TGC GCC GCT 
GCA GAT CCT CAC GAA TGC TAC GCC AAA GTG TTC 3 
HSAmod12 
5 GAG AGT ACA AAT TCC AGA ATG CGC TCT TGG TTC GCT ACA CCA AGA 
AAG TGC CCC AAG TGT CCA CTC CAA CTC 3 
HSAmod13 
5 GAA AAG TGG GCA GCA AAT GCT GCA AAC ACC CTG AAG CAA AAA GGA 
TGC CCT GCG CAG AAG ACT ACC TCT CC 3 
HSAmod14 
5 GCA CGA GAA AAC CCC AGT GAG CGA CAG GGT CAC CAA ATG CTG CAC 
CGA GTC CTT GGT GAA CAG GCG CCC A 3 
HSAmod15 
5 CCC AAA GAG TTT AAT GCT GAA ACC TTC ACC TTC CAC GCA GAT ATC 
TGC ACC CTT TCT GAG AAG GAG AGG CAA ATC AAG AAA C 3 
HSAmod16 
5 AAA GCT GTT ATG GAT GAT TTC GCA GCT TTT GTG GAG AAG TGC TGC 3 
 
Chapter VII  Appendices 
133 
HSAmod17 
5 GCC TTC GAA CAG CTG CAA GCC CAA GGC AGC TTG GCT TGC AGC AAC 
AAG 3 
HSAmod18 
5 TGC GAA ATC ATC CAT AAC AGC TTT CAG TTG CTC TTT GGT TGC CTT GGG 
C 3 
HSAmod19 
5 GTT TCA GCA TTA AAC TCT TTG GGA ACG TAG GTT TCA TCG ACT TCC AGA 
GCG GAA AAG CAT GGG CGC CTG TTC ACC AAG GAG TC 3 
HSAmod20 
5 GCT CAC TGG GGT TTT CTC GTC CAA CAC GCA CAA CTG GTT CAG GAC 
CAC GGA GAG GTA GTC TTC TGC GCA G 3 
HSAmod21 
5 GCA GCA TTT GCT GCC CAC TTT TCC GAG GTT CCT GGA GAC CTC CAC 
AAG AGT TGG AGT GGA CAC TTG GGG 3 
HSAmod22 
5 CGC ATT CTG GAA TTT GTA CTC TCC AAG CTG CTT AA AAG CTC GCA GTT 
TTG TTT GAT CAA ATT CTG AGG C 3 
HSAmod23 
5 AGT GGT TTC GTA GGT CTT GGC AAG CCT CAG CAG CAG CAC GAC AGA 
GTA ATC AGG GTG CCT CCT TGC GTA TTC GTA 3 
HSAmod24 
5 CTT TGC CTC AGC GTA GTT TTT GCA AAC ATC CTT GCT TTC AAC AAA ATC 
AGC AGC CAA GGA AGG CAA GTC AG 3 
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HSAmod25 
5 TTC GCA GAT GTA CTT GGC AAG GTC CGC CCT GTC ATC AGC GCA TTC 
AAG CAG ATC TCC GTG GCA GCA TTC 3 
HSAmod26 
5 CAC CAA CTT GGA AAC TTC TGC AAA CTC AGC TTT GGG AAA CCT CTG 
GCT CAG GCG AGC CAC TGC CCA TGC 3 
HSAmod27 
5 TTT TTG GAG GCT GGC GCA TTT GAG CCT CTG TTT GGC AGA GGA AGC 
CTT CCC TTC ATC GCG AAG TTC ATC G 3 
HSAmod28  
5 AAG GAG TTC CGG GGC GTA AAA GTA AGG GTG CCT CCT GGC AAT TTC 3 
HSAmod29 
5 GGT CTC TTC ATT GTC GTG AAA AGC AGT GCA CAT CAC ATC AAC CTC 
TGG CCT CAC CAA GCG GGG GAG GTT TG 3 
HSAmod30 
5 GCA TTC ATT CCT CTC AGG TTC TTG TTT TGC GCA GCA GTC AGC CAT TTC 
ACC GTA GGT TTC GCG AAG 3 
HSAmod31 
5 TGC AAC GGT GCA CAA TTT GTC TCC AAA AAG GGT GTG AAG AGA TTT 
GTC GCA ATT TTC AGC GGA CTC ATC 3 
HSAmod32 
5 AGT GAC TTC ATT CAC CAA TTT CAC GTG ATC TTC AAA TGG GCA CTG CTG 
AAG GTA CTG AGC AAA GG 3 
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VII.3 Rare codon distribution in HSA sequence 
1 ATG AAG TGG GTA ACC TTT ATT TCC CTT CTT TTT CTC TTT AGC TCG GCT TAT TCC AGG 
GGT GTG TTT CGT CGA GAT GCA CAC AAG AGT GAG  90  
 
91 GTT GCT CAT CGG TTT AAA GAT TTG GGA GAA GAA AAT TTC AAA GCC TTG GTG TTG ATT 
GCC TTT GCT CAG TAT CTT CAG CAG TGT CCA TTT  180  
 
181 GAA GAT CAT GTA AAA TTA GTG AAT GAA GTA ACT GAA TTT GCA AAA ACA TGT GTA 
GCT GAT GAG TCA GCT GAA AAT TGT GAC AAA TCA CTT 270 
 
271 CAT ACC CTT TTT GGA GAC AAA TTA TGC ACA GTT GCA ACT CTT CGT GAA ACC TAT 
GGT GAA ATG GCT GAC TGC TGT GCA AAA CAA GAA CCT  360                                                                               
 
361 GAG AGA AAT GAA TGC TTC TTG CAA CAC AAA GAT GAC AAC CCA AAC CTC CCC CGA 
TTG GTG AGA CCA GAG GTT GAT GTG ATG TGC ACT GCT 450                                                                                          
 
451 TTT CAT GAC AAT GAA GAG ACA TTT TTG AAA AAA TAC TTA TAT GAA ATT GCC AGA 
AGA CAT CCT TAC TTT TAT GCC CCG GAA CTC CTT TTC 540                                                                                          
 
541TTT GCT AAA AGG TAT AAA GCT GCT TTT ACA GAA TGT TGC CAA GCT GCT GAT AAA GCT 
GCC TGC CTG TTG CCA AAG CTC GAT GAA CTT CGG  630                                                                                         
 
631GAT GAA GGG AAG GCT TCG TCT GCC AAA CAG AGA CTC AAA TGT GCC AGT CTC CAA 
AAA TTT GGA GAA AGA GCT TTC AAA GCA TGG GCA GTG 720                                                                                         
 
721 GCT CGC CTG AGC CAG AGA TTT CCC AAA GCT GAG TTT GCA GAA GTT TCC AAG TTA GTG 
ACA GAT CTT ACC AAA GTC CAC ACG GAA TGC TGC  810                                                                                          
 
811 CAT GGA GAT CTG CTT GAA TGT GCT GAT GAC AGG GCG GAC CTT GCC AAG TAT ATC 
TGT GAA AAT CAG GAT TCG ATC TCC AGT AAA CTG AAG 900                                                                                          
 
901 GAA TGC TGT GAA AAA CCT CTG TTG GAA AAA TCC CAC TGC ATT GCC GAA GTG GAA 
AAT GAT GAG ATG CCT GCT GAC TTG CCT TCA TTA GCT 990     
                                                                                                                   
991 GCT GAT TTT GTT GAA AGT AAG GAT GTT TGC AAA AAC TAT GCT GAG GCA AAG GAT 
GTC TTC CTG GGC ATG TTT TTG TAT GAA TAT GCA AGA 1080 
 
1081 AGG CAT CCT GAT TAC TCT GTC GTG CTG CTG CTG AGA CTT GCC AAG ACA TAT GAA 
ACC ACT CTA GAG AAG TGC TGT GCC GCT GCA GAT CCT 1170                                                                                        
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1171 CAT GAA TGC TAT GCC AAA GTG TTC GAT GAA TTT AAA CCT CTT GTG GAA GAG CCT 
CAG AAT TTA ATC AAA CAA AAC TGT GAG CTT TTT AAG 1260                                                                                        
 
1261 CAG CTT GGA GAG TAC AAA TTC CAG AAT GCG CTA TTA GTT CGT TAC ACC AAG AAA 
GTA CCC CAA GTG TCA ACT CCA ACT CTT GTA GAG GTC 1350                                                                                        
 
1351 TCA AGA AAC CTA GGA AAA GTG GGC AGC AAA TGT TGT AAA CAT CCT GAA GCA AAA 
AGA ATG CCC TGT GCA GAA GAC TAT CTA TCC GTG GTC 1440                                                                                        
 
1441 CTG AAC CAG TTA TGT GTG TTG CAT GAG AAA ACG CCA GTA AGT GAC AGA GTC ACA 
AAA TGC TGC ACA GAG TCC TTG GTG AAC AGG CGA CCA 1530                                                                                        
 
1531 TGC TTT TCA GCT CTG GAA GTC GAT GAA ACA TAC GTT CCC AAA GAG TTT AAT GCT 
GAA ACA TTC ACC TTC CAT GCA GAT ATA TGC ACA CTT 1620                                                                                        
 
1621 TCT GAG AAG GAG AGA CAA ATC AAG AAA CAA ACT GCA CTT GTT GAG CTT GTG AAA 
CAC AAG CCC AAG GCA ACA AAA GAG CAA CTG AAA GCT 1710                                                                                        
 
1711 GTT ATG GAT GAT TTC GCA GCT TTT GTA GAG AAG TGC TGC AAG GCT GAC GAT AAG 
GAG ACC TGC TTT GCC GAG GAG GGT AAA AAA CTT GTT 1800                                                                                        
 
1801 GCT GCA AGT CAA GCT GCC TTA GGC TTA TAA *** 
 
VII.4 Comparison of authentic and plant codon optimised 
HSA sequence 
The sequence represented as HSA illustrates the original HSA sequence, whereas HSAmod 
represents the sequence that was designed in order to optimize the codon usage for expression 
in tobacco, wheat and rice plants. 
HSA gatgcacacaagagtgaggttgctcatcggtttaaagatttgggagaagaaaatttcaaa  
            |||||||||||||| ||||||||||| || |||||||||||||||||||||||||||||| 
HSAmod.     gatgcacacaagagcgaggttgctcaccgctttaaagatttgggagaagaaaatttcaaa  
                                                                         
HSA  gccttggtgttgattgcctttgctcagtatcttcagcagtgtccatttgaagatcatgta  
            ||||||||||||||||||||||||||||| ||||||||||| |||||||||||||| ||  
HSAmod.     gccttggtgttgattgcctttgctcagtaccttcagcagtgcccatttgaagatcacgtg  
                                                                         
HSA  aaattagtgaatgaagtaactgaatttgcaaaaacatgtgtagctgatgagtcagctgaa  
            ||||| ||||||||||| ||||||||||||||||| || || ||||||||||| |||||| 
HSAmod.     aaattggtgaatgaagtcactgaatttgcaaaaacctgcgtggctgatgagtccgctgaa  
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HSA  aattgtgacaaatcacttcataccctttttggagacaaattatgcacagttgcaactctt  
            ||||| |||||||| ||||| |||||||||||||||||||| ||||| |||||||||||| 
HSAmod.     aattgcgacaaatctcttcacaccctttttggagacaaattgtgcaccgttgcaactctt  
                                                                         
HSA  cgtgaaacctatggtgaaatggctgactgctgtgcaaaacaagaacctgagagaaatgaa  
            || |||||||| |||||||||||||||||||| |||||||||||||||||||| |||||| 
HSAmod.     cgcgaaacctacggtgaaatggctgactgctgcgcaaaacaagaacctgagaggaatgaa  
                                                                         
HSA  tgcttcttgcaacacaaagatgacaacccaaacctcccccgattggtgagaccagaggtt  
            ||||||||||||||||||||||||||||||||||||||||| |||||||| ||||||||| 
HSAmod.     tgcttcttgcaacacaaagatgacaacccaaacctcccccgcttggtgaggccagaggtt  
                                                                         
HSA  gatgtgatgtgcactgcttttcatgacaatgaagagacatttttgaaaaaatacttatat  
            ||||||||||||||||||||||| |||||||||||||| ||||||||||||||||| ||  
HSAmod.     gatgtgatgtgcactgcttttcacgacaatgaagagacctttttgaaaaaatacttgtac  
                                                                         
HSA  gaaattgccagaagacatccttacttttatgccccggaactccttttctttgctaaaagg  
            ||||||||||| || || ||||||||||| |||||||||||||||||||||||||||||| 
HSAmod.     gaaattgccaggaggcacccttacttttacgccccggaactccttttctttgctaaaagg  
                                                                         
HSA  tataaagctgcttttacagaatgttgccaagctgctgataaagctgcctgcctgttgcca  
            || |||||||||||||| ||||| |||||||||||||||||||||||||||||||||||| 
HSAmod.     tacaaagctgcttttaccgaatgctgccaagctgctgataaagctgcctgcctgttgcca  
                                                                         
HSA  aagctcgatgaacttcgggatgaagggaaggcttcgtctgccaaacagagactcaaatgt  
            ||||||||||||||||| ||||||||||||||||| |||||||||||||| ||||||||  
HSAmod.     aagctcgatgaacttcgcgatgaagggaaggcttcctctgccaaacagaggctcaaatgc  
                                                                         
HSA  gccagtctccaaaaatttggagaaagagctttcaaagcatgggcagtggctcgcctgagc  
            ||||| |||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
HSAmod.     gccagcctccaaaaatttggagaaagggctttcaaagcatgggcagtggctcgcctgagc  
                                                                         
HSA  cagagatttcccaaagctgagtttgcagaagtttccaagttagtgacagatcttaccaaa  
            ||||| ||||||||||||||||||||||||||||||||||| ||||| |||||||||||| 
HSAmod.     cagaggtttcccaaagctgagtttgcagaagtttccaagttggtgaccgatcttaccaaa  
                                                                        
HSA  gtccacacggaatgctgccatggagatctgcttgaatgtgctgatgacagggcggacctt  
            |||||||| ||||||||||| ||||||||||||||||| ||||||||||||||||||||| 
HSAmod.     gtccacaccgaatgctgccacggagatctgcttgaatgcgctgatgacagggcggacctt  
                                                                         
HSA  gccaagtatatctgtgaaaatcaggattcgatctccagtaaactgaaggaatgctgtgaa  
            |||||||| ||||| |||||||||||||| |||||||| ||||||||||||||||| ||| 
HSAmod.     gccaagtacatctgcgaaaatcaggattccatctccagcaaactgaaggaatgctgcgaa  
                                                                         
HSA  aaacctctgttggaaaaatcccactgcattgccgaagtggaaaatgatgagatgcctgct  
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HSAmod.     aaacctctgttggaaaaatcccactgcattgccgaagtggaaaatgatgagatgcctgct  
                                                                         
HSA  gacttgccttcattagctgctgattttgttgaaagtaaggatgtttgcaaaaactatgct  
            ||||||||||| || |||||||||||||||||||| |||||||||||||||||||| ||| 
HSAmod.     gacttgccttccttggctgctgattttgttgaaagcaaggatgtttgcaaaaactacgct  
                                                                         
HSA  gaggcaaaggatgtcttcctgggcatgtttttgtatgaatatgcaagaaggcatcctgat  
            ||||||||||||||||||||||||||||||||||| ||||| ||||| ||||| |||||| 
HSAmod.     gaggcaaaggatgtcttcctgggcatgtttttgtacgaatacgcaaggaggcaccctgat  
                                                                         
HSA  tactctgtcgtgctgctgctgagacttgccaagacatatgaaaccactctagagaagtgc  
            ||||||||||||||||||||||| ||||||||||| || ||||||||||| ||||||||| 
HSAmod.     tactctgtcgtgctgctgctgaggcttgccaagacctacgaaaccactctggagaagtgc  
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HSA  tgtgccgctgcagatcctcatgaatgctatgccaaagtgttcgatgaatttaaacctctt  
            || ||||||||||||||||| |||||||| |||||||||||||||||||||||||||||| 
HSAmod.     tgcgccgctgcagatcctcacgaatgctacgccaaagtgttcgatgaatttaaacctctt  
                                                                         
HSA  gtggaagagcctcagaatttaatcaaacaaaactgtgagctttttaagcagcttggagag  
            |||||||||||||||||||| |||||||||||||| |||||||||||||||||||||||| 
HSAmod.     gtggaagagcctcagaatttgatcaaacaaaactgcgagctttttaagcagcttggagag  
                                                                         
HSA  tacaaattccagaatgcgctattagttcgttacaccaagaaagtaccccaagtgtcaact  
            |||||||||||||||||||| || ||||| |||||||||||||| ||||||||||| ||| 
HSAmod.     tacaaattccagaatgcgctcttggttcgctacaccaagaaagtgccccaagtgtccact  
                                                                         
HSA  ccaactcttgtagaggtctcaagaaacctaggaaaagtgggcagcaaatgttgtaaacat  
            ||||||||||| |||||||| || ||||| |||||||||||||||||||| || |||||  
HSAmod.     ccaactcttgtggaggtctccaggaacctcggaaaagtgggcagcaaatgctgcaaacac  
                                                                         
HSA  cctgaagcaaaaagaatgccctgtgcagaagactatctatccgtggtcctgaaccagtta  
            |||||||||||||| |||||||| ||||||||||| || ||||||||||||||||||||  
HSAmod.     cctgaagcaaaaaggatgccctgcgcagaagactacctctccgtggtcctgaaccagttg  
                                                                         
HSA  tgtgtgttgcatgagaaaacgccagtaagtgacagagtcacaaaatgctgcacagagtcc  
            || |||||||| |||||||| ||||| || ||||| ||||| ||||||||||| |||||| 
HSAmod.     tgcgtgttgcacgagaaaaccccagtgagcgacagggtcaccaaatgctgcaccgagtcc  
                                                                         
HSA  ttggtgaacaggcgaccatgcttttcagctctggaagtcgatgaaacatacgttcccaaa  
            |||||||||||||| ||||||||||| |||||||||||||||||||| |||||||||||| 
HSAmod.     ttggtgaacaggcgcccatgcttttccgctctggaagtcgatgaaacctacgttcccaaa  
                                                                         
HSA  gagtttaatgctgaaacattcaccttccatgcagatatatgcacactttctgagaaggag  
            ||||||||||||||||| ||||||||||| |||||||| ||||| ||||||||||||||| 
HSAmod.     gagtttaatgctgaaaccttcaccttccacgcagatatctgcaccctttctgagaaggag  
                                                                         
HSA  agacaaatcaagaaacaaactgcacttgttgagcttgtgaaacacaagcccaaggcaaca  
            || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
HSAmod.     aggcaaatcaagaaacaaactgcacttgttgagcttgtgaaacacaagcccaaggcaacc  
                                                                         
HSA  aaagagcaactgaaagctgttatggatgatttcgcagcttttgtagagaagtgctgcaag  
            |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||| 
HSAmod.     aaagagcaactgaaagctgttatggatgatttcgcagcttttgtggagaagtgctgcaag  
                                                                         
HSA  gctgacgataaggagacctgctttgccgaggagggtaaaaaacttgttgctgcaagtcaa  
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
HSAmod.     gctgacgataaggagacctgctttgccgaggagggtaaaaaacttgttgctgcaagccaa  
                               
HSA  gctgccttaggcttataa  
            |||||||| ||||| ||| 
HSAmod.     gctgccttgggcttgtaa  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VII  Appendices 
139 
VII.5 Figures  
Figure I.1 Schematic presentation of the production of a recombinant protein of 
therapeutic interest in transgenic tobacco plants, suspension cell cultures and transiently 
transformed tobacco leaves. ............................................................................................... 5 
Figure I.2 The 3 dimensional structure of HSA............................................................ 14 
Figure I.3  Schematic presentation of the thesis work packages. ................................... 21 
Figure III.1 SDS PAGE analysis (A) and titer determination (B) of polyclonal antibodies 
purified from chicken egg yolk............................................................................................ 56 
Figure III.2 Diagram of overlapping cDNA inserts (A); Analysis of SOE PCR (II.2.3.6.2) 
by agarose gel electrophoresis (B). ...................................................................................... 57 
Figure III.3 Schematic representation of primer arrangement to generate the plant codon 
optimized rHSA. ................................................................................................................. 59 
Figure III.4 Schematic representation of PCR amplification of plant codon optimized 
rHSA (A); Analysis of PCR products by agarose gel electrophoresis (B)............................. 60 
Figure III.5 Schematic representation of fragment assembly by SOE PCR-I (A); Analysis 
of SOE PCR products by agarose gel electrophoresis (B). ................................................... 61 
Figure III.6 Schematic representation of fragment assembly by SOE PCR-II (A); Analysis 
of SOE PCR products by agarose gel electrophoresis (B). ................................................... 62 
Figure III.7 Schematic representation of the mutations in the plant codon optimized  
rHSA .................................................................................................................... 63 
Figure III.8  Construction of pSSH1 plant expression vectors HSA-APO and  
HSA-KDEL .................................................................................................................... 65 
Figure III.9 SDS-PAGE (A) and Immunoblot analysis (B) of purified rHSA from E. coli 
BL21λDE3 cytoplasm. ........................................................................................................ 66 
Figure III.10 Immunoblot analysis of HSA-APO (A) and HSA-KDEL (B) transiently 
expressed in N. tabacum cv. Petite Havana SR1 leaves........................................................ 68 
Figure III.11 Determination of rHSA accumulation levels in transiently transformed 
tobacco cultivars by ELISA................................................................................................. 69 
Figure III.12 Determination of rHSA accumulation levels in transiently transformed 
zucchini, SR1 and bean leaves by ELISA............................................................................ 71 
Figure III.13 Screening of stable transgenic tobacco plants expressing HSA-APO. .......... 72 
Figure III.14 Screening of stable transgenic SR1 plants expressing HSA-KDEL. ............. 73 
Chapter VII  Appendices 
140 
Figure III.15 Screening of stable transgenic T2 plants producing HSA-APO and HSA-
KDEL .................................................................................................................... 76 
Figure III.16 Determination of rHSA accumulation levels in homozygous T2 lines by 
ELISA .................................................................................................................... 76 
Figure III.17 Immunoblot analysis of transgenic HSA-KDEL T4  tobacco leaves. ............. 78 
Figure III.18 Comparative two dimensional gel electrophoresis and Immunoblot analysis of 
wild type (A) and transgenic (B) T4 stable tobacco expressing rHSA in ER. ....................... 79 
Figure III.19 Immunoblot analysis of the ER targeted rHSA extracted from transgenic 
wheat kernels. .................................................................................................................... 81 
Figure III.20 Determination of rHSA levels in the culture medium (A) and in BY2 cells (B) 
by ELISA. .................................................................................................................... 82 
Figure III.21 rHSA accumulation in the culture medium of the HSA-APO29 cells grown in 
the absence or presence of stabilizing agents. ...................................................................... 84 
Figure III.22 rHSA accumulation in the culture medium of the HSA-APO29 cells grown in 
the absence or presence of PVP with varying molecular weight........................................... 85 
Figure III.23 Immunoblot analysis secreted rHSA from HSAcmyc29 cells grown in the 
presence or absence of PVP with varying molecular weight. ............................................... 86 
Figure III.24 Cation exchange chromatography of commercially available HSA. ............. 87 
Figure III.25 Determination of rHSA in tobacco leaves using different plant extraction 
buffers. .................................................................................................................... 89 
Figure III.26 SDS PAGE (A) and immunoblot analysis (B) of rHSA extracted from 
transgenic HSAKDEL31 N. Tabacum SR1 leaves using different buffers............................ 90 
Figure III.27 SDS PAGE (A) and immunoblot analysis (B) of rHSA extracted from fresh 
and frozen transgenic HSAKDEL31 leaves. ........................................................................ 91 
Figure III.28 SDS PAGE (A) and immunoblot analysis (B) of rHSA after partial 
purification by CEX. ........................................................................................................... 93 
Figure III.29 Cation exchange chromatography of rHSA from transgenic tobacco plants. 95 
Figure III.30 SDS PAGE (A) and immunoblot analysis (B) of rHSA after partial 
purification via CEX. .......................................................................................................... 95 
Figure III.31 SDS PAGE of rHSA after partial purification via CEX................................ 97 
 
 
 
 
Chapter VII  Appendices 
141 
VII.6 Tables 
 
Table I.1 Recombinant HSA expression in different heterologous organisms. ............ 16 
Table II.1 Illustration of the steps for Immunoblot. ...................................................... 49 
Table II.2 Illustration of the steps for titer determination of chicken egg yolk. ............. 50 
Table II.3 Illustration of the steps for HSA quantification in bacteria and plant............ 52 
Table III.1 Production levels of rHSA in plants............................................................. 70 
Table III.2 Segregation analysis of the transgenic T1 lines expressing rHSA either in the 
ER (KDEL 2, 31, 32) or in the apoplast (APO 30, 22, 10). .................................................. 75 
Table III.3 Analysis of rHSA accumulation in the transgenic HSA-APO-22/5-6 in the 
field. .................................................................................................................... 80 
Table III.4  Analysis of CEX results after partial purification of rHSA from transgenic leaf 
material by ELISA. ............................................................................................................. 94 
Table III.5 Analysis of cation exchange chromatography results after purification of 
rHSA from transgenic leaf material by ELISA. ................................................................... 96 
Table III.6 Analysis of CEX results after partial purification of rHSA from transgenic leaf 
material. .................................................................................................................... 97
 142 
Acknowledgement 
It gives me great pleasure to acknowledge the people who contributed directly and indirectly 
to the completion of this thesis. 
 
I am greatly indebted to my supervisor, Professor Dr. Rainer Fisher for providing me this 
thesis and giving me a chance to work in Department of Molecular Biology at the Institute for 
Biology VII in Aachen. His support during my difficult times has been of great value for me. I 
am also thankful to him for the critical reading of the manuscript and his availability as an 
examiner. 
 
I am deeply grateful to Professor Dr. F. Kreuzaler, Head of the Botanical Institute, Aachen 
Technical University for reviewing the thesis and agreeing to be the co-examiner. 
 
I express sincere gratitude to Professor Dr. A. M. Gressner, Head of the Clinical Chemistry in 
University Hospital Aachen, for his encouragement and agreement to act as a co-examiner. 
 
I owe my most special thanks to Dr. Stefan Schillberg for entrusting me with this project. His 
understanding, encouraging and personal guidance have provided a good basis for the present 
thesis. I am also thankful to him for his detailed review, constructive criticism and excellent 
advice during the preparation of this thesis. He was the person I could always turn to. 
 
I also like to thank to Dr. Simone Dorfmüller for her valuable friendship. I appreciate her very 
much for her correction of this thesis, her helpful comments and also encouragement during 
the course of my doctoral work and writing this thesis.  
 
During this work I had to chance to work with many colleagues of different nationalities for 
whom I have great regard, and I wish to extend my warmest thanks to all those who have 
supported me. Without this people, listed in alphabetical order here, life inside and outside of 
the lab could be much more difficult. So, thank you for being a friend and a colleague; Adel, 
Carmen, Flora, Greta, Hatice, Holger, Kerstin, Markus, Neil, Rajan, Richa, Sabine, Siham, 
Simone, Sonal and Stefano. Furthermore I like to thank to all members of the Institute for 
Biology VII. I am very grateful for the cooperative spirit and the excellent working 
atmosphere, creating a unique setting for intellectual explorations. 
 
Not only the international friends but also my national friends were always supporting me 
during all these years in Aachen. So thank you Türkisch Mafia including the members of 
Hatice, Atalay, Ahmet, Canan, Ercüment, Sevgi, Ümit, Nursen, Perihan, Ali, Erdal and 
Gönül. Dostluğumuzun kollarõ birbirimizi dünyanõn bir ucundan bir ucuna kucaklayabilecek 
kadar uzundur.  
 
Most of all Hatice for her untiring support, love and the unlimited belief in me. Kedicigim 
biliyorum derdimde hep yanimdasin, sevincimde sen de mutlu. Hep böyle tatli kal canim 
arkadasim. 
 
Last, but not least I want to thank my brother Riza Mavituna and his wife and my new sister 
Rahsan Mavituna, for their love and support from my first day till this achievement. 
 
This thesis is dedicated to a very special woman who unfortunately could not read these 
sentences. But I am sure she is somewhere proud of her little daughter finally by getting her 
degree. Without her, none of this would have been possible at all. 
 143 
Lebenslauf 
 
Persönliche Daten 
 
Name: Ayse Meltem Mavituna 
Geburtsdatum: 21.08.1970 
Geburtsort: Ankara, Türkei 
Staatsangehörigkeit: Türkisch 
Vater: Riza Mavituna 
Mutter:  Mübeccel Mavituna geb. Yücelt 
 
Schulausbildung: 
 
1977-1981 Grundschule in Mustafakemalpasa, Türkei. 
1981-1988 Ankara Anatolian Gymnasium in Ankara, Türkei. 
 
Studium: 
 
1989-1993 Studium der Biologie an der Orta Dogu Teknik Universität in Ankara 
Türkei.  
 Abschluß: Bachelor of Science. 
1993-1996 Studium der Biotechnologie an der Orta Dogu Teknik Universität in 
Ankara Türkei.  
    Abschluß: Master of Science. 
Thema der Arbeit: Effect of auxin-like plant growth regulators on 
salt stressed wheat varieties 
1996-1998   Promotion am der Orta Dogu Teknik Universität in Ankara, Türkei. 
Seit 1998 Wechsel für Promotion am Institut für Biologie VII (Molekulare 
Biotechnologie) der RWTH Aachen unter Leitung von Prof. Dr. 
Rainer Fischer. 
 
Berufstätigkeit 
 
1994-1998 Research assistant in Biochemistry und Teaching assistant in 
Genetics Laboratory an der Orta Dogu Teknik Universität in Ankara, 
Türkei. 
1998-2002 Wissenschaftliche Mitarbeiterin am Institut für Biologie VII 
(Molekulare Biotechnologie) der RWTH Aachen. 
seit 2003 Wissenschaftliche Angestellte am Institut für Klinische Chemie und 
Pathobiochemie sowie Klinische-Chemisches Zentrallaboratorium 
der Universitätsklinikum Aachen. 
